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Characterization of Drosophila homologue of vmat2 and its role
in a genetic model of Parkinson’s disease
Antonio J. Tito Jr., M.Sc.
Supervisory Professor: Sheng Zhang, Ph.D.
Parkinson’s disease (PD) is a progressive neurodegenerative disorder caused by the selective loss
of the dopaminergic neurons (DN) in the substantia nigra pars compacta region of the brain. PD
is also the most common neurodegenerative disorder and the second most common movement
disorder. PD patients exhibit the cardinal symptoms, including tremor of the extremities, rigidity,
slowness of movement, and postural instability, after 70-80% of DN degenerate. It is, therefore,
imperative to elucidate the underlying mechanisms involved in the selective degeneration of DN.
Although increasing numbers of PD genes have been identified, why these largely widely
expressed genes induce selective loss of DN is still not known. Notably, dopamine (DA) itself is a
chemically labile molecule and can become oxidized to toxic byproducts while induce the
accumulation of harmful molecules such as Reactive Oxygen Species (ROS). Accordingly, DA
toxicity has long been suspected to play a role in selective neuronal loss in PD. Vesicular
monoamine transporter ( VMAT) is essential for proper vesicular storage of monoamines such as
DA and their regulated release. Increasing evidence have linked VMAT dysfunction with
Parkinson’s disease. In this study, we reexamine the gain- and loss-of-function phenotypes of the
sole VMAT homolog in Drosophila. Our results suggest that the C-terminal sequences in the two
encoded VMAT isoforms not only determine their differential subcellular localizations, but also
their activities in content release. In particular, VMAT2 orthologue potentially poses a unique,
previously unexplored activity in promoting DA release. On the other hand, by examining DA
distribution in wildtype and VMAT mutant animals, we find that there exists intrinsic difference
in the dynamics of intracellular DA handling among DN clustered in different brain regions.
Furthermore, loss of VMAT causes severe loss of total DA levels and a redistribution of DA in
Drosophila brain. Lastly, removal of both VMAT and another PD gene parkin, which is also
conserved in Drosophila, results in the selective loss of DN, primarily in the protocerebral anterior
medial (PAM) clusters of the brain. Our results suggest a potential involvement of cytoplasmic
DA in selective degeneration of DN and also implicating a role of differential intracellular DA
handling in the regional specificity of neuronal loss in PD.
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1

LITERATURE REVIEW AND INTRODUCTION

1.1

Pathological Hallmark and PD symptoms
Parkinson’s disease (PD) is the most common movement disorder and the

second most common neurodegenerative disease (Pringsheim et al., 2014). PD patients
exhibit the four cardinal symptoms, including resting tremor of the extremities,
cogwheel rigidity, bradykinesia, and postural instability; all of which are highly
debilitating to the patients and contribute to high incidence of falls (Rodriguez-Oroz et
al., 2009). The hallmark of PD is characterized by a gradual loss of dopamine (DA)
neurons in the Substantia nigra (“black substance”) pars compacta (SNPc), which is a
relatively small region of the mesencephalon that controls movement.
A common pathological feature of PD brains is the presence of proteineous
aggregates, called ‘Lewy bodies,’ containing ubiquitinated proteins and Alphasynuclein. PD symptoms manifest following a loss of 30-40% of DA neurons (Ehringer
and Hornykiewicz, 1960; Gibb and Lees, 1991; Greenfield and Bosanquet, 1953;
Hornykiewicz, 1998). Currently, there are no curative or preventive treatments against
this dreadful disease.
The first pathological observations were obtained from post-mortem brain
samples of a tuberculosis patient admitted to Charcot’s Neurology Ward at ‘la
Salpetriere’ for unilateral parkinsonian tremor. Blocq and Marinesco discovered an
encapsulated tumor in the SNPc and concluded that the symptoms were caused by the
midbrain lesion (Hostiuc et al., 2016). Edouard Brissaud hypothesized that the
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pathogenesis came from a major dysfunction in pigmented neurons. Later, Constantin
Tretiakoff conclusively linked idiopathic and post-encephalitic Parkinsonism, with the
degenerative phenotype in the SNPc (Crocker and Sehgal, 2010).
DA neurons were later identified as the specific type of cells that are targeted
for degeneration. One puzzling observation concerning PD is the regional specificity of
the disease pathology: despite the prominent loss of DA neurons in the SNPc, those in
ventral tegmental area (VTA) are largely spared (Blesa and Przedborski, 2014).

1.2

Clinical Manifestations of the Disease
PD-like symptoms were first described in 175 AD by physician Galen as

“shaking palsy.” One of the unique features of PD is the gradual appearance of cardinal
symptoms that bear a remarkable similarity to other motor dysfunctions, including
resting tremors and festination. A snapshot of the PD symptoms was elegantly depicted
Dr. Parkinson’s observation of a patient: “Involuntary tremulous motion, with lessened
muscular power, in parts not in action and even when supported; with a propensity to
bend the trunk forward, and to pass from a walking to a running pace: the senses and
intellects being uninjured” (Auluck et al., 2002).
Dr. Jean-Martin Charcot coined the term PD to group all the cardinal
symptoms associated with the disease. Charcot also differentiated bradykinesia, which
is characterized by a “considerable time lapse between thought and action,” from
symptoms of rigidity, stiffness, and tremor of the extremities (Goetz, 1986).
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1.3

PD Prevalence
PD is the most common movement disorder and the second most common

neurodegenerative disease. A meta-study determined that the prevalence of PD varies
across age, sex, and geographical boundaries.
The study demonstrated that the age of onset for most individuals with PD is
around 60 years of age. It is estimated that the disease affects 1 out of 1,000 people
between the ages of 55 and 64. Disease prevalence increases with age, as 1 out of 233
individuals are afflicted between the ages of 60 to 74, while an alarming rate of 1 out of
50 people older than 80 years of age develop the disease. Interestingly, men have a 3.5
greater risk than women (Pringsheim et al., 2014).
Results from these studies, however, produced large margins of errors, which
could have been contributed by the under-representation of PD patients.

1.4

A Bio-Molecular Snapshot of PD Treatments
George Cotzias first demonstrated that DA precursor L-dopa, which can pass

the blood brain barrier, is effective in relieving the symptoms of PD patients. For his
groundbreaking finding, Cotzias received the 1969 Lasker DeBakey Clinical Medical
Research Award “For his demonstration of the effectiveness of large daily dosages of LDOPA in the treatment of Parkinson's disease”. Patients unresponsive to treatment
with L-Dopa were originally co-administered with drugs that facilitate sustained
release of DA to the synaptic cleft and prevent the degradation of DA by enzymes, such
MAO and COMT inhibitors, thus reducing the incidence of dyskinesia and akinesia
events (Barbeau et al., 1972).
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Unfortunately, many of available therapies only treat symptoms associated
with PD, while others lead to unexpected consequences. Many of the PD symptoms
are linked to the rapid conversion of DA to highly reactive, intermediary products. Coadministration of L-Dopa with a MAO inhibitor, for instance, contribute to adverse
reactions, including uncontrolled movements and mental abnormalities (Yahr, 1978).
There are two MAO isoenzymes, including MAO-A and MAO-B. MAO-A is localized
primarily to mitochondrial membranes in DA neurons and serotonergic neurons. The
close proximity of MAO-A to the mitochondria suppresses the accumulation of
oxidative species generated by cellular respiration while MAO-B is expressed in the
cytosol of serotonergic and histaminergic neurons and in astrocytes (Myohanen et al.,
2010; Sejourne et al., 2011). The high turnover rate of DA and wide expression of MAO
in the brain, makes it difficult for L-Dopa to generate a sustained response on the
target neurons of the striatum.
However, MAO catalyzes the oxidative deamination of the amine group of DA
to 3,4-dihydroxyphenylacetaldehyde, producing toxic ammonia and hydrogen peroxide
in the process (Segura-Aguilar and Lind, 1989).
Some of L-Dopa replacement strategies include replacing L-Dopa with more
stable biosimilar compounds and co-administering DA receptor agonists (Schwab et al.,
1951). These drugs improve the quality of life of patients at advanced stages (Brooks et
al., 1995; Rinne et al., 1997). Patients showing dyskinesia during the characteristic
“off” state of L-Dopa, also benefit from methods that significantly improve drug
absorbance into the bloodstream (Goetz et al., 1989).

Tito - 4

Yet, all of these treatments only ameliorate the symptoms and/or reduce the
adverse effects of L-Dopa. Therefore, it is of utmost importance to develop treatments,
aimed at preventing the cellular death of DA neurons, rather than just focusing on
ameliorating the symptoms of PD.

1.5

Familial Cases and Cellular Pathways Implicated in PD
The vast majority of PD cases are of unknown etiology and idiopathic in

nature. Over the past 15 years, a growing number of PD-associated genes have been
identified from newly discovered hereditary PD cases (Corti et al., 2011; Martin et al.,
2011). Although they contribute to a small portion of diagnosed PD cases, many of
these mutations cause a wide variety of cellular dysfunctions that lead to disease
pathogenesis.
Mutations in these PD genes can include point mutations and deletions, or
even duplication and triplication events, which include loss of function and gain of
toxicity mutations, such as those in the SNCA gene that codes for alpha-synuclein. In
particular, mutations in SNCA contribute to rare cases of autosomal-dominant disease,
which is characterized by an induction in the levels of aggregates in the diseased brain
(Polymeropoulos et al., 1997).
Alpha-synuclein containing aggregates are also present in the Lewy body
formations of patients with sporadic PD, suggesting there are common elements in
both familial and idiopathic PD cases (Singleton et al., 2003). The most common
mutations in patients with autosomal dominant PD are found in the LLRK2 (Park8) gene
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(Paisan-Ruiz et al., 2004). Notably, a missense mutation (PARK8 - G2019S) occurs in 30
to 40% of PD patients of North African descent (Gilks et al., 2005; Lesage et al., 2006).
Another genetic risk factor includes heterozygous mutations in the
glucocerebrosidase gene (GBA), present in 4% of patients. Homozygous mutations of
the GBA gene causes Gaucher’s disease, a recessive lysosomal storage disorder
(Neumann et al., 2009).
Finally, autosomal recessive mutations in Park2 and Pink1 are the leading
cause of early onset PD, followed by recessive mutations in DJ-1 (Hardy, 2010). These
genes code for important molecular players of the ubiquitin proteasome system,
mitophagy, and anti-ROS protective mechanisms (Bonifati et al., 2003; Hague et al.,
2003; Kitada et al., 1998; Valente et al., 2004).
Functional characterization of these genes implicate multiple cellular
pathways in PD pathogenesis, including protein misfolding, mitochondria dysfunction,
excessive reactive oxygen species (ROS), defective vesicular trafficking and others (Corti
et al., 2011; Martin et al., 2011). Summaries of these mutations and associated
functions are provided in Figure 1.1. These genetic risk factors increase the
vulnerability of DA neurons to the damaging effects incurred by a continuous exposure
to harmful toxicants in the environment (Nall et al., 2016).
However, given that almost all the PD genes are widely expressed, and since
the implicated cellular pathways are ubiquitous and systematic, it again raise the
intriguing question on how these nonspecific pathogenic factors induce a relatively
selective loss of DA neurons in the brain (Blesa and Przedborski, 2014).
Tito - 6

Unknown
Ubiquitin ligase

Anti-oxidative
Metabolic enzyme
ATPase transporter
Figure 1.1 Inheritance of gene mutations that contribute to the early onset PD.
The LRRK2, alpha-Synuclein and UCHL1 genes harbor dominant mutations, while the
parkin, pink1, dj-1, and glucocerebrosidase (GBA) genes harbor recessive mutations.
The functions linked to each gene are outlined on the right column.
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1.6

Parkin
Parkin is one of the best-studied PD genes and its loss of function has been

linked to early onset, autosomal recessive juvenile form of PD (AR-PD) (Kitada et al.,
1998; Lucking et al., 2000). Parkin encodes an E3 ubiquitin ligase and is broadly
expressed in the brain and other tissues at different stages of development and
adulthood (Kitada et al., 1998).
Functionally, Parkin has been linked to the ubiquitin-proteasome system (UPS)
and autophagy pathways, especially autophagy-mediated clearance of mitochondria
(mitophagy) (Corti et al., 2011; Erion et al., 2012; Exner et al., 2012; Scarffe et al., 2014;
Trempe and Fon, 2013; Winklhofer, 2014).
Mitochondrial dysfunction is one of the earliest and most prominent cellular
defects observed in parkin mutants of different cell and animal models, including those
in Drosophila and rodents. However, parkin mutant animals do not show an apparent
loss of DA neurons, suggesting additional pathogenic factors playing a role in the
initiation and acceleration of the degeneration process of DA neurons.
These pathogenic events are normally manifested over decades in PD patients
harboring similar genetic lesions, thus, it is possible for these secondary hits to build up
in DA neurons as the person ages (Berg et al., 2015; Blesa and Przedborski, 2014; Chege
and McColl, 2014; Dawson, 2000; Guo, 2012; Matsui et al., 2014). Therefore, it will be
critical to examine age-dependent dysregulated pathways that are specifically affected
in DA neurons.
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A

B

Figure 1.2 Parkin is conserved in Drosophila
(A) Black boxes show amino acids of identical nature between Drosophila and human
sequences. Green boxes indicate amino acids with similar biochemical properties. (B)
Cartoon representation of amino acid sequences of human and Drosophila Parkin
indicates greatest similarity in the functional domains Ubl, Ring1, IBR, and Ring2.

1.7

Mitochondrial Dysfunction as a Shared Feature of PD models
Recent identification of dysfunctional mechanisms have shed light to the

etiology of DA neurons degeneration in PD patients (Shulman et al., 2011). Pathogenic
mechanisms are associated with a significant reduction in the capacity to turnover
depolarized mitochondria by mitophagy, a dysregulated metabolism of alpha-synuclein,
and an exacerbated inflammatory response (Shulman et al., 2011).
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Mitochondrial dysfunction has emerged as a major subcellular defect in most
of the animal models of PD. As an example, in Drosophila, mutations in parkin and
pink1 contribute to severe mitochondrial abnormalities due to a defective fission
process (Greene et al., 2003; Lesage et al., 2006; Pesah et al., 2004; Yang et al., 2006).
Additional studies have shown that Parkin and Pink1 function in overlapping cellular
pathways. For example, Parkin overexpression can partially rescue the pink1 mutant
phenotypes and enhance the process of mitophagy (Clark et al., 2006). Together, they
implicate an important role of mitochondria in the etiology of PD. Similar phenotypes
are also reported in several mammalian PD models.
Interestingly, mitochondrial dysfunction was first observed in people exposed
to high levels of toxic pesticides, including MPTP (1-methyl-4-phenyl-1,2,3,6tetrahydropyridine) and Rotenone (Langston and Ballard, 1983), which contribute to
the disruption of complex I (Betarbet et al., 2000).

Further pathological studies on

post-mortem samples from PD brains, showed a higher incidence of LOF mutations in
the mtDNA polymerase POLG and mtDNA helicase, Twinkle, resulting in a defective
mtDNA replication machinery (Baloh et al., 2007; Bender et al., 2006; Wanrooij et al.,
2004).
Notably, phenotypes of dysfunctional mitochondria have also been observed
in several unrelated neuronal disorders, such as Alzheimer’s and Huntington’s, which
largely spare the DA neurons in the brain (Johri and Beal, 2012). Although it is still not
clear why in PD, DA neurons in the substantia nigra are primarily affected,
mitochondria defect alone cannot account for the relatively selective degeneration of
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DA neurons in PD. Additional factors that are innate to DA neurons most likely
contribute to disease pathogenesis.

1.8

DA, an Unstable and Potentially Toxic Neuromodulator
DA neurons are defined by the ability to synthesize and utilize DA, a neuro-

modulator that is derived from the precursor L-Tyrosine. DA is primarily responsible for
modulatory functions such as motor planning, motivation, sleep, and appetitive
memory consolidation (Bromberg-Martin et al., 2010; Dayan and Balleine, 2002; Wise,
2004). DA also plays important roles in goal-oriented and reward seeking behaviors
among others (Nieoullon, 2002).
Dysfunction of the DA system has been linked to addiction and a diverse
spectrum of diseases such as ADHD, PD, and schizophrenia (Carlsson, 1972; Creese et
al., 1976; Eisenberg et al., 1988; Freis, 1954; Ritz et al., 1988; Song et al., 2012).
Notably, DA is a chemically labile molecule, since it contains a benzene group with two
hydroxyl molecules, in addition to its amine side-chain (Fig. 1.3B). Importantly, this
unique chemical motif converts DA into a highly reactive molecule in basic conditions.
DA-induced cellular toxicity has long been suspected to play roles in PD
pathogenesis, although little evidence is available, in vivo. When DA is exposed to free
oxygen in the PH-neutral cytosol, it can spontaneously oxidize into toxic by-products.
Auto-oxidation of DA results in the formation of DA Quinones (DAQ), along with the
simultaneous production of toxic reactive oxidative species (ROS), such as hydrogen
peroxide and superoxide anion.
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Both superoxide anion, DA o-quinone, and DA o-semiquinone are neurotoxic.
DA-o-quinone metabolites are quickly stabilized via glutathione mediated synthesis of
5-S-glutathionyl-DA (Bisaglia et al., 2007). Yet, the amine group of DA o-quinone can
convert into leuco-Aminochrome (commonly known as Aminochrome).
In addition, DAQ can also serve as catalysts for the subsequent polymerization
and condensation with freely floating amino acids and proteins (Bisaglia et al., 2010).
Aminochrome can rearrange into 5,6-dihydroxyindole, which can impart significant
damage to the mitochondria, induce the formation of rigid protofibrils, disrupt the
recycling of misfolded proteins, increase oxidative stress, and induce an inflammatory
response (Bisaglia et al., 2007).
Interestingly, Aminochrome inactivates DA transporter, tyrosine hydroxylase,
and alpha- and Beta- tubulin, principal components of the cytoskeleton (Whitehead et
al., 2001). Interfering with the function of the cytoskeleton is deleterious since neurons
use the microtubules to transport the autophagy vacuoles to the lysosome.
Mechanisms that halt the production of Aminochrome will, consequently, prevent the
synthesis of 5,6-dihydroxyindole and other toxic by-products (Bisaglia et al., 2007).

Neurons employ protective mechanisms that contribute to the formation of
Neuromelanin (NM), consisting of a conglomerate of pigmented molecules linked to
peptides, lipids, heavy metals, and toxic chemicals. NM contributes to the
accumulation of iron inside the eumelanin and pheomelanin polymers. Further, upon
inflammation, activated microglia disrupts the surface layer of pheomelanin (Bush et
al., 2006) (McGeer et al., 1988); (Banati et al., 1998). Neuromelanin releases toxic
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chemicals after breaking open. Iron is a strong catalyst in the oxidation of DA to DA oquinone (Wakamatsu et al., 2012).

Injection of NM into the SNPC of rats resulted in the activation of microglia
surrounding dying DA neurons (Zhang et al., 2011). In response to inflammation, the
MAO enzyme is activated, producing hydrogen peroxide. H2O2 attacks the
pheomelanin layer of the NM, releasing its inner contents (Sulzer et al., 2000).

Other chemicals detected inside NM that predispose people to PD have
included pesticides, such as paraquat and MPTP, as well as drugs, like Chlorpromazine
and Haloperidol (Lindquist et al., 1988), and heavy metals, including Mercury, Lead,
Cobalt and Cadmium (Coon et al., 2006).
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Figure 1.3 DA system and distribution of DN in adult Drosophila brain.
(A) DA neuron clusters in adult fly brain, including the protocerebral anterior medial
(PAM) and protocerebral anterior lateral (PAL) clusters in the anterior view; and the
protocerebral posterior lateral (PPL) and the protocerebral posterior medial (PPM) in
the posterior views of the brain. (B) DA and octopamine synthesis pathway. DA is
synthesized from precursor tyrosine by Tyrosine hydroxylase (TH) to DOPA, an
intermediary molecule, which undergoes decarboxylation into DA by DA decarboxylase
(DdC). Octopamine is synthesized from precursor tyrosine by Tyrosine decarboxylase 2
(Tdc2) to Tyramine, an intermediary molecule, which undergoes hydroxylation by
Tyramine B-Hydroxylase to Octopamine. (C) Intracellular handling of DA. Synaptic DA is
sequestered inside acidic synaptic vesicles by Vesicular Monoamine Transporter
(VMAT), released to the synaptic cleft, and recycled back into the cytosol by DA
Transporter (DAT).
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1.9

DAT and VMAT: Transporters Essential for DA Function and

Stability
Like all other neurotransmitters, DA is normally sequestered inside synaptic
vesicles (SVs), whose acidic environment (normally at PH ~5.5) protonates and
stabilizes the DA molecules in DA neurons (Guillot and Miller, 2009). The precursor for
DA is the amino acid, L-tyrosine.
The rate-limiting tyrosine hydrolase (TH) catalyzes the hydroxylation of tyrosine
to L-dihydroxyphenylanaline (L-Dopa). Immediately after, DA decarboxylase (DDC),
which is also known as aromatic amino acid decarboxylase (AADC), decarboxylates LDopa into DA and generates CO2 in the process.
These anabolic reactions take place inside a complex of proteins that is
localized at the periphery of the vesicular membrane and is physically linked to
vesicular monoamine transporter 2 (VMAT2), which acts for vesicular package of DA
(Cartier et al., 2010) (Miller et al., 1999). VMAT2 is a neuron-specific 12transmembrane (TM)-domain protein spanning the vesicular membrane (Liu and
Edwards, 1997; Moriyama and Futai, 1990; Torres et al., 2003).
Synthesizing DA at the periphery of the vesicular membrane prevents the
accumulation of metabolites from DA oxidation in the cytoplasm (Linert et al., 1996).
VMAT is also responsible for packaging other monoamines, such as serotonin and
octopamine, into synaptic vesicles for storage and regulated release (Torres et al., 2003;
Yamamoto and Seto, 2014). Therefore, VMAT is an important regulator of monoamine
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biology and function (Torres et al., 2003), and VMAT expression can serve as a marker
for monoamine (DA, catecholamine, serotonin, histamine, and octopamine) producing
neurons in the brain proper.
During synaptic DA release, SVs migrate to the synaptic cleft where they fuse
with the plasma membrane and release their contents extracellularly to modulate
neuronal response. Dopamine active transporter (DAT) is another 12-transmembrane
domain protein that localizes around the active sites of the plasma membrane, and is
responsible for the re-uptake of released extracellular dopamine back into the neuron,
thereby terminating its action (Figure 1C) (Torres et al., 2003).
Thus, not only does VMAT2 mediate vesicular packaging of DA, but also
protects DA from basic conditions and oxidative agents in the cytosol. Through their
concerted effort, the two monoamine transporters (VMAT2 and DAT), regulate the
proper storage and transmission of DA.

1.10

VMAT2 and PD
As discussed, VMAT2 plays a due role in protecting DA inside acidic vesicles

and facilitating its regulated release to the synaptic cleft. Consistent with its
protective role, increasing evidence have implicated a potential causative effect of
compromised VMAT2 function to PD pathogenesis (Lohr and Miller, 2014).
In particular, mice with reduced expression of VMAT2 develop progressive
degeneration of nigrostriatal DA neurons and increased vulnerability to DA neuron
toxin MPTP (Caudle et al., 2007; Takahashi et al., 1997; Taylor et al., 2014; Taylor et al.,
2011).
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Moreover, in a study that directly evaluated VMAT2 activity from samples of
post-mortem brains, the efficiency of VMAT2 on vesicular uptake of DA from
idiopathic PD patients is profoundly reduced, as compared to those from healthy
controls. Such reduction in VMAT2 activity was not observed in brains from monkeys
treated with the DA neuron toxicant, MPTP (Pifl et al., 2014), which serves as an acute
model of PD. Additionally, A loss-of-function VMAT2 mutation is linked to a familial
infantile form of PD (Rilstone et al., 2013).
Treating mice with MPTP also depletes striatal DA and causes PD-like
symptoms in the SNPc of humans and non-human primates, causing a substantial
reduction in expression of VMAT, TH and DAT. Concomitantly, MPTP significantly
reduces the levels of striatal DA and its metabolites, namely DOPAC and HVA, but does
not induce the activity of MAO and COMT.
Nevertheless, the vesicular uptake of dopamine and binding of the VMAT2selective label [(3)-H+]-dihydrotetrabenazine was significantly reduced in DA storage
vesicles obtained from the striatum of six autopsied brain tissues of PD patients (Xu et
al., 2015). Conversely, overexpression of VMAT2 protects DA neurons from the toxic
effect of MPTP in adult neurons of Drosophila and mice (Inamdar et al., 2013; Lawal et
al., 2010; Lohr et al., 2014).

1.11

VMAT Structure and Function
VMAT possesses twelve trans-membrane domains, with both terminal tails

ending in the cytoplasm. The catalytic sites for VMAT-mediated serotonin transport,
Asp 431 and Asp 404, were identified in the transmembrane segments X and XI,

Tito - 17

through mutagenic analysis. Replacing Asp 431 with either Glu or Ser, or Asp 404 with
either Ser or Cys, inhibits serotonin transport. However, mutating the proteins, does
not impair the ability of the transporter to recognize the ligand, as measured by the
high affinity ligand [3H] reserpine, nor does it hinder coupling to the Delta micro H+
gradient.

These results suggest that ligand binding activity is independent from

transport site (Steiner-Mordoch et al., 1996).
VMAT is a vesicular ATPase, which hydrolyses ATP to ADP and inorganic
phosphate, generating an H+ gradient that acidifies the vesicles. As an antiporter,
VMAT2 exchanges one monoamine molecule for two H+ protons (Bischof et al., 2013).

1.12

VMAT

Expression

Pattern,

Subcellular

Localization

and

Heterologous Systems of Investigation
Mammalian genomes have two independent vmat genes encoding two
homologous VMAT proteins, VMAT-1 and VMAT-2 (Peter et al., 1995). Both genes were
cloned from the human adrenal glands, as well as in the chromaffin granules of the rat
and bovine. The mRNA of VMAT-1 is primarily expressed in peripheral neuroendocrine
tissues such as adrenal medulla glands, whereas VMAT-2 is mainly expressed in the
central nervous system.
In the rat brain, the region with the highest expression of the transporters is
the solitary tract nuclei. The transporters are also expressed in the parotid gland,
submandibular, sublingual and salivary glands of Wistar rats (Tomassoni et al., 2015).
During the embryonic development of the rat, VMAT2 localizes to neuronal tissues,
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while VMAT1 is present in the thymus and in cells of the endocrine system, including
the adrenal glands, medulla, pituitary gland, and testis.
The central, peripheral and enteric nervous system only express VMAT2,
suggesting a role for VMAT2 in mediating the transport of psychopharmacologic and
neurotoxic agents (Hansson et al., 1998).
In the central nervous system, the monoamine transporters are localized to
both small synaptic vesicles and large dense core vesicles. Some of the first studies
describing the subcellular localization of VMAT2 and VMAT1 were performed on
adrenal glands and chromaffin cells. At the subcellular level, VMAT2 is localized to
LDCVs that are distanced from the synaptic cleft, but is also found on small synaptic
vesicles in axon terminals. The DCVs are found near organelles involved in vesicular
membrane recycling, such as near the tuberous vesicles of the smooth endoplasmic
reticulum (Nirenberg et al., 1995).
Furthermore, heterologous systems are used to assess the subcellular
localization of VMATs and determine the effects of loss of function mutations in the
vmat gene. These have included the use of chromaffin granule from bovine adrenal
glands and Xenopus laevis oocytes. For instance, the X. laevis oocytes have been
employed to express mutated versions of synthetic mRNA of the rat VMAT2. These
results demonstrated that mutations that change the localization of VMAT2 to the
plasma membrane do not alter its ability to transport DA (Whitley et al., 2004).
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1.13

Substrates of VMAT
The substrate specificity of psychoactive molecules was originally determined

using digitonin-permeabilized fibroblastic (CV-1) cells. Expression of VMAT2 in CV-1
cells induced the uptake of catecholamines, including DA, 5-HT, and histamine.
Interestingly, histamine showed a 30-fold higher affinity for VMAT2 than VMAT1. The
other catecholamines showed a 3-fold higher affinity for VMAT2 than for VMAT1
(Erickson et al., 1996). In C. elegans, cat-1 knock-outs are deficient of DA controlled
behaviors and VMAT immunostaining (Duerr et al., 1999).
The enzymatic pathways regulating DA homeostasis are also highly conserved
in Drosophila, including DA synthesis (TH and DDC), packaging (VMAT), reuptake (DAT),
and signaling (DA receptors 1 and 2).
A study examining the effects of factors modulating histamine biosynthesis
determined that VMAT2 has a specific affinity to histamine in the gastric corpus. In this
study, it was found that treating rats with the H+-K+ ATPase inhibitor, omeprazole,
increased the mRNA expression of VMAT2 in the gastric corpus. Omeprazole also
increases the transport of histamine from enterochromaffin-like (ECL) secretory
vesicles, suggesting that VMAT2 mediates histamine storage upon an induction in
Histamine biosynthesis (Dimaline and Struthers, 1996).
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1.14

VMAT-mediated Transport of Monoamine Analogs and their

Effects
Monoamine transporters such as VMAT also have the ability to transport
various cytotoxic compounds such as ethidium, rhodamine, doxorubicin, tetrabenazine,
verapamil (a calcium channel blocker), ketanserin, and reserpine. The last three
compounds are competitive inhibitors of VMAT1 and VMAT2, while tetrabenazine only
binds to and inhibits VMAT2. Tetrabenazine also induces PD like symptoms in
Huntington’s disease patients who are prescribed with the drug to treat chorea.
Mechanistically, tetrabenazine contributes to a depletion of striatal DA in rodents,
induces tremulous jaw movements (TMJ), reduces locomotion, and induces
mastication in rodents (Podurgiel et al., 2013; Podurgiel et al., 2016).
Tetrabenazine also induces depressive symptoms in humans by depleting
dopamine levels in the striatum. Rats administered with tetrabenazine showed an
increased preference for aversive food choices. This suggests that the drug confers
major effects on decision making since it reduces the intake of pleasant food by rats
(Nunes et al., 2013).
In fact, a study showed that rats administered with tetrabenazine, via IP
injection, had less preference for decisions requiring effort. This negative effect was
reversed with the co-administration of anti-depressants, which reduced the preference
for effortless behaviors (Nunes et al., 2013). The direct link between the effects of
tetrabenazine induced VMAT inhibition and PD-like symptoms in rodents are
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reaffirmed by another study that also demonstrated similar PD like symptoms after
reserpine injection to mice (de Freitas et al., 2016).

1.15

VMAT Inhibitors
IP injection of Reserpine to rats increases the quantity, size, and volume of

granules in the stomach and significantly reduces the number of secretory vesicles.
Blocking VMAT2 function in rats with a high-dose administration of METH also
redistributes VMAT-2 from vesicle-enriched synaptosomes to the soma. This suggests
that sustained release of monoamines to the synaptic cleft are mediated by VMAT2.
These results also suggest that the disruption of VMAT2 function prevents the release
of vesicular contents, and induces formation of granules and vacuoles. The latter
structures serve as repositories for monoamines and prevent the accumulation of
reactive metabolites (Riddle et al., 2002; Zhao et al., 1999).
Psychoactive agents that selectively inhibit VMAT2, including amphetamine
and phenylethylamine, induce psychosis. “Drug-induced psychosis” is prevalent in
Vmat2 heterozygous mutant Zebrafish as anxiety like behaviors, which are
demonstrated through frequent movement between dark and light zones (Wang et al.,
2016).

To the contrary, VMAT2 agonists, including Phencyclidine (PCP) and

Pramipexole, which are also used to treat restless leg syndrome, induces sedative and
anti-schizophrenic effects (Crosby et al., 2002; Rehavi et al., 2002; Torres et al., 2003).
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1.16

VMAT Regulation
VMAT activity is regulated by the N-glycosylation sites of the luminal loop, as

well as the phosphorylation sites of the cytoplasmic domains. The N-glycosylation sites
mediate the formation of trafficking complexes that regulate VMAT2 localization in
large dense core vesicles.
These results were obtained from PC12 cell lines over-expressing VMAT2.
Further, induction of VMAT2 expression in PKA-deficient cells, or in wild-type cells coadministered with a PKA inhibitor, increased trafficking of VMAT2 to synaptic-like
micro-vesicles (Yao et al., 2004).

Co-expression of the PKA catalytic subunit with

VMAT2 redistributed the transporter to large dense core vesicles.

Additionally,

injection of Reserpine into the rat striatum changes the localization of VMAT2 from the
dorsal to the caudal sub-region of the striatum (Naudon et al., 1996).

1.17

VMAT Loss of Function
VMAT2 knockout mice show aberrant neurotransmission of monoamines,

resulting in starvation and early death. VMAT knockout pups survive only up to 2
weeks following subcutaneous administration of amphetamine. Histological analysis of
their cerebral cortex show an increased incidence of cell death, a phenotype
complemented by the inhibition of MAO-A enzyme (Fon et al., 1997; Wang et al.,
1997).
Mice that only express five percent of wild-type Vmat2 levels, by contrast,
develop to adulthood but show weak age-dependent motor loss phenotypes. These
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vmat2 hypomorph mice also exhibit a more selective loss of nigrostriatal
neurodegeneration, along with the associated motor dysfunction phenotypes (Caudle
et al., 2007; Mooslehner et al., 2001).

1.18

Drosophila melanogaster as an Excellent Model to Study VMAT

Regulation and Model PD
Drosophila, a genetic versatile system, is the ideal in vivo model to study the
function and regulation of VMAT and its role in PD. The model organism Drosophila has
long been valued for its elegant genetic tools, short reproductive times, and highly
conserved molecular and cellular pathways.
The fruit fly has been successfully employed to dissect basic signaling
pathways, the patterning mechanisms of multicellular organisms, as well as
mechanisms underlying neuronal development, functions, and diseases (NagarkarJaiswal et al., 2015b; Wangler et al., 2015). Historically, due to its high fecundity, ease
of handling, and shorter generation time, Drosophila has been the ideal model system
for many fruitful genome-wide saturation screens, which have contributed to the
discovery of evolutionarily conserved signaling pathways from Wnt/wingless,
Hedgehog, to Notch (Nagarkar-Jaiswal et al., 2015b; Wangler et al., 2015).
With over a century of genetic manipulations, Drosophila biologists have
established a large arsenal of experimental tools such as targeted gene engineering,
MiMIC-based genome tagging, FRT/FLP-based mosaic analysis, and the UAS/Gal4
binary expression system, among others. The latter technology has been implemented
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in generating fly lines indispensable for anatomical and functional dissection of
neuronal circuitry in the brain (Brand and Perrimon, 1993; Jenett et al., 2012).
These versatile tools allow investigators to control the exact location and
timing of gene expression throughout development. Drosophila has been employed
extensively to study the regulation and function of DA and model related neurological
disorders. Flies also present robust neuronal-based behavioral responses which can
faithfully mimic some of the PD symptoms (Waddell, 2010; Wangler et al., 2015;
Yamamoto and Seto, 2014).
As a classical genetic model organism, the fruit fly is also emerging as an
excellent model for the study of DA neuron loss in PD patients, for the following
reasons: First, the fly has a well-characterized DA neural system with easily identifiable
DA neurons in its CNS. Compared to about 20,000 DA neurons in the mice brains
(Bjorklund and Dunnett, 2007), there are only 280 DA neurons in the protocerebrum of
the adult Drosophila brain (Budnik and White, 1988; Mao and Davis, 2009).
Resembling mammalian DA neuron distribution, the DA neurons in fly brains
are also distributed in clusters in a relatively stereotypical pattern (Figure 1.3A) with
distinct projection patterns that modulate discrete brain functions, including
locomotion, motivation, sleep, arousal, as well as learning, and memory (Bjorklund and
Dunnett, 2007; Mao and Davis, 2009; Waddell, 2010). Equally important, both the
enzymatic pathways regulating DA homeostasis are highly conserved in Drosophila,
including DA synthesis (dTH and dDDC), vesicular packaging (dVMAT), reuptake (dDAT),
and signaling (DA receptors 1 and 2) (Figure 1.3C) (Yamamoto and Seto, 2014).
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Similarly to mammals, DA is synthesized from the precursor amino acid
Tyrosine, through the sequential catalytic activities of the rate-limiting enzyme TH and
DDC (Figure 1.3B). In Drosophila, as is the case with other neurotransmitters, DA is
normally sequestered inside synaptic vesicles (SVs) and dense core vesicles for proper
storage and regulated release.
Drosophila VMAT homolog (dVMAT) on the vesicular membrane pumps and
sequesters cytosolic dopamine into the SVs. Upon stimulation, SVs fuse with the plasma
membrane to release their inner contents. There is only a single dvmat gene that
expresses two splice isoforms, dVMAT-A (hereby known as dVMAT2) and dVMAT-B. The
two VMAT proteins differ only at their very C-termini, which primarily modulates the
dynamics of intracellular trafficking of the corresponding proteins (Chang et al., 2006;
Greer et al., 2005; Grygoruk et al., 2014; Grygoruk et al., 2010; Romero-Calderon et al.,
2008).
dVMAT-A is expressed in all the DA, octopamine and 5-HT neurons in the brain
and optic lobes where it is responsible for the vesicular packaging of these
monoamines (Chang et al., 2006; Chen et al., 2013; Greer et al., 2005; Simon et al.,
2009). By contrast, dVMAT-B shows a more restricted expression pattern. It is expressed
in a layer of glial cells in the eye and is involved in the packaging and recycling of
histamine, the primary neurotransmitter in fly photoreceptor cells (Romero-Calderon
et al., 2008).
Finally, multiple PD genes exist in the fly genome, such as Parkin, Pink1 and
LRRK2. In fact, the PD-related mitochondrial defects were first reported by studying
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parkin mutants in the fly (Guo, 2012). Fly lines carrying mutations for all of these genes
have been generated, and all the reported homozygous mutants are viable as adults
(Guo, 2012). Together, given the high degree of conservation of DA system and PDrelated genes, as well as its abundance of experimental tools, Drosophila is an ideal in
vivo model system to study the regulation and function of VMAT, and to evaluate its
role in PD pathogenesis.

1.19

Challenges in PD Studies and Rationale for this Study
Currently there is no effective preventative or therapeutic methods to treat

PD. Despite extensive studies in different model organisms, the pathogenic
mechanisms underlying PD are still unclear. In PD studies, several important questions
should be addressed. First is on the selective death of DA neurons.
Almost all the PD-associated genes are broadly expressed in the brain and
other tissues, and the cellular pathways implicated in the disease, such as mitochondria
dysfunction and defective protein turnover and aggregate formation, are mostly
systematic and not restricted simply to DA neurons. But why DA neurons are
particularly vulnerable and degenerate in PD brains?
Additionally, why DA neurons in the substantial nigra region are selectively
affected whereas those in the VTA are mostly spared in PD? Lastly, the most important
phenotype of PD, the selective destruction of DA neurons, is barely recapitulated in
most of the established genetic PD models, such as Parkin, Pink1 and DJ-1 knockout or
αSyn overexpression in mice or Drosophila.
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Does this suggest that additional pathogenic factors are required to unmask or
initiate/accelerate the pathogenic events controlled by these PD genes in these model
systems that normally entertain much shorter lifespans than humans, considering that
it takes decades before the considerable loss of DA neurons and the manifestation of
the symptoms in PD patients?
As discussed, a growing body of evidence is implicating DA toxicity and
dysfunctional VMAT as an important and potentially specific contributor of PD
pathogenesis. Despite the long-recognized roles of VMAT in regulating DA function and
its subcellular sequestration, there are limited systematic investigations on its role in
the degeneration of dopamine neurons in the context of animal PD models.
The objectives of this dissertation are to apply the Drosophila model system to
investigate the function and regulation of VMAT, to examine the effect of its depletion
in the survival of DA neurons in a whole animal model, and to further test whether its
disruption can potentiate selective degeneration of DA neurons in a sensitized parkin
mutant background, which by itself does not manifest overt loss of DA neurons.
I expect that outcome of the study should establish a platform for future
functional study of this important regulator of dopamine activity and protection, and
clarify its role in PD pathogenesis, thereby providing clues for potential therapeutic and
intervention avenues. My studies have been grouped into three related topics:

Tito - 28

Aim1: Establish platform to study DA neuron organization and VMAT function in
Drosophila
To facilitate future analysis of VMAT function and DA neurons in an intact brain
tissue, I have developed a more efficient method to dissect and analyze adult
Drosophila brains (Chapter 2).
I have also established new tools to study dVMAT, including an endogenous
Gal4-trap and GFP-tagging lines for the dVMAT gene. I have subsequently
carried out a detailed analysis of DA neurons in adult brains and demonstrated
that in the Protocerebral Anterior Medial (PAM) cluster of Drosophila brain,
where the majority of DA neurons reside, octopamine neurons also exist
(Chapter 3).
Aim2: Functional characterization of VMAT in Drosophila
As a first step for the future functional study of VMAT in Drosophila, I have
characterized the overexpression phenotypes of dVMAT isoforms (Chapter 4).
I have also established a heterologous system to study the subcellular
localization patterns of dVMAT isoforms. I have further examined the
phenotypes of new dVMAT mutant alleles (Chapter 4).
Aim3: Test the “two-hit” PD hypothesis: evaluate whether dysregulation VMAT will
specifically accelerate the loss of DA neurons in parkin mutant animals.
I have tested in the sensitized parkin mutant background, a well-characterized
PD models, whether dysregulation of VMAT can induce selective degeneration
of DA neurons (Chapter 4).
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2

A ONE-STEP DISSECTION OF ADULT BRAINS

2.1

Introduction
The relatively small size of the fruit fly makes it permissive to perform whole-

mount preparations of the adult fly brain, which can be examined with a regular
compound or confocal microscope. This feature enables detailed anatomic and
functional analyses of single neurons and neuronal circuitries, thus providing a better
understanding of their functionality at the cellular and subcellular levels.
With recent advances in cell labeling and imaging technologies, the fruit fly’s
brain has become especially powerful in fine mapping of neuronal circuitry and in
dissecting the molecular and cellular basis of higher brain functions such as learning,
memory, and circadian rhythm (Aso et al., 2014; Nern et al., 2015; Reiter et al., 2001;
Waddell, 2016; Wangler et al., 2015; Wolff et al., 2015; Yamagata et al., 2015).
However, the rather miniature size of the brain also makes it technically
challenging to isolate an intact brain from the protective head case. Various effective
dissection methods have been described in detail, which involve careful and step-wise
removal of the head case and the associated tissues, including the eyes, trachea, and
fat from the brain proper (Sweeney et al., 2011; Wu and Luo, 2006).
These microsurgical dissection methods often place rather stringent demands
on the quality of the dissection forceps, requiring forceps with fine well-aligned tips
that can be easily damaged. Moreover, the dissected brains can be easily lost during
the subsequent staining and washing processes since they are separated from the rest
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of the body.

Their small sizes and transparency makes it difficult to see in the

processing buffer. Here, we describe a relatively simple and easy-to-learn, one-step
dissection protocol that keeps the dissected brains attached to the torso. The
dissection process clears away most of the brain-associated tissues, such as the eye,
and reduces the demand for good quality dissection forceps.
Additionally, when imaging the brain under the fluorescent compound
microscope or confocal microscope, the side of the brain that is away from the
fluorescent light source often produces a weaker signal and less clear images due to
the thickness of the whole-mount brain. Here, we also describe a simple mounting
method that allows easy flipping of the brain samples, enabling convenient imaging of
both sides of the brain with similar signal intensity and quality.
As a proof-of-concept for the application of this method, we further examined
the presence of DA neurons in the brains of w1118 flies; a genotype that is often used as
the parental line for generating transgenic flies and the wildtype control in many
Drosophila studies.
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2.2

Results
TH controls the rate-limiting step in DA synthesis and is the enzyme specific for

DN. Using immunofluorescent staining with anti-TH antibody on whole-mount adult
brains, we analyzed the presence and distribution of DN in the protocerebrum from
w1118 flies (Figure 2.2).
Figure 2.1 illustrates the main procedures for adult brain dissection. Figures
2.2 and 2.3 are representative images of 3-day-old w1118 adult fly brains, which were costained with an antibody against tyrosine hydroxylase (TH, colored in red in Figure 2.2
and white in Figure 2.3), in addition to the DNA dye DAPI that labels all the cell nuclei,
and an antibody against Elav protein, which is a marker for all differentiated neurons in
the fly (colored in green). Taken together, IF staining with these markers revealed the
overall structure of the brain.
We grouped the DN into different clusters largely following the early
designation (Mao and Davis, 2009) (Fig. 1.3a). Figures 2.2A-D and 2.3 A and C show
the anterior view of a brain, whereas Figures 2.2 E-H and 2.3 B and D show the
posterior view of the same brain after flipping the cover slips that hold the brain
samples, which display a similar level of signal intensity between two sides of the brain
for all the three imaged channels.
The panels in figure 2.3 show anterior and posterior views of the same brain in
high-magnification, revealing the different clusters of DN on both sides of the brain.
The DN were grouped into different clusters following the early designation (Mao and
Davis, 2009), although here we use the name Paired Posterior Medial (PAM); Paired
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Posterior Medial (PPM) to include the PPM1, PPM2, and PPM3 clusters at the anterior
side of the brain; and the name Paired Posterior Lateral (PPL) to cover the PPL1 and
PPL2 clusters from the posterior side of the brain, as depicted in Figures 2.3A (Anterior
view) and 2.3B (Posterior view). The white dashed lines highlight the prominent PAM
and Paired Anterior Lateral (PAL) clusters in the anterior side of the brain (Figure 2.3A)
as well as the PPL and the PPM clusters in the posterior side of the brain (Figure 2.3C).
Figure 2.4A and 2.4B show quantification results for DN clusters in w1118 flies.
We counted DN slice by slice and also from 3-D reconstructed images, which should
prevent the generation of imprecise results. We estimate that the 3-day-old w1118 flies
have an average of 27 DA neurons in the PPM clusters of the whole brain, 16 DN in the
PPL cluster per hemisphere, 5 DN in PAL cluster per hemisphere (Figure 2.4A), and 97
DN in each of the PAM clusters (Figure 2.4B).
Figure 2.4C is a representative 3-D reconstruction of DA neurons in the PAL
and PAM clusters, projected from high-magnification images. It is apparent that
compared to other clusters such as the PAL, DA neurons in the PAM cluster have
relatively smaller cell sizes and weaker TH staining signal.
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Figure 2.1: Graphical illustration of the dissection protocol for adult Drosophila brain.
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(A) Flies are positioned with the anterior side upwards, and held by the thorax using
the non-dominant hand. Force was gently applied (red arrows) to the forceps to induce
backward tilting of the fly head and slight outward extension of the proboscis, exposing
the white transparent region below. (B) Forceps are inserted in the transparent region
beneath the proboscis, creating a shallow incision. Note that the forceps we use do not
have very fine tip ends. (C) Forceps are allowed to come apart through its own force.
The momentum generated by opening the forceps removes the eyes and exoskeleton,
exposing a relatively clean Drosophila brain. Most of the trachea are removed in the
process. (D) Excess tissue surrounding the brain is removed for full exposure of the
brain proper.
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Figure 2.2: Adult fly brain morphologies are preserved

Tito - 36

This figure depicts representative images of dissected adult brains, reconstructed using
Z-stacked images of the brain region of interest obtained with the compound
fluorescent microscope. (A-D) Anterior and (E-H) Posterior views of the same adult
brain; (A & E) Cell nuclei were imaged by DAPI staining (white) and (C and G) neurons
were labeled by pan-neuronal marker anti-Elav antibodies (green); (B & F) DN are
revealed by anti-TH antibodies (red). (D & H) Overlay of images for DAPI, TH and Elav
treatment. (E & J) Enlarged view of the brain regions with DN shown in white. All
genotypes are adult males of w1118 flies. Scale bars = 20 µm.
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Figure 2.3: DN revealed with anti-TH antibody in the adult male and female
Drosophila brain (acquired with 20X objective).
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(A-D) Anterior (A and C) and posterior (B and D) views of DA neuron distribution in
wildtype adult Drosophila brain.
PAM cluster neurons are located near the antennal lobe regions. (A & C) Anterior and
(B & D) Posterior views of the same adult brain; (A-D) DN are revealed by anti-TH
antibodies (red). (D) Overlay of images for TH and Elav treatment. All genotypes are
adult (A & B) males and (C & D) females of w1118 flies. Scale bars = 20 µm.

Tito - 39

Figure 2.4. Quantification of DN in brains of male adult w1118 flies (acquired with 40X
objective).
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(A-B) Quantification of DN, revealed by anti-TH staining. Data are represented by
whisker box plots showing minimum and maximum values as the outliers; as well as
the first, second and third quartiles. The second quartile is represented as the mean
(average) value. (A) PPM (n = 28) Min: 21, Q1: 24, Average: 27, Q2: 30, Max: 32, PPL (n
= 26) Min: 10, Q1: 12, Average: 16, Q2: 18, Max: 25, and PAL (n = 24), Min: 2, Q1: 4,
Average: 5, Q2: 5, Max: 10 clusters; and (B) PAM (n = 20) Min: 86, Q1: 94, Average: 97,
Q2: 97, Max: 99 cluster of day 3 male w1118 flies. (C) A representative projection image
showing DN in the PAM and PAL clusters of male w1118 flies at day 3. Scale bar
represents 20 µm.
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2.3

Discussion
With an increasing interest in using adult Drosophila brain to study human

brain diseases, neuronal circuitry, and higher brain functions, it is important to develop
simple and quick methods to harvest intact fly brains for whole-mount analyses. These
will be especially important in supporting large-scale brain-based screens.
Our method provides a simple and easy-to-learn approach to dissect out a fly
head (often in less than 10 seconds with gained experience) and obtain samples with
well-preserved morphology and largely devoid of associated tissues. Our method also
significantly minimizes sample loss, which can be a prominent issue in processing brain
samples of tiny sizes.
As the dissected brains are still attached to the rest of the fly bodies, they
quickly sink to the bottom of the sample tube and are not easily lost during the
washing and staining steps. Therefore, our method provides a robust way to perform
the washes without losing the brains in the pipette tip. The brains are then detached
after completion of the staining procedure. As shown in the representative images in
Figures 2.2-2.3, brains prepared using this protocol produce satisfactory results.
Previous characterization of DN in adult Drosophila brains, including fly
models of human disease genes, such as parkin mutants, have largely focused on the
PAL, PPL, and PPM clusters with relatively large cell sizes and prominent expression of
TH (Kim et al., 2012; Pesah et al., 2004; Trinh et al., 2010; Whitworth et al., 2005; Yang
et al., 2006). However, the majority of DA neurons in the fly brain are found in the
PAM clusters, with about 100 DN per hemisphere.
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DA neurons in the PAM cluster show reduced protein levels of TH and have
smaller cell sizes, in contrast to other DN clusters. DA neurons in the PAM cluster can
be clearly imaged at high resolution following our dissection and staining method,
which circumvents the need for a confocal microscope. Given the large number of DA
neurons in the PAM cluster, our method allows for the incorporation of a larger sample
size. We suggest that the DA neurons in the PAM cluster represent a useful system for
studying DA biology and model DA-related disorders, such as PD.
The improved microsurgical technique is effective in saving time and providing
morphologically preserved, well-structured, brain samples, which is useful in studying
the anatomical areas of interest in detail. Visualization of DN in the adult brain serves
as a putative strategy to study various genetic manipulations and toxins that can
contribute to DN degeneration.
Moreover, our method significantly reduces the dissection time, which is
crucial for the investigation of kinase activities in vivo. Our procedure minimizes the
time of dissection from 2-5 minutes to less than 10 seconds, which is important to
probe for the kinase activity of LRRK2. For instance, the kinetic activities of enzymes,
such as PKA and LRRK2, may become compromised in brain samples that are not
placed on ice, quickly after dissection.
This three-step method also enhances the brain sample quality by facilitating
the removal of almost all trachea and cuticle, which normally interfere with the
imaging process. The previously defined adult brain dissection techniques (Luo, L. &
Wu, J., 2006 and Sweeney, S. et al. 2011) detach the head from the body. The brain
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tissues are exposed by carefully holding the anterior and posterior ends of the head.
This can prove difficult for students and novice investigators. The simple action of
releasing the forceps on the head case, as shown in Figure 2.1c, leaves the brain
attached to the body and does not induce damage to the brain.
Critical steps for the protocol involve positioning the fly correctly in the CSF,
maintaining the proper angles when removing the exoskeleton from the fly head, and
providing the right amounts of force required in performing each step. In the event
that the head is removed from the body, it is recommended to hold the head from the
dorsal side of the heads while using the forceps in the dominant hand to remove the
head case. It is also not required that the investigator performs the protocol in less
than 10 seconds.
Overall, the investigator must pay careful attention not to squeeze the
abdomen too tightly, as this will only damage the internal organs of the fly.
Nevertheless, it is preferable for the investigator to master the procedure in
dispensable flies before attempting to work on the experimental samples.

Also, the

best way to assess for changes in neuronal survival is to count the neurons on each thin
section of the z-stack, which is particularly relevant for studying the PAM cluster.
Although our method significantly reduces the time required to perform each
dissection, it is limited, in that, it is difficult to maintain consistent forces across
experimental trials.

The technique requires a significant amount of focus from the

investigator and a lot of time to master. It is also complicated by the fact that hands
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become tired after performing the experiments for long periods of time. Hence, it is
recommended for the investigator to take breaks during the experiments.
Finally, brain studies of the adult fly often require imaging cells on both sides
of the same brain. For example, DA neurons are present in clusters of both the anterior
and posterior sides of the brain. However, due to its thickness, the side away from the
light source usually yields weaker signals and less clear images.
Mounting the samples in between two cover slides allows for the convenient
flipping of the brains, which is useful in imaging both sides of the same brain with
similar signal intensities. Figures 2.2-2.3 show images of DA neurons in both sides of
fly brains, resulting in a relatively comparable signal intensity and imaging quality.
In our experience, the apotome function from a Zeiss compound fluorescence
microscope can significantly reduce the background signal from imaging the fly brains.
Although the confocal microscope produces images with more details, higher
magnification and better quality, it is often time-consuming and costly.
This is especially true for imaging a large number of thick samples that require
series of Z-stack section for clear 3-D reconstruction and deconvolution analysis. In this
perspective, the apotome function represents a fast and cost-effective alternative for
producing images of sufficient quality (e.g., images in Figures 2.2 and 2.3), which may
become applicable for the imaging of other organ types of other species.
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3

NEURONAL COMPOSITION OF THE PAM CLUSTER

3.1

Introduction
In mammals, the DA-synthesizing neurons are organized into nine discrete

clusters that project to different regions of the brain and modulate diverse types of
neurological activities (Konrad and Marsh, 1987; Lauvrak et al., 2005; Lee et al., 2008;
Lundell and Hirsh, 1994). Notably, not every cluster is equally vulnerable to
pathological conditions. In particular, the progressive loss of DN in PD patients
primarily occurs in the pars compacta of the substantia nigra (SNPC), a region with a
high density of DN (Damier et al., 1999; Gibb and Lees, 1991). Yet, the cause for such
selectivity is unknown.
In Chapter 1, I introduced how Drosophila, a classic genetic model organism,
can be employed to study the regulation and function of DA and to model related
neurological disorders including PD (Waddell, 2010; Wangler et al., 2015; Yamamoto
and Seto, 2014). Resembling those in mammals, the DA neurons in fly brains are
distributed in clusters in a relatively stereotypical pattern (Figure 1A) with distinct
axonal projections that modulate discrete brain functions, including locomotion,
motivation, sleep and arousal, as well as learning and memory (Bjorklund and Dunnett,
2007; Mao and Davis, 2009; Waddell, 2010).
Notably, the majority of DA neurons in fly brains are contained in two
protocerebral anterior medial (PAM) clusters, with about 100 neurons per hemisphere
(Budnik and White, 1988; Mao and Davis, 2009). Although these PAM cluster DA
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neurons mainly project to the medial lobes of the mushroom bodies, distinct subsets of
DA neuron projections have been shown to innervate different regions of the medial
lobes and mediate a diverse set of distinct functions. These include reward signals for
short- and long-term memories and startle-induced locomotion(Burke et al., 2012;
Huetteroth et al., 2015; Liu et al., 2012; Mao and Davis, 2009; Riemensperger et al.,
2013; Yamagata et al., 2015).
Although these functions are linked to monoamine neurotransmission, it is not
clear whether the relatively tightly packed PAM cluster also contains other
catecholamine synthesizing neurons apart from DN. In this chapter, I will present an
in-depth characterization of the types of neurons present in a relatively understudied
area of the adult fly brain.
In Drosophila, the cellular machineries involved in DA synthesis and
regulation, such as DA transporters dVMAT and dDAT, synthetic enzymes dTH and dDDC
are also highly conserved.

The Gal4-based enhancer trap lines have been

indispensable for anatomical and functional dissection of neuronal circuitry in the fly
brain (Brand and Perrimon, 1993; Jenett et al., 2012).
To characterize the tools useful in studying the PAM cluster in detail, we
compared several existing Gal4 lines and further generated a new vmat-Gal4 driver line
and an endogenous GFP-tagging line for vmat gene that expresses VMAT-GFP fusion
protein from its own native genomic loci. Both the vmat-derived reporter lines can
largely recapitulate the endogenous expression pattern of vmat gene, including its
prominent expression in the PAM cluster neurons.
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Analyses of these lines reveal that, in addition to the predominant DN, the
PAM cluster also contains a small number of octopamine neurons. This raises an
interesting possibility that DA and octopamine neurons in the PAM cluster might form a
functional circuitry to mediate brain functions, such as learning and memory.
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3.2

Results

3.2.1 Distribution of DA Neurons and DA in the Adult Drosophila Brains
TH controls the rate-limiting step in DA synthesis and is an enzyme that is
specifically expressed in DA neurons. Using immunofluorescent staining with anti-TH
antibody on whole-mount adult brains, we analyzed the presence and distribution of
DA neurons in the protocerebrum from w1118 flies (as shown in Figures 2.2 and 2.3). We
grouped the DA neurons into different clusters, largely following an early designation
scheme (Mao and Davis, 2009) (Fig. 1.3A).
Consistent with previous reports (Mao and Davis, 2009), 3-day-old fly brains
have an average of 27 DN (n = 28, SD = 0.93) in the PPM cluster in the whole brain; 97
DA neurons (n = 20, SD = 1.01) in each of the two PAM clusters (Figure 3.1 G); 16 DN
(n = 26, SD= 0.96) in each of the two PPL clusters; and 5 DA neurons (n = 24, SD = 0.31)
in each of the two PAL cluster (Figure 3.1 H).
Anti-TH staining also revealed the relatively smaller sizes and weaker levels of
TH expression in DA neurons of the PAM cluster (e.g., highlighted in dashed cycle in
Figure 3.1E and F) as compared to those in other clusters, such as the neighboring PAL
cluster (yellow arrows in Figure 3.1E and 2F).
Although DA neurons in PAM clusters are tightly packed, we noticed stretches
of TH-negative areas (yellow arrows in Figure 3.1C and 3.1D). Additionally, in some
brains we found that DN in PAM clusters are tightly packed together, while in others,
they are more dispersed (Figure 3.1E and F).
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3.2.2 Expression of multiple DA Pathway Gal4 Drivers in the PAM
Cluster Neurons
We next examined a collection of Gal4 lines involved in the synthesis of DA,
derived from the th and ddc genes; and those involved in the regulation of DA, derived
from the dat gene. Gal4-expressing cells were labeled with membrane-associated
fluorescent protein reporters including UAS-mCD8::GFP, UAS-mCD8::RFP or UASLamin::GFP, and double stained with anti-TH and anti-GFP or anti-RFP antibodies.
A TH-Gal4 line, generated using a ~11kb genomic DNA fragments from the dth
gene that covers ~4.3 Kb of its 5’ regulatory region in addition to about 7Kb of its
coding and 3’ UTR region, has been used extensively to monitor DN in the fly brains
(Friggi-Grelin et al., 2003).
DDC controls the last step of DA synthesis, converting L-Dopa to DA (Figure
1.3B). In addition to DA, DDC is also required for the synthesis of neurotransmitters
serotonin from L-5-hydroxytryptophan, and thus it serves as a marker for both DA and
serotonin neurons. A DDC-Gal4 line, generated using a 7.5kb genomic DNA fragment
encompassing the dDdc gene, has been used to examine and manipulate DA and
serotonin neurons in the fly brains (Li et al., 2000).
Consistent with previous reports (Friggi-Grelin et al., 2003; Liu et al., 2012;
Mao and Davis, 2009), for DA neurons in the PAM cluster, a majority can be labeled by
DDC-Gal4 but only a small number of them are positive for TH-Gal4 (data not shown).
DA-specific DAT functions to recycles synaptic DA back into the cytosol of DA neurons
and terminate DA action (Torres et al., 2003).
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A PAM-specific Gal4 driver, R58E02-Gal4, was generated using a 1,235 bp
fragment from the first intron region of dDat gene (Liu et al., 2012; Pfeiffer et al.,
2008). Double labeling with mCD8-RFP (Figure 3.3A-D) or Lamin-GFP (Figure 3.2 C and
E) reporters and anti-TH antibody labels the projections from the DA neurons and
reveal that a majority of neurons in the PAM clusters are positive for both markers.
Specifically, the R58E02-Gal4 are expressed in the majority of TH-positive
neurons (white arrows in Figure 3.2E), in addition to a small number of TH-negative
neurons (yellow arrows in Figure 3.2E) in the PAM cluster. Note that the R58E02-Gal4
expression is absent from other DN clusters (e.g., PAL neurons in Figure 3A) in the
brain, as previously reported (Liu et al., 2012).
Thus, similar as to the TH-Gal4 and DDC-Gal4 lines, the genomic fragment
used to make the R58E02-Gal4 construct lacks the full regulatory elements controlling
the proper expression of the native dDat gene in the brain. Consistent with the
previous reports (Liu et al., 2012; Mao and Davis, 2009), R58E02-Gal4-positive neurons
mainly project to the medial lobes of the mushroom bodies, as revealed by the
membrane-bound mCD8-RFP reporter and double stained for mushroom body-specific
anti-FasII antibody (Figure 3.3 A-D).
Recent studies reveal a reinforcement circuitry for learning and memory
through DA and octopaminergic neurons in Drosophila brain (Burke et al., 2012;
Huetteroth et al., 2015). Consistent with this finding, an -adrenergic-like octopamine
receptor OAMB (Octopamine receptor in mushroom bodies) is highly expressed in a
subset of DN in the PAM cluster (Han et al., 1998), a pattern that is also captured by
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the R48B04-Gal4 driver line, whose expression is controlled by a genomic fragment
from the oamb promoter regions (Huetteroth et al., 2015; Jenett et al., 2012; Yamagata
et al., 2015).
Examination of the R48B04-Gal4 line confirmed its expression in about 80% of
TH-positive DN, in addition to a small number of TH-negative neurons within and
around the PAM cluster (examples indicated by yellow arrows in Fig. 3.4C). Additionally,
R48B04-Gal4 also labels some cells within the optic lobes, as previously reported (data
not shown) (Huetteroth et al., 2015).
Notably, R48B04-Gal4 expressing neurons innervate almost all the mushroom
body structures, including both the vertical lobes and the horizontal lobes (compare
the trident-like structure on Figure 3.5 with the mushroom body structures revealed by
anti-FasII staining in Figure 3.3B). This is in contrast to the rather restricted projection
to primarily the medial lobes by the dDat promoter-derived R58E02-GAL4 line (Figure
3.3D), which closely resembles the results obtained from independent oamb-Gal4
lines, harboring the complete promoter regions of oamb gene (El-Kholy et al., 2015).
These results are also in line with the broader expression of oamb gene, observed
outside the PAM cluster neurons (Figure 3.5A and B).

3.2.3 MiMIC-derived VMAT-Gal4 and VMAT-GFP lines recapitulate the
Endogenous VMAT Expression Pattern
To generate vmat-derived marker lines that can label DA and other
monoamine neurons in the brain, we utilized the recently developed Minos-mediated
integration cassette (MiMIC) technique (Nagarkar-Jaiswal et al., 2015a; NagarkarJaiswal et al., 2015b; Venken et al., 2011). We used a coding intronic insertion MI07680
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for EGFP tagging of endogenous VMAT, that we called VMATMI-GFP; and a 5’ UTR intronic
insertion MI03756 for creating a VMAT-Gal4 line, that we called VMAT-Gal4MI03756.
More specifically, the MI03756 line is inserted in the 5’ regulatory region of
vmat, in-between the first two non-coding exons. We then examined the expression
pattern of the VMAT-Gal4MI03756 along with UAS-Lamin::GFP, which marks the nuclear
membrane and thus allow more clear identification of individual cells. The VMATGal4MI03756 line shows similar expression pattern as endogenous dVMAT proteins
(Figure 4 and data not shown).
Importantly, in the PAM cluster, which is prominently labeled by the VMATGal4MI03756, all TH-expressing DN are positive for Lamin-GFP reporter (white arrows in
Fig. 4F). Outside of the PAM cluster, except for a cluster of DN around the esophagus
region in the ventral brain, almost all the other TH-expressing neurons were labeled by
VMAT-Gal4Mi03756, including numerous cells within the optic lobes and the clusters of
DN in the protocerebrum (Figure 3.6A-B).
MI07680 is inserted in a coding intron in-between exon 5 and 6 near the 3’ of
vmat gene, thus the expression of EGFP tagged gene is controlled by the native
regulatory elements. Indeed, the VMAT-EGFP fusion protein expressed from VMATEGFPMI07680 line closely mirrors the expression pattern of endogenous dVMAT protein
(Figure 3.7).
For example, VMAT-EGFP co-localizes with all the TH-positive DN in the PAM
clusters and in other brain regions (white arrows in Fig. 3.7C and data not shown).
Together, they support that both the MiMIC-derived VMAT-Gal4MI03756 driver and the
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VMAT-EGFPMI07680 line can largely recapitulate the endogenous expression pattern of
vmat gene, and thus can be used as new tools to analyze DA and other monoamine
neurons in Drosophila.

3.2.4 VMAT-positive PAM cluster is primarily composed of DA and
octopamine neurons
Examination of the two VMAT reporter lines also revealed that, within the
PAM clusters, a number of VMAT-expressing neurons do not express TH (yellow arrows
in Figure 3.6F and 3.7C and 3.9C), suggesting that besides DN, the PAM cluster also
contains other types of monoamine neurons. Notably, these TH-negative PAM neurons
show relatively higher levels of VMAT expression and mostly have larger cell sizes when
compared to the neighboring TH-positive neurons within the same cluster, as observed
in both VMAT-EGFPMiI7680 and VMAT-GAL4MI03756 lines (yellow arrows in Figures 3.6F,
3.7C and white arrowheads in Figures 3.9A-D and 3.10 D).
These “VMAT-expressing, TH-negative” neurons are

unlikely to be

histaminergic, which mainly utilizes histamine as a neurotransmitter for phototransduction in the eye (Hardie, 1987; Sarthy, 1991). To determine their identities, we
next performed co-immunofluorescence studies on the adult brain from the two VMAT
reporter lines. Staining with anti-Serotonin antibody revealed no serotonin-positive
neurons in the PAM cluster (data not shown), which is consistent with the previous
studies on the distribution of serotonin neuron that largely exclude its presence in the
PAM cluster region (Liu et al., 2012; Sitaraman et al., 2008; Valles and White, 1988).
Given that serotonergic and histaminergic neurons are not present in the PAM
cluster, it suggests that octopaminergic neurons, another class of monoamine
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producing neurons, could be part of this PAM cluster. The neuronal TDC2 enzyme is
required for the synthesis of octopamine from precursor tyrosine (Figure 1.3B), and a
TDC2-Gal4 line has been used to label octopamine neurons (Cole et al., 2005;
Monastirioti et al., 1996).
Co-labeling with anti-TH antibody revealed about fifteen TDC2-Gal4 expressing
cells located within or near the TH-positive PAM cluster (Figure 3.8A and 3.9A,
indicated by yellow arrows in Figure 3.8C). This group of TDC2-Gal4 neurons are
reminiscent of the “anterior superior medial (ASM)” cluster of octopamine neurons
described in a previous study using the same TDC2-Gal4 (Busch et al., 2009), located
near the similar region.
Furthermore, most of these TDC2-Gal4 positive neurons also have relatively
larger cell sizes. Together, they suggest that the “VMAT-expressing, TH-negative” cells in
the PAM cluster are octopamine origin. Consistent with this conclusion, when the mitoRFP reporter driven by TDC2-Gal4 was expressed in VMAT-EGFPMI07680 brains, mito-RFP
signal largely overlapped with the GFP-positive cells (white arrows in Figure 3.9A-D and
3.10D). Collectively, they support that the “VMAT-expressing, TH-negative” neurons in
the PAM cluster are octopamine neurons, and the PAM cluster is primarily comprised
of DA and to a lesser extent octopamine neurons.

Tito - 55

Figure 3.1: DA system in adult Drosophila brain.
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DN in the PAM cluster region of adult Drosophila brain.
(A-D) immunofluorescent imaging of 3-day-old male brains visualized with DNA dye
DAPI for cell nuclei (A, white), pan neuronal marker anti-ELAV antibody (B, green), antiTH antibody for DN (C, red), and their overlaid images (D). Yellow arrows in (C) indicate
apparent gaps among the TH-positive neurons in PAM clusters. PAM cluster neurons
are located near the antennal lobes.
(E and F) Examples of variable distribution pattern of DN in the PAM clusters (outlined
by red dashed lines) from two individual adults, revealed by anti-TH antibody. PAM
cluster DN in (E) are more dispersed than those in (F). Yellow arrows in E and F point to
PAL cluster of DN. (G) Quantification of DN in the PAM cluster. There is an average of 96
DN per hemisphere in 3-day-old (n = 20, SD= 1.01). (H) Quantification of DN in PPM,
PPL, and PAL clusters at day 3. There is an average of 27 DN in the PPM cluster (n = 28,
SD = 0.93) from the whole brain, as well as 16 and 5 DN per hemisphere in PPL (n = 26
SD= 0.96) and PAL (n = 24, SD = 0.31), respectively. All genotypes are adult males of
w1118 flies. Scale bars in (A-F) represent 20 µm, while scale bars in (I and J) represent 50
µm.
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Figure 3.2: Expression patterns of the R58E02-Gal4 line in the PAM cluster region
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(A-B) TH expressing DN in the PAM cluster region of the left and right hemisphere. (CE) R58E02-Gal4 is expressed in almost all the DN in the PAM cluster (white arrows in E
indicate examples of overlapping expression). Note that some GFP-positive cells do not
express TH (yellow arrows in E). All images are from anterior view of w1118 male brains.
Scale bars in (A-I) represent 20 µm.
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Figure 3.3: Projection patterns of the R58E02-Gal4 line in the PAM cluster region
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The projection patterns of the Gal4 line in the PAM cluster was revealed mCD8-RFP
reporters (red in A-D). The brains were also co-stained for anti-TH antibody (green in
A). R58E02-Gal4 line mainly projects to the medial lobes (white arrows) in the
mushroom bodies , as revealed by the overlap between the mCD8-RFP reporter (red)
and the mushroom body marker anti-Fas II (cyan in B and white in overlaying image D).
All images are from anterior view of w1118 male brains. Scale bars in (A-I) represent 20
µm.
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Figure 3.4: Overlapping but distinct expression patterns of Oamb-GAL4
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(A-C) R48B04-Gal4 line is expressed in only a subset of DN (white arrows) in the PAM
cluster, in addition to some neighboring non-DN (yellow arrows) nearby (C). In (C)
white arrows indicate examples of cells co-expressing both TH and GFP markers, while
yellow arrows indicate GFP-expressing cells that are negative for TH.

All images are

from anterior view of w1118 male brains. Scale bars in (A-C) and (D-E) represent 20 µm
and 50 µm, respectively.
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Figure 3.5: Overlapping but distinct projection patterns of Oamb-GAL4
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(A-B) R48B04-Gal4 projects to both lateral and vertical lobes of the mushroom bodies.
The expression and project patterns of the Gal4 line in the PAM cluster was revealed by
Lamin-GFP (green in B) and mCD8-RFP (red in D) reporters, respectively, as indicated.
The brains were also co-stained for anti-TH antibody (green in E, and red in B), as
indicated. All images are from anterior view of w1118 male brains. Scale bars in (A-C)
and (D-E) represent 20 µm and 50 µm, respectively.
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Figure 3.6: Expression pattern of VMAT-Gal4 line in adult brains
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Fluorescence images of an adult brain expressing Lamin-GFP reporter (green) driven by
VMAT-Gal4, co-stained with anti-TH (red) antibody. Except for cells around esophageal
region at the ventral brain, almost all the TH-expressing cells in the adult head and
optic lobes overlap with Lamin-GFP. (C, D & F) High-magnification view of the PAM
regions (highlighted in yellow dashed circles in (A)). All TH-positive neurons co-express
Lam-GFP (examples as indicated by white arrows in F). Also note the existence of nonDArgic neurons in the PAM cluster (examples as highlighted by yellow arrows). Purple
insert in (A) shows DAPI staining for cell nuclei to outline the overall morphology of the
whole brain. Images are from anterior of the brain. All genotypes are adult males of
w1118 flies. Scale bars = 50 µm in (A-C) and 20 µm in (D-F).
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Figure 3.7: Octopamine neurons in the PAM cluster of VMAT-Mi-GFP
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(A-C) Expression pattern of VMAT-GFP tagging line in the PAM region showing its
predominant overlap with the majority of DN, as revealed by anti-GFP (A, white) and
anti-TH (B, red) antibodies and their overlaying images (C). Note the presence of THnegative cells (yellow arrows in C) in the middle of the GFP-expressing PAM cluster.
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Figure 3.8: Octopamine neurons in the PAM cluster of VMAT-Mi-GAL4
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(A-C) Distribution of octopamine neurons in the PAM cluster, revealed by the
expression of Lam-GFP (green in A) reporter driven by TDC2-Gal4. Note the localization
of octopamine neurons (green in A, C), also highlighted by yellow arrows in C, with the
region outlined by dashed lines shown at higher magnification in C), showing larger cell
sizes, within and around the TH-expressing DN (red in B and F) in the PAM cluster.
All images are anterior view of the brain. All genotypes are adult males of w1118 flies.
Scale bars = 20 µm in (A-F) and 50 µm in (G-J), respectively.
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Figure 3.9: Zoom-in of octopamine neurons in the PAM cluster
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(A-D) Overlapping expression of TDC2-Gal4 driver and VMAT-GFP reporter in the PAM
cluster, as revealed by UAS-mito-RFP reporter (red in A, C, and D) and anti-GFP
antibody (green in B, and D), respectively, co-stained with anti-TH (white in B and C) for
DN. (B-D) Overlaying images of (B) anti-TH and anti-GFP, (C) anti-TH and anti-RFP, as
well as (D) anti-GFP and anti-RFP staining. White arrowheads indicate “TH-negative,
VMAT-GFP-expressing” neurons that overlap with Tdc2-Gal4-expressing cells,
supporting that they are octopaminergic.
All images are anterior view of the brain. All genotypes are adult males of w1118 flies.
Scale bars = 50 µm in (A-D).
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Figure 3.10: Zoomed-in view of octopamine neurons in the PAM cluster
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(A-D) shows the high-magnification view of the regions highlighted by dashed lines in
(Figures 9 C, F, I and J). (A) Zoom in showing expression pattern of VMAT-GFP tagging
line in the PAM region showing its predominant overlap with the majority of DN, as
revealed by anti-GFP (white) and anti-TH (red) antibodies. Note the presence of THnegative cells (yellow arrows in A) in the middle of the GFP-expressing PAM cluster.
(C) Distribution of octopamine neurons in the PAM cluster, revealed by the expression
of Lam-GFP (green) reporter driven by TDC2-Gal4. Note the localization of octopamine
neurons (green), showing larger cell sizes, within and around the TH-expressing DN
(red) in the PAM cluster.
(B and D) Zoom in of anti-GFP and anti-RFP staining. Overlapping expression of TDC2Gal4 driver and VMAT-GFP reporter in the PAM cluster, as revealed by UAS-mito-RFP
reporter (red) and anti-GFP antibody (green in D), respectively, co-stained with anti-TH
(white in B) for DN. White arrowheads indicate “TH-negative, VMAT-GFP-expressing”
neurons that overlap with Tdc2-Gal4-expressing cells, supporting that they are
octopaminergic.
All images are anterior view of the brain. All genotypes are adult males of w1118 flies.
Scale bars = 20 µm in (A and C) and 50 µm in (B and D), respectively.
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3.3

Discussion
In this chapter, we focus on the cellular characterization of the PAM cluster, a

small defined region in the adult fly brain that contain the majority and also the highest
concentration of DN, with a total of about 200 out of all the ~280 DN in the brain
(Budnik and White, 1988; Mao and Davis, 2009). The PAM clusters are often not
extensively analyzed in many DA-related studies in Drosophila, which might be due to
the difficulty in examining the DN in the PAM cluster with a relatively weaker THexpression level and smaller cell sizes.

Examination of the existing DA-related Gal4

lines shows variable patterns of expression of these drivers in the PAM cluster.
Using the MiMIC-based gene conversion approach, we established a new
VMAT-Gal4 driver and an endogenously tagged VMAT-EGFP line and showed that these
lines recapitulate the expression pattern of endogenous VMAT.
recently reported a VMAT-T2A-Gal4 driver line, as well.

Gnerer J. et al.

However, they applied the

revised T2A-protein trap method to incorporate the Gal4 gene into the same MI07680
line, and it has not been determined whether this inserted T2A cassette disrupts the
normal splicing and translation of VMAT (Gnerer et al., 2015).
In contrast, the MI03756 line is inserted in the 5’ regulatory region of vmat, inbetween the first two non-coding exons, thus the established VMAT-GaAL4MI03756 line
may not interfere with the translation of the encoded VMAT proteins. Additional
studies are needed to compare the expression pattern of these two VMAT-GAL4 lines
and their effects on the expression of native VMAT proteins. Since the vmat-derived
lines are expressed in all monoamine neurons (Figure 3.6 and data not shown) they
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would be useful tools for dissecting the anatomic connections and functional
interactions among these monoamine neurons in Drosophila brain.
An interesting question about the relatively tightly packed PAM clusters is that,
apart from harboring the majority of DN, whether they contain other neuronal cell
types and whether they operate together as an integrated functional unit in
modulating animal behaviors. By analyzing the two VMAT-marker lines, we show that,
in addition to containing the majority of DN, VMAT-positive PAM cluster also contains a
small number of octopamine neurons.
Interestingly, recent studies have demonstrated functional connections
between octopamine and DA signaling in various high functions, such as memory
formation and sleep/wakefulness regulation. For instance, it has been shown that
octopamine neurons mediate wakefulness by connecting with DN of the PAM clusters,
and an increase of octopamine signaling leads to an increase in wakefulness of the
animal due to excess DA release in the brain (Crocker and Sehgal, 2008).
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TRANSPORTER 2 AND ITS ROLE IN PD PATHOGENESIS
4.1

Introduction
Animal models of PD show a loss of VMAT2 activity, a deficiency that is not

observed in monkey models with acute destruction of DN of the brain induced by DA
neuron toxin, MPTP (Pifl et al., 2014). Conversely, in both mouse and Drosophila,
targeted overexpression of VMAT2 and dVMAT2 protects DA neurons from MPTP and
other environmental toxicants (Inamdar et al., 2013; Lawal et al., 2010; Lohr et al.,
2014).
Furthermore, the catechol-based structure of DA makes it into a chemically
labile molecule and a potential toxin. When exposed to free oxygen in a pH-neutral
cytosol, DA can be spontaneously oxidized to toxic by-products, such as quinone and
NM, and induce the production of ROS (Graham et al., 1978; Hastings et al., 1996;
Spencer et al., 1998; Stokes et al., 1999; Sulzer and Zecca, 2000). Because of this, DAassociated neuronal toxicity has long been suspected to play a significant role in PD
pathogenesis (Goldstein et al., 2013).
Lastly, higher levels of dVMAT2 expression or activity have been implicated
with increased protection against PD in humans (Brighina et al., 2013; Glatt et al.,
2006). Together, they support the hypothesis that PD might be “a vesicular DA storage
disorder” (Lohr and Miller, 2014; Pifl et al., 2014).
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These observations raise an

intriguing question as to whether defective VMAT and the resulting disruption of
intracellular DA handling can act as a trigger to initiate and/or accelerate DA neuron
degeneration in parkin mutant animals, which, by themselves do not show an overtly
manifestation of DA neuron degeneration.
We tested this hypothesis using Drosophila, a model organism with wellcharacterized DN system and highly conserved mechanisms for DA synthesis and
intracellular handling (Yamamoto and Seto, 2014).

The protocerebrum of wildtype

adult flies contains about 220 DN (see Chapter 3).
Just like in mammalian brains, DA neurons are distributed in nine clusters with
distinct projection patterns, which are thought to mediate discrete brain functions. The
majority of the DA neurons, about 100 out of the total 120 reside in the PAM clusters
of each hemisphere.
These particular DA neurons mainly send their projections to the mushroom
bodies, the structure involved in learning and memory in Drosophila (Mao and Davis,
2009). Besides DA neurons, the PAM clusters contain about thirty mutually exclusive
octopamine neurons (manuscript in preparation), which is particularly important for
our study, since we are interested in determining whether DA neuron loss is specific to
DN (Tito et al., under review).
Importantly, both dVMAT and dParkin genes are highly conserved in
Drosophila and the corresponding mutant lines have been established and extensively
characterized. Flies lacking the parkin gene are viable but show severe mitochondria
defects in muscle and reproductive tissues, together with abnormal levels of oxidative
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stress and immune responses (Greene et al., 2005; Greene et al., 2003; Whitworth et
al., 2005). Adult vmat mutant flies are also homozygous viable with highly reduced
levels of DA and other monoamines. However, there is no apparent loss of DN in flies
mutated for either dparkin or dVMAT genes (Greene et al., 2003; Simon et al., 2009).
Conversely, overexpression of VMAT in Drosophila leads to increased monoamine
storage in vivo and altered motor and other amine-linked behaviors (Chang et al., 2006;
Rana et al., 2013), while higher level of dParkin can extend adult lifespan (Chang et al.,
2006; Rana et al., 2013).
Here, we have also re-examined the gain- and loss-of-function phenotypes of
VMAT gene in Drosophila. We show that ectopic expression of dVMAT2 can induce
darker pigmentation of adult cuticles, a phenotype normally associated with increased
DA synthesis and secretion, supporting an additional specific role of VMAT2 in
facilitating DA release.
Conversely, lack of dVMAT causes a significant loss of total DA, including the
complete lack of detection in the mushroom bodies that are prominently enriched with
DA in wildtype flies. DA become conspicuously accumulated in the soma of PAM
clusters neurons that innervate the mushroom bodies, a phenotype not observed in
wildtype flies. Although there is no apparent loss of DA neurons in flies mutated for
VMAT, additional removal of parkin results in an age-dependent loss of DA neurons
primarily in the PAM cluster, while the total levels of DA also become further reduced.
Together, our data support a critical role of VMAT2 in vesicular packaging of DA
and the devastating effects of altering its function in vivo. Disrupting VMAT function
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potentiates selective degeneration of DN in PD-associated parkin mutant. Moreover,
given the observation that DA distribution in the PAM cluster neurons shows particular
sensitivity to VMAT activity, it suggests an intrinsic difference in the dynamics of
intracellular DA handling among different DA clusters, which might be partially
responsible for the selective vulnerabilities of DN in the aging brain.
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4.2

Results

4.2.1 Characterization of new dVMAT Mutant Alleles
Previous studies have shown that flies lacking the VMAT gene can survive as
adults despite significantly reduced levels of monoamines, including DA, serotonin and
octopamine in the brain (Simon et al., 2009). Phenotypically, female adults devoid of
VMAT are sterile and display prominent accumulation of mature eggs in the ovary, one
of the most recognizable phenotypes, a defect caused by the loss of norepinephrinelike octopaminergic signaling that controls egg retention and egg laying.
The existing VMAT mutant alleles are mostly derived from dVMATp1, a null
mutant allele with no detectable level of VMAT protein in the homozygous animals.
dVMATp1 is generated from a P-element insertion in the last coding exon of VMAT gene
that disrupts its proper expression (Simon et al., 2009).
From a large-scale MiMIC insertion screen, we identified two novel MiMIC
lines that are inserted in the dVMAT gene (Nagarkar-Jaiswal et al., 2015a; NagarkarJaiswal et al., 2015b; Venken et al., 2011). Mi07680 is located in an intron in-between
two coding exons near the C-terminus of VMAT.
Applying the Recombinase-Mediated Cassette Exchange (RMCE) method to
this line, we generated an eGFP-tagging line named as VMATeGFP-Mi07680 that has an
eGFP epitope fused in-frame with the endogenous VMAT protein at a location near its
10th transmembrane domain. Mi03756, another MiMIC line, is inserted in the first
intron of dVMAT, in-between the first two non-coding exons.
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Using the RMCE method to insert a Gal4-expression cassette into the Mi03756
site, we established a VMAT-Gal4 trap line that we called VMAT-Gal4Mi03756. In these two
MiMIC-derived lines, the expression of both dVMAT-eGFP fusion protein and Gal4 are
under the control of the native regulatory elements of VMAT gene. Indeed, both lines
can faithfully recapitulate the endogenous expression pattern of VMAT (Tito, et al.,
2016, manuscript under review), thus serving as new tools for studying VMAT
expression and function in Drosophila.
Both VMAT-Gal4Mi03756 and VMAT-eGFPMi07680 lines are homozygous lethal
before eclosion, with no viable adult progenies found. However, when crossed with the
null dVMATp1 allele, they produced trans-heterozygous progenies that hatched at the
expected ratio and adults were viable up to 75 days (Fig. 4.5), suggesting that the
lethality is due to background mutations that existed or were spontaneously generated
in these lines.
Furthermore, the trans-heterozygous females from both crosses are sterile
with prominent egg retention phenotype, which is a characteristics of VMAT loss of
function mutants (Fig. 4.1B). Quantification of the egg laying efficiency showed that the
females with dVMAT-Gal4Mi03756 trans-heterozygous over dVMATp1 (dVMAT-Gal4Mi03756 /
dVMATp1 ) hardly laid any eggs in the first 20 days after they hatched, and afterwards
only produced a smaller number of eggs as compared to the age-matched controls (Fig.
4.1C).
The dVMAT-eGFPMi07680/dVMATp1 trans-heterozygous females laid few if any
egg over a 40-day period, similar as that reported for the homozygous null dVMATp1
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line (Simon et al., 2009). Consistently, there was a significant reduction of the levels of
DA in adult heads of the dVMAT-eGFPMi07680 /dVMATp1 trans-heterozygous flies, as
revealed by HPLC quantification, with the degree of reduction comparable with that
reported in the null dVMATp1 homozygous flies (Simon et al., 2009). Together, these
data suggest that both MiMIC lines are novel loss-of-function alleles of VMAT. dVMATeGFPMi07680 behaves as a strong mutant allele similar to the null dVMATp1 line, while
dVMAT-Gal4Mi03756 acts as a weaker VMAT mutant allele.
In the VMAT-Gal4Mi03756 line, the inserted Gal4-expression cassette likely
disrupts the regulatory elements of VMAT gene, altering the expression pattern or
levels of endogenous VMAT protein. Indeed, we noticed that although the overall
expression pattern of dVMAT-Gal4Mi03756 in the brain closely mirrors that of endogenous
VMAT, it is conspicuously absent from expression in the esophagus region that VMAT
normally presents (Tito, et al., 2016, manuscript under review).
In the VMAT-eGFPMi07680 line, the VMAT-eGFP fusion protein is expressed in a
pattern almost identical as the endogenous VMAT. However, the eGFP epitope is
inserted in the dVMAT protein at a position very close to its 10th TM domain,
potentially disrupting its proper folding or substrate binding ability, resulting in a
nonfunctional transporter.

4.2.2 Differential Rescue Efficiency by VMAT Isoforms and DAT
We next examined the effect of overexpressing VMAT in Drosophila tissues. In
mammals, two VMAT genes with distinct expression patterns are present: the brainspecific VMAT2 and the more ubiquitously expressed VMAT1 (Peter et al., 1995).
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Drosophila has only one VMAT gene in its genome but produces two protein isoforms,
dVMAT2 and VMAT-B, due to alternative splicing of the last exons encoding its very Cterminal sequences (Greer et al., 2005). Accordingly, the two dVMAT isoforms share the
majority of their sequences, including the regions responsible for substrate binding.
Their sequences differ only at their very C-termini, where the respective short
stretches of sequences are responsible for the proper subcellular distribution and
trafficking of the respective VMAT isoforms. However, these two VMAT isoforms do
have distinct expression patterns: dVMAT2 is expressed in all catecholamine
synthesizing neurons (DA, 5-HT and octopamine) in the central nervous system,
whereas dVMAT-B is expressed in a restricted subset of glial cells in the eye and
regulates the vesicular package of histamine, the predominant neurotransmitter in fly
visual system (Chang et al., 2006; Greer et al., 2005; Romero-Calderon et al., 2008).
To facilitate the overexpression study, we generated UAS-based transgenic fly
lines for the two dVMAT isoforms and also for DAT to serve as a control. For convenient
detection of the ectopically expressed proteins, the transgenes were tagged at their Nor C-terminus with eGFP epitope. To verify that the eGFP-tagged VMAT isoforms are
functional, we tested their ability to rescue the VMAT mutants.
Since the VMAT-Gal4Mi03756 driver line largely recapitulates the expression
pattern of endogenous VMAT gene, we used it to direct the ectopic expression of
VMAT-eGFP and eGFP-dDAT transgenes. Female flies trans-heterozygous for VMATGal4Mi03756 and dVMATp1 alleles were sterile and hardly laid any eggs before day 20.
However, in the presence of either of the dVMAT isoforms, the egg-laying defect was
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almost completely rescued, demonstrating that both eGFP-tagged dVMAT isoforms are
functional and the VMAT-Gal4Mi03756 line is a loss-of-function allele of VMAT gene.
Although both dVMAT isoforms from the transgenes rescued dvmat mutants,
they exhibited subtle differences in their rescue efficiency, with dVMAT-B showing a
more effective rescue than that by dVMAT2. Specifically, for the flies rescued by
dVMAT-B, they laid eggs at a similar rate as the age-matched controls from the very
beginning after their hatching. However, for flies rescued by dVMAT2, the female adults
only become as effective in egg-laying as controls about 8 days after they hatched.
Interestingly, although DAT was originally employed in the experiment as a control for
VMAT, it also exhibited a weak but significant rescue ability, as VMAT mutant females
overexpressing DAT begun to lay small number of eggs a few days after their hatching.
Although DAT normally locates on the plasma membrane to reuptake
extracellular DA back into the cytosol, a higher level of ectopically expressed DAT might
lead to promiscuous subcellular localization as well as non-specific binding and
transport of other monoamines such as octopamine, partially supplementing the
transport function normally carried out by endogenous VMAT.

4.2.3 Ectopically expressed dVMAT2 facilities DA release from Epithelial
Cells
In Drosophila, in addition to DN in the nervous systems, epithelial cells also
synthesize DA, which controls the pigmentation of adult cuticles (Neckameyer and
White, 1993; Wittkopp et al., 2003; Wright, 1987). During the late pupae stage, before
eclosion, DA is secreted from the epithelial cells underneath the forming cuticle, where
they are oxidized to Dopa and polymerized to form yellow melanin.
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Consistently, when pannier-Gal4 driver was used to express dsRNA against DAsynthesis enzymes TH or DDC in epithelium along a longitudinal dorsal domain covering
the thoracic and abdominal segments, they induced a clear stripe of de-pigmented
cuticles in the adult dorsal notum, largely along the panier expression domain (Calleja
et al., 2000). Earlier studies have shown that the level of VMAT is not detectable in
epithelial cells, and flies lacking VMAT do not have cuticle pigmentation defect (Greer
et al., 2005; Simon et al., 2009).
Indeed, VMAT mutant flies with VMATp1 trans-heterozygous over VMATGal4Mi03756 or VMAT-eGFPMi07680 alleles also have normal pigmented cuticles. Further,
targeted depletion of VMAT or DAT by RNAi through panier-Gal4 driver did not cause
any cuticle effect. Together, they confirm that VMAT is not necessary for the secretion
of epithelium-derived DA. Currently it is still not clear how DA is trafficked and released
from epithelial cells, and whether a vesicular-based mechanism is involved.
It was also reported that overexpression of dVMAT2 using different Gal4
drivers such DDC-GAL4 does not induce apparent cuticle or pigmentation phenotypes
(Chang et al., 2006). However, interestingly, when DDC-Gal4 was used to direct ectopic
expression of dVMAT2, it induced darker pigmentation in adult cuticles.
Such pigmentation effect is specific to VMAT2, as it is not observed in flies
overexpressing DAT or VMAT-B, even at higher dosages. In addition, the pigment
phenotype is also dosage-dependent, as animals with additional copies of UAS-dVMAT2
transgene and/or DDC-Gal4 driver show darker cuticles.
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Moreover, co-expression of TH, the rate-limiting enzyme for DA synthesis, or
halving the dosage of ebony (data not shown), an enzyme involved in DA metabolism,
all could enhance the dVMAT2-induced dark pigmentation phenotype, suggesting that
the darker pigment effect is associated with increased levels of DA. DDC-Gal4 is
expressed in both DA and serotonin neurons and also in epithelial cells(Li et al., 2000).
Importantly, neuronal-specific overexpression of DVMAT2, such as by elav-Gal4 driver,
do not cause dark pigmentation, indicating that the effect is due to DA from epithelial
origin (data not shown). Together, these data suggest that although VMAT is not
required for the package and release of DA from epithelial cells, the presence of
dVMAT2 is sufficient to facilitate the extracellular release of pre-existing DA, potentially
by promoting its vesicular packing.

4.2.4 Differential Subcellular Dynamics of dVMAT2 and dVMAT-B
proteins
It is surprising that overexpression of VMAT-B, even at higher-dosage, did not
induce dark pigmentation phenotype as DVMAT2, although they both can rescue the
dvmat mutant phenotypes and share majority of their protein sequences, including the
substrate binding domain. The two VMAT isoforms differ only at their very C-terminal
sequences, which have been shown to modulate their subcellular trafficking and
localization(Fei et al., 2007; Greer et al., 2005; Grygoruk et al., 2014; Grygoruk et al.,
2010).
Considering this, we further investigated the subcellular distribution patterns
of the two VMAT isoforms. In the brain, the majority of cells have small cell bodies and
the sizes of SVs are too small to be clearly visualized by standard immunofluorescent
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imaging. Accordingly, we employed the salivary gland, a secretory tissue with large cell
sizes, as a heterologous system to mimic neuronal cells for the study.
The secretory cells in salivary glands are highly polarized epithelial cells that
synthesize large amount of glue proteins, which are normally packaged and stored
inside large-sized granules (Biyasheva et al., 2001; Fraenkel and Brookes, 1953). At late
3rd instar larval stage, upon stimulation by the peaked ecdysone signal, these glue
granules migrate to the apical side of the cells where they fuse with plasma membrane
in a Ca2+-dependent manner to release the glues into the lumen, which are
subsequently pumped out of the body to attach late stage larvae that enter
metamorphosis onto solid surfaces.
Thus, both neurons and salivary gland cells are highly polarized secretory cells
with several shared properties, including vesicular storage of their contents (glue
proteins or neurotransmitters), the polarized transport of the vesicles (granules or SVs),
as well as the activity (hormonal stimulation and calcium)-dependent fusion of the
vesicles with the specialized domains in plasma membrane (apical membrane or
synapse) for their content release. It has been further suggested that, in neurons, the
synaptic terminus from projected axons corresponds to the apical side of epithelial cells
where activity-dependent membrane fusion and regulated content-release occur. By
contrast, the peri-synaptic region that DAT normally resides to re-uptake extracellular
DA bears more similarity to the basal-lateral membranes of the epithelial cell
(Rodriguez-Boulan and Powell, 1992; Torres et al., 2003).
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When DAT and VMAT isoforms were ectopically expressed in the salivary gland
cells, DAT mainly located to the basal-lateral plasma membrane, but was conspicuously
absent from the apical side of the membrane and from structures inside the cell. In
contrast, both dVMAT2 and VMAT-B both were largely absent from basal-lateral
membrane but instead primarily localized on the vesicular membranes inside the cell,
in addition to their prominent enrichment on the apical side of the membrane.
Thus, when ectopically expressed in the polarized salivary gland cells, VMAT
and DAT likely employ similar mechanisms as in neurons for their proper sorting and
trafficking to their appropriate destinations, with VMAT being trafficked specifically to
the vesicular membrane that enclose the secretory granules, whereas DAT being
targeted to basal-lateral plasma membrane. Noticeably, although both dVMAT2 and
VMAT-B show similarly vesicular localization inside the cell, dVMAT2 exhibits a more
polarized subcellular localization pattern than VMAT-B.
More specifically, the majority of dVMAT2-positive granules were clustered
near the apical side of the cell, as compared to a more dispersed distribution of VMAT-B
in the cell. Such an observation, combined with their different overexpression effects
on cuticle pigmentation, raising the possibilities that dVMAT2 not only is important for
vesicular package of monoamines, but also can potentiate membrane fusion and
content release. Additionally, it is possible that dVMAT2 is actively trafficked to granules
and SVs that are fusion-competent, the ones that are being positioned in proximity to
the fusion active sites on the plasma membrane.
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4.2.5 Loss of VMAT leads to increased cytosolic accumulation of DA but
does not cause loss of DA neurons
Consistent with a previous report, quantification by HPLC analyses revealed a
significant reduced level of total DA in dvmat mutant brains (Simon et al., 2009). In an
early study, it has been shown that DA neurons develop normally in dvmatp1 mutant
flies and do not exhibit apparent degeneration as the fly ages (Simon et al., 2009).
However, this study only focused on a small group of DA neurons from the PAL
and PPL cluster, but did not analyze the PAM clusters that contain the majority of DA
neurons in the brain. To obtain a more comprehensive evaluation of the role of VMAT
on the development and survival of DA neurons, we expanded the study to more DA
clusters in the brain, including the PAM clusters.
The viability of VMAT mutant flies was found to be highly sensitive to their
cultured conditions and genetic background (Simon et al., 2009). To minimize such
background effect on the survival of DA neurons, we performed the studies on VMAT
mutant flies trans-heterozygous for VMATp1 and VMATeGFP alleles, two strong vmat
alleles that were each derived from an independent parental line of different genetic
background.
Examination with anti-TH antibody revealed that in both the PAM cluster and
several other clusters we examined, there was no significant loss of DA neurons
between young and 30-day-old VMAT mutant flies transheterozygous for
dvmatp1/dvmateGFP. For example, in each PAM cluster, there are on average 89 DA
neurons in 3-day-old VMAT mutant flies as compared to about 91 DA neurons in 30day-old VMAT mutant flies.
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To examine the effect of VMAT on the distribution of DA in adult brains, we next
performed immunofluorescent staining with anti-DA antibody. In most of the DA
neuron clusters such as PAL and PPL of wildtype flies, anti-DA staining clearly
recognized the soma of individual DA neurons, indicating a significant retention of DA
in the cell bodies of these neurons.
One noticeable exception is in the PAM clusters, where anti-DA staining hardly
revealed any individual cell bodies, despite the fact that it contains the majority of DA
neurons in the brain. Instead, there is a prominent enrichment of DA in the mushroom
bodies (MBs), the primary target of innervation by DA neurons from the PAM clusters.
Such an observation implies that the majority of DA produced by the PAM cluster cells
are effectively packaged and delivered out of the soma into the axonal termini, which is
in contrast to the clear retention of DA in the soma of the neighboring PAL cluster cells.
Besides the mushroom bodies, there is also an extensive and widespread
distribution of DA throughout the brain, including its heavy enrichment in the
commissures that connect the two brain hemispheres and around the esophagus
region. In VMAT mutants, the elaborate and extensive distribution of DA in the brain
was abolished, and the signal intensity of DA in almost all the brain regions was greatly
reduced, including a complete loss of DA in the mushroom bodies, in agreement with
the significantly reduced levels of total DA as revealed by HPLC study.
However, for DA neurons in the PAM cluster, their soma became clearly labeled
by anti-DA staining, in contrast to their lack of immunoreactivity in wildtype
background, indicating a significant accumulation of cytoplasmic DA in these cells in
the absence of VMAT. Additionally, DA was also still clearly present in the soma of most
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DA neurons in other clusters such as the neighboring PAL and in the large commissures
connecting two sides of the brain. These findings suggest that vesicular-package of DA
is absolutely required for its distribution out of the soma into the projected axons.
Further, considering the apparent difference between the PAM and other DA
clusters in the subcellular distribution of DA, both in wildtype and under VMAT mutant
background, it raises a possibility that the dynamics of handling intracellular DA are
different between DA neurons of different brain clusters.

4.2.6 Normal Distribution Patterns but Reduced Levels of DA in parkin
mutant brains
We next examined the effect of parkin depletion on the distribution of DA in
adult brains. It has been shown that parkin mutant flies do not manifest apparent loss
of DA neurons, despite their prominent mitochondria defects and oxidative stresses
(Greene et al., 2005; Greene et al., 2003).
Similar as to VMAT, the viability of parkin-deficient flies is highly sensitive to
different genetic background and can be altered by disturbance in a variety of cellular
pathways such as mTOR, protein synthesis, metal clearance and oxidative responses
(Humphrey et al., 2012; Kim et al., 2012; Ng et al., 2012; Ottone et al., 2011; Saini et
al., 2011; Tain et al., 2009; Whitworth et al., 2005; Zhu et al., 2015). Considering this,
we focused the study on flies that are trans-heterozygous for two strong parkin loss-offunction alleles, parkinΔ21 and parkinf01950 derived from independent parental lines with
different genetic background (Pesah et al., 2004).
When different DA clusters were examined by anti-TH staining, there was no
apparent loss of DA neurons in these parkin mutant flies. For example, in both 3- and
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30-day-old parkin mutants, anti-TH staining could clearly identify about 90 DA neurons
in each of the PAM clusters, similar as that in VMAT loss of function flies.
Interestingly, although anti-TH staining revealed no apparent loss of DA
neurons in parkin mutant flies, the immunoreactivity for DA were significantly reduced,
which is especially apparent in the mushroom bodies, although the pattern of DA
distribution in parkin mutant brains was similar as that in wildtype, including its
characteristic enrichment in mushroom bodies, in a region around esophagus and in
large commissures connecting two brain hemispheres. Such an observation suggests
that Parkin directly or indirectly regulates DA production and/or its subcellular package
and delivery in the brain.

4.2.7 Significant loss of DA neurons in the PAM cluster of flies lacking
both VMAT and Parkin
We next examined whether the altered DA subcellular distribution associated
with VMAT depletion can become a toxic factor in parkin deficient background. To test
this, we generated adult flies carrying both VMAT and parkin mutations. Additionally, to
obtain comparable results with flies from similar genetic background and also to
minimize background effect, we used the same VMATp1 and VMATeGFP alleles to remove
native VMAT gene and parkinD21 and parkinf01950 alleles to delete Parkin.
Flies trans-heterozygous for parkinD21/parkinf01950 flies are viable with a mean
life span of 22 days, with 80% of them die by day 28. The mean life span of
VMATp1/VMATeGFP adults is at day 55, with 80% of them die by day 62. The mean life
span of VMAT/parkin double mutants (genotype “w1118; VMATp1/VMATeGFP;
parkinD21/parkinf01950”) double mutant flies was slightly shortened to day 22, with 80%
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of them die by around day 29. We therefore focused the remaining studies on aging
flies primarily to 22-day-old adults.
We first examined the presence of DA neurons by anti-TH staining. In 3-day-old
young flies of “VMAT/parkin” double mutants, cell bodies of DA neurons were clearly
recognizable for all the clusters we examined, including the PAM, PPM, PAL and PPL.
The number of DA neurons was similar in VMAT/parkin double mutants as those in
VMAT or parkin single mutant alone. By day 22, for VMAT/parkin double mutants, the
cell bodies of DA neurons in the PAL, PPM and PPL clusters were clearly recognizable by
anti-TH staining, and their number were largely the same as those in the young flies,
and also similar as the single mutants of the same ages.
However, in the PAM clusters, the number of DA neurons were significantly
reduced, from an average of 92 DA neurons per PAM cluster in day 3 to about 72 by day
22, a significant 30% reduction. Additionally, there was a noticeably big variation on the
number of DA neurons per PAM cluster among individual flies, and the signal intensity
of anti-TH staining also became markedly lower.
Examination of these animals with anti-DA antibody revealed a more dramatic
change in “VMAT/parkin” double mutants flies. When processed in parallel, the signal
intensity for DA became almost completely diminished from the brains of the
“vmat;parkin” double mutant animals even in 3-day-old flies, in contrast to the
characteristic patterns of DA distribution that were clearly present in either of the
mutants alone.
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Taken together, our findings reveal that simultaneous loss of VMAT and Parkin
causes a significant perturbation of DA production and/or metabolism in the brain
accompanied by an accelerated loss of DA neurons especially in the PAM clusters.

4.2.8 Selective loss of DA neurons in the PAM cluster of dvmat;parkin
double mutant flies
The noticeable loss of the DA neurons in the PAM cluster raised a question
whether other cell types in this cluster were also affected in “VMAT/parkin” double
mutant flies. In addition to its majority composition of DA neurons, the PAM cluster
also contains a small number of octopamine neurons, which can be identified as the
cells that express VMAT transporter but not the DA synthesis enzyme TH.
We used the established VMATeGFP genome tagging line, which expresses a
nonfunctional VMAT-GPF fusion protein that faithfully recapitulate the endogenous
expression pattern of VMAT gene in the brain, to both disrupt native VMAT function
and to label all the endogenous VMAT-expressing cells. We specifically quantified the
number of octopamine neurons (i.e., “VMAT-eGFP positive, TH-negative” cells) in the
PAM clusters by double-labeling of the VMATp1/VMATeGFP brains with anti-TH and antieGFP antibodies.
In

the

“VMAT/parkin”

double

mutant

flies

(genotype:

“w1118;

VMATp1/VMATeGFP; parkinD21/parkinf01950”), despite the loss of DA neurons in the PAM
clusters, octopamine neurons (i.e., “VMAT-eGFP positive, TH-negative”) were still
clearly present and their number was similar as that observed in VMAT mutant alone of
the same age (genotype: w1118; VMATp1/VMATeGFP), suggesting that the cell loss is more
restricted to DA neurons within the PAM cluster.
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Figure 4.1: New MiMIC-derived insertional lines disrupt VMAT function
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(A)

Schematics of Drosophila VMAT gene structure. Gray boxes indicate exons and

filled boxes represent protein coding regions. White dashed lines near the C-terminus
of VMAT gene indicate the alternative splicing sites that produce the dVMAT2and
VMAT-B protein isoforms. Inverted triangles indicate the sites of insertion by the two
MiMIC-lines.
(B)

The characteristic egg retention phenotype associated with the new VMAT

alleles derived from the MiMIC lines. The ovaries were dissected from 8-day-old
females adults carrying transheterozygous VMAT mutations: the null VMATP allele over
the VMATGal4 line (top, genotype: w1118; VMATp1/VMATGal4), VMATP allele over the
VMATeGFP line (middle, genotype: w1118; VMATp1/VMATeGFP), or over a wildtype control
(bottom, genotype: w1118; VMATp1/+). Notice the dramatic accumulation of mature
eggs in the top two VMAT mutants.
(C)

Quantification of the egg laying efficiency by VMAT mutant females, plotted as

the average number of eggs produced per day by one female over a 36-day timespan.
Flies that were transheterozygous with the null VMATP allele over the VMATeGFP line
(green) laid almost no eggs during the study, while the VMATP/VMATGal4 flies (blue) laid
eggs much later and produced fewer eggs than the heterozygous VMATP/+ control
(green).
(D)

Rescue of the egg-laying defect in the transheterozygous VMATP/VMATGal4

females through the ectopic expression of eGFP-tagged dVMAT2, VMAT-B and DAT
transgenes. The transgene expression was driven by the VMATGal4 trap line, which
expresses Gal4 driver under the control of the native VMAT regulatory elements.
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Genotypes: WT (w1118, brown column), heterozygous VMATP/+ control (red),
transheterozygous VMATP/VMATGal4 mutants (green column), transheterozygous
VMATP/VMATGal4

mutants

co-expressing

dVMAT2-eGFP

(dark

blue

column,

w1118;VMATP/VMATGal4; UAS- dVMAT2-eGFP/+), transheterozygous VMATP/VMATGal4
mutants co-expressing VMAT-B-eGFP (yellow column, w1118;VMATP/VMATGal4; UASVMAT-B-eGFP/+), transheterozygous VMATP/VMATGal4 mutants co-expressing eGFP-DAT
(brown

column,

w1118;VMATP/VMATGal4;

UAS-eGFP-DAT/+),

transheterozygous

VMATP/VMATGal4 co-expressing DDC (light blue column, w1118;VMATP/VMATGal4; UASDDC/+).
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Data generated by Hirsh Lab at the University of Virginia
Figure 4.2: New MiMIC-derived insertional lines reduce DA and 5HT synthesis
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Significantly reduced levels of total DA (A) and 5HT (B) in the brains of VMAT mutant
adults, as quantified by HPLC from the following genotypes at day 3 (blue columns)
and day 22 (orange columns): wildtype control (w1118), heterozygous VMAT control
(w1118; VMATeGFP/Cyo), and transheterozygous VMAT mutants (w1118; VMATeGFP/
VMATP).
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Figure 4.3: Ectopic expression of dVMAT2 induces darker cuticle pigmentation
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Bright-field images of the notum from 3-day-old adult flies.
(A-F) Ectopic expression of dVMAT2 (A, D), but not VMAT-B (B,F) or DAT (C), by DDCGal4 driver induces darker pigmentation in adult cuticle.
(A-C) Flies carried two copies of DDC-Gal4 with two copies of the UAS-transgenes.
Genotypes: (A) w1118; DDC-Gal4, UAS- dVMAT2-EGFP/ DDC-Gal4, UAS- dVMAT2-EGFP.
(B) (A) w1118; DDC-Gal4, UAS-VMAT-B-EGFP/ DDC-Gal4, UAS-VMAT-B-EGFP. (C) w1118;
DDC-Gal4, UAS-EGFP-DAT/ DDC-Gal4, UAS- EGFP-DAT.
(D) Flies carried one copy of DDC-Gal4 driver with two copies of the UAS-transgenes.
Genotypes: (D) w1118; DDC-Gal4, UAS- dVMAT2-EGFP/ UAS- dVMAT2-EGFP. Note that it
showed lighter pigmentation than flies in (A) that carried two copies of DDC-Gal4
driver. (E and F) Co-expression of TH enhanced the dark pigmentation effect induced by
(E) dVMAT2but not (F) VMAT-B. (E) A fly that co-expressed dVMAT2and TH showed
similar level of dark pigmentation as fly in (D) that with two copies of UAS- dVMAT2EGFP transgene.
Flies carried only one copy of DDC-Gal4 and one copy of UAS- dVMAT2-EGFP (data not
shown) have lighter pigmentation that in (D) and (E). Genotype: w1118; DDC-Gal4, UASdVMAT2-EGFP/ UAS-TH. (F) A fly that co-expressed TH with VMAT-B showed normal
pigmentation as in wildtype. Genotype: w1118; DDC-Gal4, UAS-VMAT-B-EGFP/ UAS-TH.
(G-I) VMAT and DAT are not required for cuticle pigmentation. Depletion of (G) TH, but
not (H) VMAT or (I) DAT, led to de-pigmentation of adult cuticle. The knock down of
target gene expression along the dorsal cuticle region was achieved by expressing
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dsRNA constructs against the respective target genes using the panier-GAL4 driver.
Genotypes: (G) w1118; panier-GAL4/+; UAS-THdsRNA/+. (H) w1118; panier-GAL4/+; UASVMATdsRNA/+; (I) w1118; panier-GAL4/+; UAS-DATdsRNA/+.
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Figure 4.4: Secretory salivary gland cells as a heterologous system to study the
subcellular localization of DA transporters
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(A and B) Images of the highly-polarized structure of salivary gland epithelial cells by
transmission electronic microscope (TEM) from (A) an early 3rd instar stage larva,
before the initiation of massive synthesis of glue proteins showing mitochondria with
yellow arrows, or from (B) a late 3rd instar larva that showed the presence of many glue
granules of large sizes in the cell (representative unit within a dashed circle). Apical side
of the cells (top) is characterized by the presence of extensive microvilli that project
into the lumen of the salivary gland.
(C-H) Subcellular localization of ectopically expressed (C, E) DAT, (D, G) dVMAT2and (E,
H) VMAT-B in salivary glands from late third-instar larvae. The EGFP-tagged transporters
were revealed by anti-GFP antibody (green), overall tissue morphology and cell
membrane were labeled by phalloidin staining (red) for filamentous Actin (F-Actin) and
cell nuclei by DAPI staining (blue). Salivary glands at this stage produce large numbers
of secretory granules that are filled with glue proteins.
(C-E) Overview of the salivary glands. The lumens are highlighted by the F-Actin (red)
highly enriched on the apical side of the cells. (C) DAT is localized to the basal-lateral
membrane where it co-localizes with F-actin, but is largely excluded from the apical
region of the cells surrounding the lumen.
(D and E) Both dVMAT2 (D) and VMAT-B (E) are mainly localized to the vesicular
membrane on the granules inside the cell and are also highly enriched on apical side of
the plasma membrane surrounding the lumen. Compared to VMAT-B-positive granules
(D), granules positive for dVMAT2show a more polarized distribution (D), being heavily
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concentrated to the apical side of the cells and conspicuously absent from the basal
side, a pattern that is more apparent in close-up view of the cells in (H).
(F-H) Close-up view of individual cells from salivary glands in (C-E), respectively. (F) A
close-up view of the membrane surface on the basal side of a cell (center). DAT is
enriched on cell-cell junction where it co-localizes with F-Actin (red) and shows an
uneven distributed pattern on the membranes surface, likely due to its preference for
lipid raft-rich membrane structures. Note that the image also captured the area just
below the basal surface of two neighboring cells (bottom part of the image), where no
vesicular-location of DAT was observed (compare it with the large number of GFPpositive vesicles in G).
(G) A close-up view of an area below the basal surface of a cell expressing VMAT-B,
which was heavily enriched on the vesicular membrane of the granules that filled the
cell. (H) A cross-section view of the middle region of two cells, including both their
apical and basal-lateral sides, with the cell nuclei (blue) sitting in the middle.
dVMAT2 positive granules are highly enriched on the apical surface (bottom, as
revealed by the intense yellow color showing the co-localization of dVMAT2-GFP with
F-Actin in the lumen area, both at high protein levels). dVMAT2 positive granules are
also enriched in apical half of the cells below the lumen, but are prominently absent
from the basal half of the cells.
A part of a third cell sitting in between these two cells was also captured, showing a
region below its lateral surface and close to its apical lumen region that is filled with
GFP-positive granules. Note that in all the three cells, dVMAT2-EGFP is clearly absent
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from the basal-lateral membrane labeled by F-Actin. In all cells, patched-GAL4 was used
to direct the target gene expression in salivary glands. Genotypes: (A and B). Orange R.
(C and F) w1118; ptc-GAL4/+; UAS-EGFP-DAT/+. (D and G): w1118;ptc-GAL4/+; UAS- VMATB-EGFP/+. (E and H): w1118; ptc-GAL4/+; UAS- dVMAT2-EGFP/+. Scale bars: 20 µm.
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Figure 4.5: Early lethality in double mutants due to parkin mutation.
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(A-C) Representative life-span curves of (A) male and (B) female adult flies mutated on
VMAT (blue), parkin (grey) or vmat/parkin double mutants (red). (C) Average of the lifespan curves for males and females. Flies were kept at a density of 20-25 flies per sex
and vial on standard fly food and passed every 3 to 4 days. Dead flies were counted
every passage.

Results show a 50% survival rate of 22 days to VMAT/parkin double

mutants.
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Figure 4.6: Distribution of DA in wildtype and parkin and VMAT mutant brains*
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(A and B) Anterior (A) and posterior (B) view of DA distribution in 3-Days old wildtype
adult Drosophila brains.
DA shows extensive distribution throughout the brain, with characteristic enrichment
in the large commissures (arrowheads) connecting the two brain hemispheres, the
mushroom bodies and a region around esophagus (arrows). For DA neuron clusters
including PAL, PPL and PPM, DA is clearly present in the soma of the cells (arrow),
however it is undetectable in the soma of DN in the PAM clusters (arrowheads). * DA
immunohistochemistry performed by Hirsh Lab.
Antonio Tito.
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Image projection performed by

Figure 4.6: Quantification of DA and Serotonin in 3-Days and 22-Days old flies*
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(A) Quantification of DA signal intensity in different areas of the brain of wildtype (blue
bars) and VMAT mutant (orange bars) flies using a DA antibody. The levels of DA were
significantly lower in all regions examined of VMAT mutant than in wildtype (indicated
by yellow arrowhead),
Genotypes: (A-C): w1118 (wildtype control), w1118; VMATeGFP/ VMATP (vmat mutant),
w1118; VMATP / CyO (vmat control). * DA signal analysis performed by Hirsh Lab and
confirmed by Antonio Tito.
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Figure 4.7: Distribution of DA in WT, park, vmat, and vmat; park mutants*
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(A-D) Anterior view of DA distribution in 22-day-old adult brains (vmat mutant are 3days old) and (E-H) close-up view of the mushroom body and PAM cluster regions.
(A and E) Wildtype. DA is prominently present in the giant commissures, the
mushroom bodies, around the esophagus region as well as in the soma of PAL neurons
(arrows), but is absent from the soma of DN (arrowheads) in the PAM clusters.
(C and G) VMAT mutant. DA is absent from the mushroom bodies and the region
around the esophagus as well as in the soma of PAL neurons (arrows in C), but the
soma of DN in the PAM cluster became clearly labeled by DA immunoreactivity
(arrowheads in G).
(B and F) parkin mutant. DA shows similar distribution pattern as in wildtype, including
its enrichment in the mushroom bodies and the region around the esophagus, is
absent from the soma of DN in the PAM cluster. However, the levels of signal intensity
from DA immunoreactivity become significantly weaker.
(D and H) “VMAT; parkin” double mutant. The signal intensity from anti-DA staining
became barely detectable throughout the brain. DA signal is observed in PAL cluster
neurons. Genotypes: (A and E): w1118 (wildtype control). (C and G) w1118; VMATeGFP/
VMATP. (B and F) w1118; park21/ park f01950. (D and H) w1118; VMATeGFP/ VMATP; park21/
park

f01950

Scale bar: 50 µm. * DA immunohistochemistry performed by Hirsh Lab.

Image projection performed by Antonio Tito.
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Figure 4.8: Loss of DN in aged w1118 (WT) flies
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(A-D) Representative images of DN of w1118 in the PAL and PAM clusters in (A-D) 3- and
(E-H) 22-day-old adult brains, as revealed by anti-TH antibody staining. (A and E)
Wildtype flies.
(C-D) Quantification of the number of DN in (C) PAM and (D) PPM, PPL, and PAL brain
clusters. For wildtype control, there were no significant change between young and
aged flies in all clusters, except for PAM cluster, which showed a 15% reduction in the
number of DN.
Genotypes: (A-D): w1118 (wildtype control). Scale bar: 20 µm.
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Figure 4.9: No apparent loss of DN in aged VMAT or parkin single mutant flies

Tito - 120

(A-D) Representative images of DN in the PAL and PAM clusters in (A and C) 3- and (B
and D) 22-day-old adult brains, as revealed by anti-TH antibody staining.
(A and B) VMAT mutant and (C and D) parkin mutant flies.
(E and F) Quantification of DN in different brain clusters.
Genotypes: (A and B): w1118; VMATeGFP/ VMATP. (C and D) w1118; park21/ park
Scale bar: 20 µm.
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f01950.

Figure 4.10: Age-dependent loss of DN in the PAM clusters in flies mutated for both
VMAT and parkin
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(A and B) Representative images of DN in the PAL and PAM clusters in the brains of (B)
3-day-old or (C) 22-day-old “VMAT/parkin” double mutant adults. DN in the PAM
clusters were clearly recognizable by anti-TH antibody staining in the 3-day-old brains,
but many became unrecognizable in 22-day-old brain, although DN in the neighboring
PAL clusters (arrows) were clearly present.
(C and D) Quantification of the number of DN in different brain clusters. For wildtype
control or flies carrying VMAT mutant alone or parkin mutant alone, there were no
significant changes between young and aged flies in all the cluster examined. In the
VMAT/parkin double mutant flies, there was a significant loss of DN in the PAM cluster
in aged flies compared that in young ones, while the number of DN in other clusters
largely remained the same.
Genotypes: (B and C) w1118; VMATeGFP/ VMATP; park21/ park f01950
Scale bar: 20 µm.
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Figure 4.11: Quantification of DN in the PPM, PPL, and PAL clusters of Day-3 fly
brains.
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(A-C) Quantification of the number of DN of (A) PPM, (B) PPL, and (C) PAL clusters of 3day-old WT, vmat, parkin, and “VMAT/parkin” double mutant adults.
There were higher number of neurons in the PPL cluster of parkin mutant flies,
compared to wildtype, and no significant changes in all the other clusters examined.
For vmat mutant flies, there was a trend for a loss in the number of DA neurons in the
PAL cluster, and no significant changes in all the other clusters examined.
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Figure 4.12: Quantification of DA neurons in the PPM, PPL, and PAL clusters of Day-22
fly brains
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(A-C) Quantification of the number of DA neurons of PPM, PPL, and PAL clusters of (B)
3-day-old w1118, vmat-/-, parkin-/-, and “VMAT/parkin” double mutant adults.
In wildtype control or flies carrying VMAT mutant alone or parkin mutant alone, there
were no significant changes between aged flies in all the clusters examined.
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Figure 4.13: Quantification of DA neurons in the PPM, PPL, and PAL clusters of Day-3
and Day-22 fly brains
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(A-C) Quantification of the number of DA neurons of PPM, PPL, and PAL clusters of 3day-old and 22-day-old w1118, vmat-/-, parkin-/-, and “VMAT/parkin” double mutant
adults.
In wildtype control or flies carrying VMAT mutant alone or parkin mutant alone, there
were no significant changes between young and aged flies in all the clusters examined.
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Day-3

Day-22

Figure 4:14: No apparent loss of octopamine neurons in the PAM cluster in flies
lacking both VMAT and parkin
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(A-F) Projected images of brain region covering the PAL and PAM clusters in 22-day-old
(A-C) dVMAT single mutant (genotype: w1118; dVMATeGFP/ VMATP) or (D-F)
dVMAT/dParkin double mutant flies (genotype: w1118; dVMATeGFP/ dVMATP; dpark21/
dpark

f01950).

dVMATeGFP is a VMAT genome-tagging line, which expresses a

nonfunctional VMAT-GFP fusion protein in a pattern mirroring that of endogenous
VMAT protein from wildtype flies.
(A-C) In 22-day-old dVMATeGFP/ dVMATP flies, the VMAT-expressing cells were revealed
by (A) anti-GFP antibody (green) and DN by (B) anti-TH antibody (red). DN express both
TH and VMAT. Within the PAM clusters, octopamine neurons are identified as cells that
express VMAT but not TH (highlighted by white dashed lines). These octopamine
neurons also have relative larger cell sizes and higher level of VMAT expression as
compared to the TH-expressing DN within the same cluster.
(D-F) In 22-day-old dVMAT/dParkin double mutant flies, most of the “GFP-positive, THnegative” octopamine neurons were still present (highlighted by white dashed lines).
The signal intensity for both TH and VMAT-GFP were apparently diminished in most
other cells there.
(G) Quantification of the number of octopamine neurons within the PAM clusters in 22day-old VMAT single mutant (blue bar, Genotype: w1118; dVMATeGFP/ VMATP) or the
VMAT/parkin double mutant (orange bar. Genotype: w1118; dVMATeGFP/ dVMATP;
dpark21/ dpark

f01950)

flies, which shows no significant difference between the two

genotypes. Scale bar: 20µm.
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4.3 Discussion
VMAT is essential for the proper vesicular storage of monoamines and their
regulated release. Increasing evidence have linked VMAT dysfunction with PD. In this
study, we have re-examined the gain- and loss-of-function phenotypes of the sole vmat
homolog in Drosophila. Our results suggest that dVMAT2 (a homologue of dVMAT2)
potentially confers a previously unexplored unique activity in promoting DA release and
that the C-terminal sequences in the two encoded VMAT isoforms, not only determine
their differential subcellular localizations, but also induce content release.
Additionally, we show that the fly’s secretory epithelial systems, such as
hypodermal tissues and salivary glands, can be useful heterologous systems to study
the activity and subcellular trafficking of DA transporters. Moreover, by examining DA
distribution in WT and dvmat mutant animals, we find intrinsic differences in the
dynamics of intracellular DA synthesis within DA neurons of the PAM clusters compared
to DA neurons from other clusters.
Loss of dVMAT causes severe loss of total DA levels and a redistribution of DA
in the whole brain. Lastly, removal of both dVMAT and dParkin result in the selective
loss of DA neurons in the PAM clusters, but not in octopaminergic neurons; supporting
a potential involvement of cytosolic DA in selective degeneration of DA neurons.
Overall, our results implicate a differential intracellular DA handling mechanism that,
when dysfunctional, may contribute to the regional specificity in PD.
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4.3.1 Comparison with the previous human Parkin Mutant/VMAT-RNAi
Study
A previous study by Sang et al. showed that depletion of dVMAT in Drosophila
through RNAi, enhances the defects associated with the overexpressed human Parkin
mutants, including DN loss in adult fly brains (Sang et al., 2007). These findings
demonstrate the importance of VMAT in protecting cells from DA toxicity. However, it
is important to note, that the underlying mechanisms of cellular defects studied in that
report, is very different from the ones analyzed in our study.
Firstly, while our study used loss-of-function dParkin as the sensitized
background to study DA toxicity and a protective role of VMAT; the previous study
focused on overexpressed human Parkin mutants, which does not recapitulate the lossof-function phenotypes of dParkin mutant animals nor exhibits the traits of a dominant
negative mutant. Rather, human parkin mutants likely cause cellular toxicity through an
unknown gained function, as pointed out by the investigators of this study.
Secondly, in agreement with other studies on VMAT mutants in both mouse
and Drosophila (Caudle et al., 2007; Fon et al., 1997; Simon et al., 2009; Takahashi et
al., 1997; Taylor et al., 2014; Wang et al., 1997), we observed a significant loss of total
DA levels and a dramatically altered pattern of DA distribution in the brains of dVMAT
mutant flies. In contrast, the Sang study showed a significant induction in the level of
total DA in flies depleted of VMAT expression with RNAi knockdown.
Lastly, we observed significant loss of DA neurons, primarily in the PAM
clusters of flies lacking both endogenous dVMAT and dParkin. Yet, in flies overexpressing human Parkin mutants, the degeneration was observed in the DM and DL
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clusters. Nevertheless, both studies similarly demonstrate that in different sensitized
genetic backgrounds, VMAT plays an important role in protecting cells from the toxicity
of cytoplasmic DA.

4.3.2 Drosophila Salivary gland as a Heterologous System to study the
Sorting and Trafficking Mechanisms for Monoamine Transporters
In Drosophila, hypodermal tissues synthesize and secrete DA molecules, which
are subsequently oxidized and polymerized, leading to the hardening (sclerotization)
and pigmentation of adult cuticles (Neckameyer and White, 1993; Wittkopp et al.,
2003; Wright, 1987). Since VMAT expression is not detected in hypodermal tissues and
given that VMAT is not required for cuticle formation and pigmentation, it is still
unclear as to how DA is packaged and secreted, in and out of epidermal cells.
Nevertheless, it is interesting that ectopic expression of dVMAT2 can induce
dark pigmentation in adult cuticles. Such a finding raises a possibility that in epithelial
cells, the ectopically expressed dVMAT2 can be properly sorted and trafficked to the
surface of endogenous secretory vesicles. It is in these active vesicles that dVMAT2
may function similarly as in the DA neurons: sequestering existing cytosolic DA into the
vesicles, thereby inducing extracellular release of its inner contents.
Interestingly, when expressed in epithelial cells in the salivary gland, another
heterologous system and a highly polarized secretory tissue, both dVMAT isoforms and
dDAT are targeted to subcellular destinations reminiscent to the locations where they
normally reside, in their native neurons. For instance, dVMAT primarily localizes on the
surface of glue granules and is excluded from basal-lateral plasma membrane, whereas
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dDAT resides almost exclusively on the basal-lateral plasma membrane, where it is
further enriched at sub-membrane, lipid-raft like domains.
These observations suggest that the secretory epithelial cells employ similar
mechanisms as neuronal cells. These may involve the recognition of protein targeting
signals embedded in these transporters which execute proper sorting and trafficking of
the vesicles.
Salivary glands (SGs) may, therefore, represent an ideal heterologous tissue for
imaging-based studies, since it contains big glue granules, with relatively large
diameters, often 3-7µm wide.

This simple physical attribute makes the SG an

important system to dissect the regulatory mechanisms that could potentially mediate
subcellular trafficking of these monoamine transporters in the neurons as well.

4.3.3 A Fusion-Promoting Activity by dVMAT2?
It has been shown that the expression levels of neurotransmitter transporters
correlate with the number of transporters residing on an SV, as well as the capacity of
each vesicle to package neurotransmitters. The later correlates with the increased
amplitude (quantal size) of elicited responses, triggered by signals that initiate vesicular
release (Daniels et al., 2004; Edwards, 2007; Fei et al., 2008; Pothos et al., 2000; Prado
et al., 2006; Song et al., 1997; Tordera et al., 2007; Wilson et al., 2005; Wojcik et al.,
2006; Wojcik et al., 2004).
However, the vesicular packaging of DA by VMAT should not be sufficient to
promote extracellular DA release, considering existing evidence that both dVMAT2 and
VMAT-B are equally capable of packaging monoamines into secretory vesicles, and yet,
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only dVMAT2 induce dark cuticle pigmentation. dVMAT2 and VMAT-B share majority of
their sequences, including all of the 12 TM domains that determine their substrate
affinity and transport activity, and differ on at their very C-terminal sequences, which
modulate the trafficking and subcellular localization of the respective proteins (Fei et
al., 2007; Greer et al., 2005; Grygoruk et al., 2014; Grygoruk et al., 2010).
Indeed, both VMAT isoforms are functional, in vivo, and can fully rescue the
female sterility phenotype of VMAT mutant flies. Similarly as to mammalian VMAT2,
dVMAT2 contains multiple motifs in its C-terminal domain, which are known to be
involved in protein endocytosis and sorting, and which are absent in dVMAT-B.
These include the di-leucine sequence, a string of acidic residues and an YXXY
tyrosine-based motif (Greer et al., 2005; Grygoruk et al., 2010). Consistent with this,
dVMAT2 primarily localizes to intracellular membrane in transfected insect S2 cells, and
exhibits much faster endocytosis rate than dVMAT-B (Greer et al., 2005).
However, even for the dVMAT2 derivatives that show aberrant subcellular
trafficking, due to mutations in these C-terminal sorting motifs, they still show equal
capability as wildtype dVMAT2 in their storage capacity of monoamines, in vivo. These
findings suggest that subcellular trafficking of dVMAT2 is mutually exclusive from its
vesicular activity to package DA (Grygoruk et al., 2014; Grygoruk et al., 2010).
Furthermore, when expressed in the polarized secretory cells of the fly salivary
glands, both dVMAT2 and VMAT-B are primarily localized to vesicular membrane, albeit
with subtle modifications (see discussion below). Taken together, these observations
would suggest that in hypodermal cells, both dVMAT2 and VMAT-B are equally capable
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of packaging cytosolic DA into the vesicles. However, since only dVMAT2 is able to
induce darker pigmentation, it could be possible that the C-terminal sequence in
dVMAT2 confers it with additional functions, such as promoting membrane fusion
and/or triggering content release. It will be interesting to determine whether the Cterminal of dVMAT2 can physically interact with proteins involved in membrane fusion,
such as the SNARE complex components and their regulators.

4.3.4 Differential Sorting of dVMAT2 and VMAT-B into Vesicles with
Unique Properties?
Partially in agreement with the above hypothesis, it is also interesting that,
although both the ectopically expressed VMAT isoforms localize to vesicular membrane
in salivary gland cells, they show substantial differences. These include dVMAT2
containing granules which exhibit a striking polarized distribution inside the cells, are
largely absent in the basal-half of the cells, but are heavily concentrated in close
proximity to the apical surface, where membrane fusion and secretion of glue proteins
occur. In contrast, although the granules positive for dVMAT-B show polarized
distribution toward the apical surface, their distribution is more dispersed.
Additionally, secretory vesicles with different properties also exist, including
those act as ‘reserve” and those that are more “readily releasable”(Evans and Cousin,
2007; Kidokoro et al., 2004; Paillart et al., 2003; Richards et al., 2000; Rizzoli and Betz,
2005). In neurons, VMATs are localized both to synaptic vesicles (SVs), which are
mostly clustered around the active zone at the synapse, and also to large dense-core
vesicles (LDCVs), which are highly dispersed throughout the cytosol (Nirenberg et al.,
1996, 1997; Nirenberg et al., 1995). Interestingly, resembling that observed for
Tito - 137

dVMAT2 in salivary gland cells, overexpression of VMAT2 in mice leads to an increase in
vesicle volume, and translocation to the active zones (Lohr et al., 2014).
It is unknown whether salivary gland cells harbor different subtypes of glue
granules, such as the ones that store glue proteins, or the ones with less competency
for membrane fusion. However, given the apparently differential subcellular
distribution pattern of the two VMAT isoforms in salivary gland cells, it is possible that
dVMAT2 is selectively trafficked to a subset of granules similar to SVs present in the
active zones of neurons.
These vesicles are fusion competent and “readily releasable.” On the other
hand, dVMAT-B is targeted to a subset of granules resembling the more dispersed
LDCVs and/or the SVs in reserve pools. In support of this, dVMAT2 contains amino acid
sequences that signal the subcellular localization of the transporter to SVs, but not to
LDCVs.
Such sorting signals may also be recognized in salivary gland cells to further
refine the trafficking of dVMAT2 among subsets of glue granules with different
properties. These signals are embedded in C-terminal sequence of dVMAT2 and are
absent from dVMAT-B (Grygoruk et al., 2014; Grygoruk et al., 2010).
It will be interesting to dissect out the functional significance for such subtle
changes in the pattern of distribution and identify upstream mechanisms that regulate
the precise timing of such events. The GFP-tagged dVMAT isoforms expressed in
Drosophila salivary gland cells offer a convenient platform to carry out such studies.
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4.3.5 Parkin in Regulating DA Homeostasis
In Drosophila, extensive characterization of different parkin mutant alleles
from various scientific groups have produced conflicting results on the health of DA
neurons in the adult fly brains (Greene et al., 2003; Pesah et al., 2004). Our studies
failed to reveal a prominent loss of DA neurons in the brains of flies that are transheterozygous for two strong parkin mutant alleles (parkinΔ21/f01950).
However, it is interesting to observe a markedly reduced level of DA staining in
parkin mutant brains, although its distribution pattern was not altered. Consistent with
this finding, early reports described the shrunk morphology and diminished TH
immunoreactivity in DA neurons of the DM, as well as reduced level of total DA in
parkin mutant flies (Cha et al., 2005; Greene et al., 2003).
Such an observation implies an unexplored role of Parkin in maintaining
normal DA homeostasis. Since TH expression is not apparently affected by the loss of
Parkin, it is unlikely that Parkin modulates DA synthesis by controlling the levels of TH.
It is possible that Parkin achieves such regulation, directly or indirectly, through
mechanisms that affect DA metabolism, such as glia-mediated sequestration and
recycling of DNA, and change in dVMAT expression or activity.
On this latter aspect, it is interesting to note that Glutathione S-transferase
Omega 1 (GSTO1), a key antioxidant gene, can act as a potent suppressor of parkin
mutants and also become significantly up-regulated in dVMAT mutant, suggesting a
shared functional link between VMAT and Parkin in stress response (Hanna et al., 2015;
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Kim et al., 2012). Future studies are warranted to address this interesting question that
might bear important implications in understanding Parkin-associated PD pathogenesis.
4.3.6

Exposed DA Toxicity in parkin Mutant Flies
In dVMAT mutant flies, we observed a significant loss of total DA levels, as

indicated by both HPLC-ECD and DA immunoreactivity, as well as a profoundly altered
distribution pattern of DA in the brain. These findings support the critical role of
dVMAT in maintaining DA homeostasis and in the appropriate allocation of DA to
discrete brain regions to modulate different brain functions.
The observation of a significant loss of DA neurons in the PAM cluster of
dVMAT/dparkin double mutant flies, support the hypothesis that cytosolic DA can be
toxic and its abnormal accumulation can exacerbate the vulnerability of Parkin mutant
animals, thereby further disrupting the already perturbed cellular pathways. It is of
interest to show that, although TH is clearly present in the brains of young
dVMAT/dparkin double mutant flies, the overall DA immunoreactivity is greatly
diminished.
Such a dramatic loss could be due to the additive effect from simultaneous
loss of dVMAT and dparkin, as either mutant alone similarly results in a reduction of DA
levels in the brain. As dparkin mutants are associated with increase accumulation of
abnormal mitochondria and heightened oxidative stress (Greene et al., 2005; Greene et
al., 2003), it is possible that cytosolic DA, when left unprotected in the absence of
VMAT, would become quickly oxidized and/or metabolized to products that are no
longer recognizable by the anti-DA antibody. Such a rapid turnover of cytoplasmic DA

Tito - 140

would predict a vicious positive feedback cycle that creates a more stressed cellular
environment by increasing ROS production, eventually resulting in the degeneration of
DA neurons.
In order to obtain a better understanding of how accumulation of cytoplasmic
DA can accelerate the degeneration of DA neurons in parkin mutant brains, it will be
important to characterize the identity and quantity of DA derivatives in fly brains from
different genetic background, especially in flies carrying single and double mutations
for dParkin and dVMAT. Similarly, it will be informative to develop assays that permit in
vivo examination of the stress pathways activated in these mutant animals. Except for
DA itself, the current technique is still not sensitive enough for us to detect DA
metabolites from the adult brains (data not shown).

4.3.7 Differential Dynamics in Intracellular Handling of DA and
Selective Vulnerability of PAM Cluster DA neurons
It is intriguing that in dVMAT/dparkin double mutants, the loss of DA neurons
is more restricted to the PAM cluster, revealing potential intrinsic difference between
DA neurons in different brain regions. Consistent with this finding, among the known
DA clusters in the fly brain, the PAM cluster stands out on several aspects.
First, it contains the majority of DA neurons in the protocerebellum, with
~200 out of 280 DA neurons confined within a rather small region in the brain (Mao
and Davis, 2009). Additionally, compared to DA neurons in other clusters such as the
neighboring PAL, DA neurons in the PAM cluster mostly have relatively smaller cell
sizes and lower levels of TH expression, although the underlying mechanism behind
these differences are still not clear. Moreover, in wildtype background, although DA is
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clearly present in the soma of DA neurons in most of the other clusters such as PAL, it is
largely undetectable in the soma of PAM cluster cells.
Importantly, such a difference is unlikely, due to low level of total DA in these
cells, as there is an intense enrichment of DA in the mushroom bodies, the structure
that is heavily innervated by DA neurons from the PAM clusters. Such an observation
would suggest that PAM cluster neurons might in fact contribute the majority of
existing DA in the brain.
Thus, the almost absence of DA immunoreactivity in the soma of PAM cluster
cells might imply a highly effective packaging and delivery mechanism employed by
these cells to transfer the synthesized DA out of the soma and into the axonal terminal
target. On the other hand, this pattern of DA distribution in PAM cluster cells is
reversed in VMAT mutants. PAM cluster neurons show a clear accumulation of DA in
their soma, accompanied by an almost complete absence of DA in the mushroom
bodies.
Taken together, given the apparent difference in subcellular allocation of DA in
cells of the PAM clusters, as compared to cells in most other clusters, suggest
intrinsically different dynamics in the intracellular handling mechanisms of DA. These
findings indicate that the packaging and delivery of DA in these cells is heavily VMATdependent, a finding that becomes further manifested by the loss of dVMAT.
Consistent with our finding, in a recent study on a Drosophila PD model using
another PD gene αSynuclein (αSyn), it was shown that DA neurons within the PAM
cluster have higher vulnerability to αSyn toxicity. In particular, the progressive
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locomotion deficits induced by pan-neuronally expressed αSyn can be mostly
attributed to the degeneration of a subset of fifteen DA neurons in the PAM cluster
(Riemensperger et al., 2013).
In humans, PD mainly affects DA neurons of the Substantia nigra while largely
spare DA neurons

in the VTA system (Blesa and Przedborski, 2014). It will be

provocative to speculate an underlying similarity between the DA neurons in the SNPC
region in human brains and DA neurons in the PAM cluster of Drosophila brain. It will
be especially interesting to explore whether the intrinsic difference in intracellular
handling of DA among different brain clusters play a role in selective degeneration of
DA neurons in PD brains.
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5

CONCLUSION AND PERSPECTIVES
Ever since Hornykievicz established PD as a DA depletion disease that slowly

robs the patient from motor and cognitive faculties, millions of PD patients have been
treated with DA based drugs. Although these drugs are quite effective in treating motor
symptoms, PD continues to be the most common movement disorder and the second
most common neurodegenerative disease. Its detrimental effects are due to cardinal
symptoms not manifesting in PD patients until after 70-80% of striatal DA and 40-50%
of nigral cell bodies have degenerated. Therefore, understanding the pathogenic events
and the associated therapeutic targets will help develop drugs that could potentially
slow down, or even reverse, the course of the disease. Despite the unsurmountable
efforts to develop palliative treatments for the disease, there are still no effective
treatments for such a devastating disorder. One of the major disadvantages of L-Dopa
administration is its contribution to the spontaneous onset of dyskinesia, giving
clinicians a small treatment window, after which the drug yields off-target effects.
As previously indicated, the neurotransmitter DA is a chemically labile
molecule. When exposed to free oxygen in the PH-neutral cytosol, DA can
spontaneously oxidize into toxic by-products, like the o-semiquinone and 5, 6indolequinone. The DA metabolites can form protein adducts with alpha synuclein,
parkin, and mitochondrial complex I, III, and V. DA neurons employ various
mechanisms to prevent the accumulation of toxic products. For example, the enzyme
glutathione peroxidase catalyzes the transfer of glutathione to DA o-quinone through
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the nucleophilic attack of glutathione (Tse et al., 1976) (Bisaglia et al., 2010) (SeguraAguilar and Lind, 1989).
To suppress the production of superoxide anion and DA o-semiquinone, cells
can also induce the activity of cytochrome P450, prostaglandin H synthase,
lactoperoxidase, DA B-monooxygenase, and tyrosinase (Graham et al., 1978; Hastings,
1995; Baez et al., 1997; Foppoli et al., 1997; Thompson et al., 2000). However,
detecting the levels of toxic chemicals in physiological conditions is not trivial since the
DA metabolites undergo intramolecular cyclization, causing difficult detection in vivo
using conventional methods. Hence, other research paradigms must be established to
determine the toxic effects of cytosolic DA in DA neurons.
Improving the vesicular storage of L-Dopa derived DA has been postulated to
extend the treatment window of the drug and reduce the risk of unwanted effects (see
Chapter 1). Growing evidence has implicated DA toxicity and dysfunctional VMAT in PD
pathogenesis and the inability of L-Dopa to sustain long therapeutic effects. For
instance, reducing VMAT2 activity in vivo results in substantial alterations in DA levels.
Mice expressing 5% of wild-type levels of VMAT2 show a remarkable reduction
of total DA level in the brain (Want et al., 1997; Caudle WM et al., 2007). Also, the
ability of Reserpine to induce the translocation of VMAT2 to non-synaptic reservoirs in
neurons, suggests that VMAT2 orchestrates protection against the gradual buildup of
toxic DA-adducts in mice (Yelin and Schuldiner, 1995). Therefore, a VMAT2 agonist that
can cross the blood brain barrier could potentially have a remarkable therapeutic effect
on patients. Pifl et al. showed a significant reduction in the VMAT2 ability to fill vesicles
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with monoamines in pigmented neurons from mesencephalic tissues of postmortem
PD brains (Pifl et al., 2014). Such impairment is also evident in infantile patients
harboring a familial vmat2 mutation (Glatt et al., 2006). Both patient populations
exhibited the cardinal symptoms of PD, including loss of motor and cognitive abilities
(Glatt et al., 2006).
Conversely, gain-of-function SNPs in the promoter region of the vmat2 gene
confer a reduced risk of developing PD (Brighina et al., 2013). Over-expression of
VMAT2 in DA neurons also results in a significant induction in DA synthesis, DA
neurotransmission, and protection from MPTP toxicity (Lohr KM et al. 2014).
Deciphering the role of VMAT2 in genetic models of PD, therefore, will make it
plausible to develop targeted therapies that enhance VMAT2 function, replenish DA
levels, and improve DA neurotransmission in surviving neurons.
In this study, we performed a detailed investigation of the VMAT homolog in
the model organism Drosophila and further evaluated its role in affecting the selective
degeneration of DA neurons in normal and a sensitized dParkin-mutant background.
The nervous system of adult Drosophila serves as a sophisticated model to study the
pathogenic mechanisms of various neurodegenerative disorders. Evidently, exposing
fruit flies to the volatile fungal chemical 1-octen-3-ol induces DN degeneration and
significantly reduces DA levels in the brains, phenotypes which are rescued by targeted
over-expression of dVMAT2 in dopaminergic and serotonergic neurons (Inamdar et al.,
2013).

The adult Drosophila brain is also a powerful model used for investigating

cellular mechanisms regulating DA synthesis, packaging, release, and reuptake.

Tito - 146

Using Drosophila to model age dependent DA neuron loss requires
microsurgical techniques that can reliably provide access to brains with excellent
morphology. Several easy-to-follow approaches for dissecting adult fly brains have been
described (Sweeney et al., 2011; Wu and Luo, 2006). To further simplify the dissection
process of adult fly brains, a highly efficient technique taking less than ten seconds, has
been introduced to dissect adult fly brains. With the advent of large-scale studies that
promise to map out the neuronal circuitry of Drosophila, it is foreseeable that our
dissection procedure will facilitate the development of high-throughput genetic and
drug screens in the adult fly brain.
Furthermore, by examining the ectopic overexpression phenotypes of the two
dVMAT isoforms in the salivary glands of the fruit fly, we found that, although both
share similar sequences, they have apparent functional differences, regardless of being
capable to fully rescue the dVMAT mutants. The two proteins are also targeted to
different populations of secretory vesicles. To determine the biological significance of
specific subcellular localization pattern of the transporters, we also performed a
phenotypic assessment from ectopically expression of the transporters in Ddc positive
hypodermal cells. DVMAT2 is the only isoform capable of inducing darker cuticle
pigmentation, potentially by stimulating an excess in DA release.
Consistently, VMAT2 immunoreactivity was detected in the peripheral blood
lymphocytes, further confirming its role in a systemic response to toxic molecules
(Amenta et al., 2001). By contrast, loss of dVMAT contributes to both a significant
reduction in the total levels of DA and a drastically altered distribution pattern of DA in
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the adult fly brain. Moreover, DA redistributes from the innervation targets to the soma
of DA neurons, a phenotype that is especially prominent in DA neurons within the PAM
clusters.
These observations help us reach the following conclusions: (1) Our data
support the critical role of VMAT in the homeostasis of cellular DA, which is required
for proper delivery of DA to the innervation targets; (2) The efficiency of intracellular
handling of DA is different among different clusters of DA neurons in the fly brain; (3)
DA neurons in the PAM cluster cells operate a more active VMAT-dependent
mechanism to package and deliver cytosolic DA out of the soma.
We also confirmed that removal of either dVMAT or parkin alone does not
cause a significant degeneration of DA neurons in the respective mutant animals.
Additionally, loss of parkin does cause a significant reduction of the total level of DA
but does not alter its distribution pattern in the brain, implicating a role of Parkin in
regulating DA homeostasis. Lastly, simultaneous removal of both dVMAT and dParkin
causes an age-dependent loss of DA neurons primarily in the PAM cluster, in addition to
a more dramatically reduced level of DA in the brain. This is the first demonstration
linking a dysfunction in dVMAT2 to the selective loss of DA neurons in a region of the
adult parkin mutant brain that is involved in learning and memory.
Our results further suggest that disruption of VMAT2 function can potentiate
the selective degeneration of DA neurons in the mutant background of parkin, one of
the causative genes of familial juvenile PD. The phenotypes associated with the loss of
function of dvmat, consisting of a significant reduction in egg laying ability and a
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decline in DA and 5HT levels in the fly brain (Figure 4.1), serve as functional readout of
VMAT2 function in disease models of Drosophila.
Our results also support the hypothesis that toxicity of cytosolic DA
contributes to the initiation and/or acceleration of targeted destruction of DA neurons.
In this study, the toxicity of cytosolic DA was unveiled in animals lacking both
endogenous dVMAT and parkin, leading to the manifestation of the phenotypes within
a short period of time. It is likely that under normal conditions DA toxicity is largely
negligible/undetectable and its detrimental effects become apparent only after long
periods of time. However, such toxicity might become unmasked and dominant in
sensitized background such as with genetic perturbations (e.g., VMAT or Parkin
mutations), natural aging, increased inflammatory stresses, or chronic exposure to toxic
contaminants (e.g., paraquat and MPTP-like toxins).
It is also possible that the difference in intracellular handling of DA might also
be responsible for the selective vulnerability of PAM cluster neurons in dVMAT/parkin
double mutant flies. For example, it is noticeable that DA is clearly present in the soma
of the DA neurons within the PAL and PPM clusters in both wildtype and dVMAT
mutant backgrounds, raising a possibility that these neurons normally maintain a more
active endogenous protective mechanism against cytosolic DA. This property could
render them more immune to DA toxicity in dVMAT/parkin double mutant background.
In contrast, for DA neurons in the PAM cluster, the near absence of DA
immunoreactivity in the soma of these cells raises the likelihood that they normally
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employ a less active protective mechanism against cytosolic DA and, thus, are on a low
threshold to succumb to the toxic effects of increased cytosolic DA.
Our results in Drosophila are consistent with primate data showing significant
decrease of VMAT2 activity in the caudate and putamen of subjects with PD (Pifl et al.,
1990; Pifl et al., 2015; Pifl et al., 1988). Consistently, administering (METH) to the
ventral midbrain DA region of vevet monkey brains induced long-term defects in DA
neurons. Such defects are accompanied by a substantial decrease in striatal binding of
the DA transporter (DAT)-binding ligand, as well as a significant reduction in the IR
signal of VMAT-2, TH, DAT, and the subsequent loss of DA neuron connections (Harvey
et al., 2000). The exact mechanism of action by which METH causes degradation of DA
terminals is still unknown. Interestingly, co-administration with methylphenidate
increases the protein levels of VMAT2 and enhancing vesicular DA uptake, thus
preventing the deleterious effects of METH at the terminals. The neuroprotective effect
of methylphenidate supports the hypothesis that VMAT2 may prevent METH induced
toxicity (Hanson et al., 2004).
Moreover, the age-dependent behavioral decline in mice harboring complete
and partial knockouts of Vmat2 and Park, implicates DA neuron toxicity as a common
denominator. VMAT2 knockout mice show an aberrant neurotransmission of
monoamines resulting early lethality (Wang et al., 1997). Histological analysis of their
cerebral cortex show an increased incidence of cell death, a phenotype that is rescued
by the inhibition of MAO-A enzyme (Fon et al., 1997). For instance, mice that only
express five percent of wild-type Vmat2 level develop to adulthood but show weak
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age-dependent motor loss phenotypes. vmat2 hypomorphs also exhibit a more
selective loss of nigrostriatal neurodegeneration, along with the associated motor
dysfunction phenotypes (Mooslehner et al., 2001) (Caudle et al., 2007). In contrast,
vmat mutants in Drosophila do not exhibit a loss of DA neurons, suggesting
nigrostriatal degeneration in mice and primates involve other complex mechanisms.
Therefore, our findings are consistent with the long-proposed protective effect
of VMAT against DA toxicity. They also support a potential causative role of VMAT in PD
pathogenesis, as suggested by several recent studies. Taken together, results from this
study also raise an interesting possibility that varying dynamics in intracellular DA
handling among different groups of DA neurons might contribute to the regional
specificity of cell loss in PD brains.
Questions to be addressed
Results from our study raise many questions that should be addressed in future studies
and are briefly listed below:
First, why can a combined loss of Parkin and VMAT lead to a more selective
destruction of dopamine neurons? One explanation is that in the absence of parkin,
the majority of cells in the body are in heightened stress and produce an overall
weakened organism due to global disruption of Parkin-associated pathways. These
pathways include an accumulation of malfunctioned mitochondria and Parkin
substrates normally targeted for the UPS and autophagy pathways, increased ROS
levels and heightened oxidative stress associated with damaged mitochondria, and
defective Parkin-assisted vesicular trafficking.
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At the same time, disruption of VMAT leads to additional insults, specifically in
the DA neurons due to the accumulation of cytosolic dopamine and resulting
production of additional ROS and other toxic dopamine metabolites and conjugates,
further inflaming the already susceptible system. Such two-fronted assaults may
eventually overwhelm the anti-oxidative system and other protective mechanisms in
the dopamine neurons, resulting in their gradual degeneration.
Secondly, what are the toxic reagents in the VMAT/Parkin double-mutant
animals that kill the DA neurons? Is there a significant increase of ROS species in the
double mutant animals? What are the potential toxic DA metabolites in the DA
neurons? To address these questions, we will need a more sensitive assay to directly
measure the DA metabolites in adult brains of different genotypes, such as only Parkin,
dVMAT and dVMAT/Parkin double mutant animals. It might also be necessary to
develop in vivo reporters to evaluate the levels of ROS species and the status of cellular
stress in dopamine neurons in adult brains and to determine the cellular pathways that
become selectively activated in the double mutant animals.
Additionally, Parkin itself is being associated with increasing number of cellular
pathways from the UPS, to mitophagy and mitochondrial integrity, to immune response
and vesicular trafficking.

Which of these pathways is mostly responsible for the

increased vulnerability of dopamine neurons to the accumulated cytosolic dopamine?
Furthermore, in addition to Parkin, about a dozen additional PD-associated
genes have been identified and animals models based on these different PD genes have
been established. Similar to parkin mutants, most of these PD models do not exhibit
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selective loss of dopamine neurons. Can cytosolic dopamine play a similar role in
potentiating the degeneration of dopamine neurons in these PD models?
Since many of the PD genes are conserved in Drosophila and their respective
mutant lines are available, they can be tested using similar strategies. For genes that
are not conserved in the fly, such as αSynuclein, transgenic fly lines expressing wildtype
and mutated genes can be similarly tested.
In light of these questions, I postulate new research directions aimed at
addressing: (1) questions pertaining to the physiological role of VMAT2 in the aging fly
brain; (2) examine the pathophysiology from mouse models with a concomitant
disruption of both VMAT and Parkin; and (3) examine the pathophysiology of postmortem brain samples of patients with disruption of VMAT or Parkin. I also outlined the
significance of pursuing these research directions and discuss their implications to
clinical medicine.
Future studies can be established to produce brain-specific dvmat mutant
clones in DA neurons of adult flies. In collaboration with Dr. Hugo Bellen, we have
implemented the MiMIC method to establish a Gal4-trap line in the 5’-UTR region of
dVMAT gene (Tito et al., under review), which allows targeted expression of studied
proteins and RNAi lines specifically in dVMAT-expressing cells. Such studies may
implement this line to target knockdown of parkin specifically in the VMAT-expressing
cells and examine the effects in neighboring neurons. T h i s m o s a i c technique will
allow us to study parkin loss-of-function phenotypes at later developmental stages
and in adult tissues to circumvent potential involvement of Parkin in early
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developmental stages. We can also perform targeted knockout of VMAT in adult
animals using MIMIC technology, which can be especially important for the study of
neurodegeneration as it circumvents any possible lethality.
Validation of Findings in Mammalian System
Results from Drosophila-based studies have their apparent limitations, due to
the different physiology between invertebrate flies and mammals. However, similar
issues also face the commonly used mouse model. For example, both Parkin and Pink1knockout mice cannot recapitulate the apparent degeneration of DA neurons as in PD
patients.
Additionally, although flies and mammalians share highly conserved pathways
for dopamine synthesis and intracellular handling, they utilized different metabolic
mechanisms to remove/recycle DA. For example, flies do not have L-Monoamine
oxidases (MAO) and catechol-O-methyl transferase (COMT) systems to breakdown
dopamine, but instead utilize the beta-alanyl-dopamine synthase Ebony in glial cells to
link beta-alanine and DA to form N-β-alanyldopamine (NBAD), and a hydrolase Tan to
convert NBAD back to DA to recycle the transmitter.
Thus, it will be important to further validate the findings from the fly system in
mammalian models and, if possible, in samples from human patients. Data can be
gathered from a proposed mouse model to explore the pathophysiology of VMAT2
deficiency in DA neurons of wild-type and Parkin knock-out mice. Various imaging
modalities, such as positron emission tomography (PET) and single-photon emission
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computed tomography (SPECT), can be used to examine the expression and
distribution of DA transporters (VMAT2 and DAT) in live mice brains.
A mechanistic factor to consider is the effect of mutations on VMAT2 density
on the membrane surface of SVs since the quantal size of neurotransmitter release
positively correlates with the amount of VMAT2 protein at the vesicular lumen
(Edwards, 2007). Further research should also clarify the effects of disrupting both
parkin and dVMAT in monoamine neurons of the Drosophila brain. Such experiments
must discriminate the effects of the mutations on the ability of the transporter to
uptake monoamine or in the recycling process mediated by Parkin.
Finally, I also propose a longitudinal study to genotype familial juvenile PD
patients and identify those with deficiencies in the regulatory machinery of DA
homeostasis. The purpose will be to determine which of the characteristic phenotypes
of PD is linked to deficiencies in the DA homeostasis. All patients would be asked for
permission to harvest their brains, post-mortem, so as to correlate these findings with
DA neuron loss in the SNPc.
PAM cluster as the fly counterpart of the Substantia nigra region in human brain?
In Parkinson’s disease, the loss of DA neurons is mainly concentrated in the
substantia nigra region of the brain, while the DA neurons in the Ventral tegmental
area (VTA) are largely spared, though the mechanism behind this regional specificity is
still unclear. Similar as those in humans, DA neurons in Drosophila brain are distributed
in characteristic clustered patterns, raising a question as to whether cells in these
clusters are intrinsically different and with differential vulnerability to stresses.
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Although the Drosophila model has been employed extensively to study
Parkinson’s Disease-associated gene, most of the studies have been mainly focused on
a few dopamine neuron clusters such as PPL and PAL, with few detailed analysis on the
PAM clusters that contain the majority of DA neurons in the protocerebral brain.
Notably, compared to DA neurons in the PAL and PPL clusters, DA neurons in the PAM
clusters have relatively smaller cell sizes and lower levels of TH and VMAT expression in
addition to their distinct projection patterns and different brain functions.
In this study, we further showed an apparent difference in intracellular
handling of DA in the PAM cluster neurons as compared to neurons in other clusters
such as PAL. Moreover, PAM cluster neurons exhibit a higher vulnerability to the
simultaneous loss of VMAT and Parkin.
Consistent with this finding, a recent study on αSynuclein toxicity also
reported the particular sensitivity of PAM cluster neurons to the ectopically expressed
human PD gene products. Together, they raise an intriguing possibility on whether DA
neurons in the PAM cluster of the Drosophila brain, bear certain similarity to the
substantia nigra region of human brain, and whether in human brains, the dynamics of
intracellular DA handling is different between neurons in the substantia nigra and
those in the VTA system.
Our results also suggest that in future Drosophila based studies on Parkinson’s
disease, more attention should be paid to the DA neurons in the PAM clusters.
Although they have smaller cell sizes and lower level expression of TH and VMAT
markers, the larger number of DA neurons in the PAM clusters should allow a more
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reliable, accurate, and representative quantification on the degree of potential
dopamine neuron loss in the brain.
Moreover, DA neurons in the PAM clusters might be intrinsically more
sensitive to different genetic perturbations, thus representing a better and more
sensitive system for detecting pathogenic events related to Parkinson’s disease.
Perturbed DA package and metabolism as one unifying theme of Parkinson’s disease
pathogenesis.
From a broad point of view, our study also raises a question on whether
dopamine toxicity is a common thread linking most, if not all, of the pathogenic
mechanisms associated with different PD genes. Does DA toxicity plays similar effect in
potentiating the selective destruction of DA neurons in parkin mutants as in other PDlinked genetic alterations and even in the majority idiopathic cases?
In Parkin mutant flies, there is a significant loss of dopamine in the brain,
though the distribution of DA appears normal and there is no apparent loss of DA
neurons in the mutant. Similarly, one early study reported a 50% loss of VMAT and DAT
expression in Parkin-knockout mice, despite no overt degeneration of DA neurons. It is
possible that other PD-associated genes may directly or indirectly regulate different
aspects of DA biology, such as its synthesis, the dynamics of its vesicular sequestration
and subcellular delivery, and its metabolism and recycling both in DA neurons and in
surround glial cells. Such a scenario will help explain the selective vulnerability of DA
neurons in PD.
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Finally, one potentially important therapeutic strategy is to minimize the
cellular toxicity from cytosolic DA, by boosting the expression level or activity of VMAT
and/or stimulate the efficiency of endogenous metabolic pathways involved in the
breakdown of cytosolic DA. These questions should be addressed using Drosophila, in
order to unravel the mystery surrounding the molecular events that lead to the
selective destruction of dopamine neurons in PD brains.
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6

MATERIALS AND METHODS

Molecular Biology - The EST clones GH22929, GH16917, and GH10249, encoding fulllength cDNAs for DAT, dVMAT2 (dVMAT2) and dVMAT-B (dVMAT1) transcripts
respectively were obtained from the Berkeley Drosophila Genome Project (BDGP) and
further verified by DNA sequencing. The following primers were used to clone the eGFP
tag in-frame to the N-terminus of DAT protein and to the C-terminus of dVMAT
proteins.
For eGFP-DAT fusion construct, we used the following eGFP primers:
5’ primer (V22/pEGFP-N1+586):
GCTGGTTTAGTGAACCGTCAG
3’ primer (sz-V38N):
tatgcggccgccCTTGTACAGCTCGTCCATGC
DAT primers:
5’ primer (DAT-P1-N):
tgagcggccgcagcTCACCAACCGGACATATATCC
Removed the starting Methione in the encoded DAT protein and also introduced a
GGRS linkere sequence in-between eGFP and DAT sequences.
3’ primer for amplifying DAT cDNA:
the SP6 primer from the pOT2a vector in the EST clone GH22929.
The ligated eGFP-DAT chimera construct was cloned into the EcoRI and XhoI restriction
enzyme sites in the pUAST transgenic vector, as shown in Appendix 1.
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For dVMAT-A-eGFP fusion construct, we used the following EGFP primers:
5’ primer (sz-V37NBH):
AAGCTAGCGGATCCAAGCTTGTGAGCAAGGGCGAGGAGCTG
3’ primer (V24/pEGFPN1-1424):
CTCTACAAATGTGGTATGGCTG
dVMAT2 (GH16917) primers:
5’ primer (dVMAT-A-P5):
CTGCTACAGTTGTTCATGCTG.
3’ primer for amplifying C-terminal sequence of dVMAT-A cDNA (dVMAT2-P8NBH):
ccaagcttggatccgctagcTTCGTCTTCCTCGTAGTTTTG.

The ligated dVMAT-A-eGFP chimera construct was cloned into the EcoRI and XbaI
restriction enzyme sites in the pUAST transgenic vector.
dVMAT-B (GH10249) primers:
-5’ primer (dVMAT-B-P5):
CTGCTACAGTTGTTCATGCTG.
-3’ primer for amplifying C-terminal sequence of dVMAT-B cDNA (GH10249, primer
dVMAT-P9NBH):
ccaagcttggatccgctagcAAGCCTCTCGCTCTCGTACGC.
The ligated dVMAT-B-eGFP chimera construct was cloned into the EcoRI and XbaI
restriction enzyme sites in the pUAST transgenic vector.
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The pUAST constructs were injected together with helper DNA encoding 2-3
p-element transposase into embryos of w1118 flies and transgenic fly lines were selected
and established following standard transgenic protocols (Spradling and Rubin, 1982).
Standard Drosophila husbandry were applied to maintain fly stocks and genetic
crosses.
Transmission Electronic Microscope - Salivary glands from early 3rd instar or late
wandering 3rd instar were dissected and fixed following by standard fixation (1.25%
formaldehyde, 2.5 % glutaraldehyde and 0.03% picric acid in 0.1 M Sodium cacodylate
buffer, pH 7.4. Room temperature for 2 hours) and embedding protocol. Thin
sectioning of the fixed tissues was performed and imaged using JEOL 1200EX (80kV)
scope at the Electron Microscope facility, Cell Biology Department at Harvard Medical
School.
Drosophila melanogaster husbandry and stocks - Adult flies were grown and
maintained with standard fruit fly food at 25oC. The following Gal4 lines were used in
the study: VMAT-Gal4MI03756, R48B04-Gal4 (BL-50347), R58E02-Gal4 (BL-41347), DdcGal4 (BL-7010), TH-GAL4 (BL- 8848), w1118 as wildtype control, VMAT-EGFPMI07680
tagging and driver lines were derived using MI07680 and MI03756, respectively as
described in Venken et al. (2011) and Nagarkar-Jaiswal et al (2015).
Over-expression studies - Ddc-Gal4 (BL-7010) was recombined with UAST-VMAT-A-GFP,
UAST-VMAT-B-GFP, UAST-mCD8-GFP, and UAST-DAT-GFP on the second chromosome.
The recombined lines were observed under the dissecting microscope and crossed in
the following combinations:
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1. VMAT-A:
a. DdC-Gal4, UAST-VMAT-A-eGFP x DdC-Gal4, UAST-VMAT6-eGFP
b. DdC-Gal4, UAST-VMAT-A -eGFP x UAST-VMAT-A -eGFP
2. VMAT-A / TH :
a. DdC-Gal4, UAST-VMAT-A -eGFP x DdC-Gal4, UAST-TH
b. DdC-Gal4, UAST-VMAT-A -eGFP x UAST-TH
*UAS-TH was obtained from Bloomington stock center (BL-37539).
3. VMAT-B
a. DdC-Gal4, UAST-VMAT-B -eGFP x DdC-Gal4, UAST-VMAT-B -eGFP
b. DdC-Gal4, UAST-VMAT-B -eGFP x UAST-VMAT-B -eGFP
4. VMAT-B / TH
a. DdC-Gal4, UAST-VMAT-B -eGFP x DdC-Gal4, UAST-TH
b. DdC-Gal4, UAST-VMAT-B -eGFP x UAST-TH
5. DAT
a. DdC-Gal4, UAST-eGFP-DAT x DdC-Gal4, UAST-eGFP -DAT
b. DdC-Gal4, UAST-eGFP -DAT x UAST-eGFP -DAT
6. DAT / TH
a. DdC-Gal4, UAST-eGFP -DAT x DdC-Gal4, UAST-TH
b. DdC-Gal4, UAST-eGFP -DAT x UAST-TH
The phenotypes were confirmed to be selective for DA and serotonergic neurons using
Ddc-Gal4 since crossing the UAST lines with the following GAL4 lines does not
contribute to the pigmentation phenotype. Crosses are indicated by the checkmarks.
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Genetic interaction studies – The following crosses were performed at 25oC incubator
with 3-4 females and 4-5 males on each vial.

“vmat ; park” double mutants
VMATeGFP/ CyO; parkin
VMATp1 / CyO ; parkin

Δ21

f01950

/ TM6C



/ TM6C

“vmat” mutant
VMATeGFP/ CyO


VMATp1 / CyO

“parkin” mutant
parkin
parkin

Δ21

/ TM6C

f01950

/ TM6B



vmat mutant rescue studies – The
following crosses were performed at 25oC
incubator with 3-4 females and 4-5 males
on each vial.

Complementation of “vmat” mutants

VMATp1 / CyO
VMATGal4 / CyO ; UAS-VMAT6-GFP / TM6C



/ CyO ; UAS-VMAT9-GFP / TM6C



VMAT

Gal4
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VMATGal4 / CyO ; UAS-GFP-DAT / TM6C



VMATGal4 / CyO ; UAS-Ddc / TM6C


w1118 ; +/+

VMATGal4 / CyO ; UAS-VMAT6-GFP / TM6C



“vmat” mutant
VMATeGFP/ CyO


VMATp1 / CyO

“parkin” mutant
parkin
parkin

Δ21

/ TM6C

f01950

/ TM6B



Aging - Male and female adult flies were aged in separate vials holding 20 adult flies in
each vial along with fresh fly food and transferred every 3-4 days into a new vial.
Solutions for adult brain dissection -

The adult fly brains were dissected in artificial

cerebral spinal fluid (aCSF): 119 mM NaCl, 26.2 mM NaHCO3, 2.5 mM KCl, 1 mM
NaH2PO4, 1.3 mM MgCl2, and 10 mM glucose. Before use, aCSF was gassed with 5%
CO2/95% O2 for 10-15 min and spiked with 2.5 mM CaCl2. The aCSF solution was
sterilized by filtering through a 0.22 μm membrane filter. The aCSF was stored at 4oC.
Fly brains can also be dissected in a phosphate-buffered saline (PBS) solution although
detailed comparisons of the effects of the two dissection solutions on the final imaging
quality of the dissected brains have not been performed. 4% paraformaldehyde (PFA)
was used to fix the brains.
Solution for fixation - PFA was prepared in 1XPBS as the fixative solution, which is
normally aliquoted and stored at -20oC. 1X phosphate-buffered saline (1xPBS) was used
to rinse the formaldehyde from the brains and after the last washing step during the
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immunofluorescent staining of the dissected brains.
Solutions for rinses and washes - The 1XPBS was prepared from 10X PBS stock
solution (1.37 M NaCl, 27 mM KCl, 100 mM Na2HPO4, and 18 mM KH2PO4). 0.3% of
Tween-20 was prepared in 1XPBS (1XPBT) and used for all the subsequent washing
steps during immunofluorescent staining of the dissected brains.
Antibodies -

The primary antibodies in Figures 2 and 3 were rabbit anti-tyrosine

hydroxylase antibody (Pel-Freez, catalog # P40101-0) at a 1:200 dilution and rat antiElav antibody (7E8A10, Developmental Studies Hybridoma Bank) at a 1:100 dilution,
prepared in 1XPBT with 5% normal goat serum (Sigma-G9023) to block nonspecific
binding. For secondary antibodies, we used AlexaFluor 488-conjugated goat-anti-rat
antibody and AlexaFluor596-conjugated goat anti-rabbit antibody (Invitrogen) at a
1:500 dilution in 1XPBT.
Anesthetization - The adult flies were anesthetized with CO2. A fly is picked using
forceps and its cuticle is briefly de-waxed by dipping it in 70% ethanol for 3-5 s. This
ensures that no bubbles adhere to the fly cuticle when immersed in the aCSF or 1XPBS
dissection solution.
Fly immobilization - Under a dissecting microscope with a light source at an
angle that will not be blocked by hands, the objective lens is set to attain a clear view
of the fly (i.e. 1.2X magnification). The fly was then immobilized using forceps with the
non-dominant hand, and immersed into the cold dissection solution with its abdomen
facing upwards, as shown in Figure 1A.
The forceps were maintained at a 160o – 170o angle with respect to the
dissection plate, while exerting a small force onto the abdomen of the fly (illustrated as
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arrows in Figure 1A). This step immobilizes the fly and forces it to move its head
backwards by 15 o-25o while extending the proboscis upwards. In the process, a soft
and translucent region of the cuticle, underneath the proboscis, becomes apparent.
The magnification is increased and the focal plane is adjusted to fix the view onto this
region. The forceps are not held too tightly, but rather just firm enough to stabilize the
fly. Too much force causes the inside organs to rupture into the solution.
Priming forceps for brain surgery - The dominant hand was then used to press the
dissecting forceps so that its tips are closed, generating a mild force on the tips of the
forceps. The forceps spring open when pressure from the holding hand is released. The
dissecting forceps are positioned perpendicularly to the forceps holding the fly, as
shown in Figure 1B. The dissection forceps are then used to pierce through the soft
and translucent region of the cuticle underneath the proboscis, as illustrated by the red
arrow in Figure 1B. It is important not to penetrate the forceps too deeply to protect
the brain. The brain proper should become visible.

A stable grasp of the fly is

maintained with the non-dominant hand.
Removing the head case exoskeleton - The tips of the dissecting forceps are quickly but
steadily released. The momentum from opening the forceps is used to tear away the
exoskeleton surrounding the fly head. An intact brain proper should become visible
(the white tissue immediately above the tip of the bottom forceps in Figure 1C). An
imaginary line is used to guide the momentum of the released forceps tips (illustrated
as the outward red arrows shown in Figure 1C). The natural force from the momentum
of the opening forceps, gently removes the exoskeleton and most of the brainassociated eye and trachea, while leaving the exposed brain attached to the rest of the
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body.
The proper timing and force applied to open the exoskeleton depends on the
investigator’s experience, and the removal of remnant accessory tissues, such as the
tracheal tissue that appears as white fiber structures attached to the brain. The brain
proper is not damaged in the process.
Fixation process - The dissected brain samples are fixed with their associated torsos in
approximately 1 mL of 4% paraformaldehyde for 40-60 min.

Note: For this and

subsequent steps, the tubes or plates with samples are kept on a nutator to properly
mix the samples in the solution.
Rinsing and washing - The brains are rinsed with 1 mL of 1XPBS by pipetting the
solution 3 times (3X). Proper care is maintained to not aspirate the brains into the
pipette. The brains are then washed 5 times with 1XPBT for 5 min each.

The samples

are kept on the nutator during wash incubations at all times.
Antibody incubation - Samples are incubated with primary antibodies at proper dilution
overnight at 4oC. DN are visualized using a TH antibody, which recognizes the ratelimiting enzyme for the synthesis of DA (Figure 2) (Kim et al., 2012; Pesah et al., 2004;
Trinh et al., 2010; Whitworth et al., 2005; Yang et al., 2006).

The following day,

primary antibodies are removed, and the brains washed 5 times with 1XPBT.

The

brains are placed on the nutator and left for 5-10 min in the 1XPBT solution in between
each wash.

The washed samples are incubated in appropriate secondary antibodies

with the suggested dilution and time of incubation.
Washing - The samples are washed six times with 1XPBT with a 10 min incubation
between each wash. This step is critical for the removal of non-specifically bound
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secondary antibodies from the sample.
Nuclear Staining - The samples are incubated in a 1:10,000 dilution of 1 mg/mL 4’,6’diamidino-2-phenylindole (DAPI) in 1XPBT solution for 30 min. DAPI is a DNA dye that
binds to the AT regions of DNA and can be used to reveal the overall brain morphology.
The samples are then rinsed three times with 1XPBS and transferred to a dissection
dish where the brains are detached from the bodies using forceps.
Mounting - After the staining and washing steps, the brains are mounted in between
two cover-slips. The cover-slips are then placed on top of a mounting slides allowing
the brain samples to easily flip so both sides of the brain can be imaged with similar
signal intensity. The brains are then mounted on an 18 x 18 mm cover-slip which is then
placed on top of a mounting slide. The opening of the pipette tip is widened by cutting
the tip with a blade. The cut tip is used to transfer the brains in 1xPBS solution onto the
18 x 18 mm cover-slip. The liquid around the brains is removed with a fine pipette tip.
20-40 µL of anti-fade mounting medium (0.2% (w/v) n-propyl gallate in 99.5% ACS
grade glycerol) is then added over the brains. The amount of mounting medium added
depends on the number of brains examined.
The viscous mounting medium is displaced outwards by using a pipette tip. A
second 18 x 18 mm cover slip is placed on top of the brains by first lowering the slide
from one side until it makes contact with the surface of the mounting slip, and then
slowly lowering the other side to minimize inclusion of air bubbles. Note: There is no
need to use a spacer in between the two cover slips as the volume of the mounting
medium and the brains should provide sufficient space to separate the two cover slips.
The slides are allowed to settle. Any excessive liquid that comes from the sides of the
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slips is removed with laboratory tissue. To prevent the cover-slips from falling off of the
mounting slide, we use a small piece of tape that attaches the cover-slips to the
mounting slide.

Note: Brains mounted in between the slides can be imaged

immediately or preserved at 4oC for up to one week without significant loss of
fluorescent signal. For long-term preservation of the stained brains, the side of the two
slips can be sealed with clear nail polish and stored in a -20oC freezer, although stained
brains might lose their signals over time.
Apotome and Image processing - To image the brains, we used an upright compound
fluorescent microscope (Zeiss Imager Z.1) equipped with an Apotome function
(Apotome 2.1) to acquire Z-stack images of brain slices that cover the whole depth of
the region at interest. To obtain a clear visualization and reliable quantification of DN in
the PAM cluster region, we used a 40X objective lens. In the Z-series acquisition
function from the commercial software, we selected a section thickness of 0.5-1 µm
between each imaged slice, which ensured an optimal image quality in a 3-D
reconstruction of the PAM cluster region. The thickness of PAM cluster in the brain that
covers all the DN is about 8-10 µm in total.
The 40X magnification shows a PAM cluster of about 8-10 µm in thickness,
while the 20X magnification shows DN in the anterior and posterior sides of 20-25 µm
each. In our experience, the Apotome function can significantly reduce the background
signal in imaging the whole PAM cluster or the whole brain.
Head and body tissue homogenization – Flies are first placed under CO2
anesthesia, then weighted in a pre-weighted Eppendorf tube, and homogenized in RIPA
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buffer with protease and phosphatase inhibitors.

A hand-held homogenizer was

utilized to homogenize the tissues in ice six times, for five seconds each.

The

homogenates are separated into multiple Eppendorf tubes on ice. The aliquots are
centrifuged at maximum speed (14,000 rpm) for thirty minutes and supernatants are
aliquoted in 10 µl and frozen. Thawing and freezing is minimized to preserve protein
structure.
Protein loading, gel electrophoresis, transfer, and protein detection with
antibody - The tissue samples (fly brains separately from fly bodies) in RIPA buffer are
treated with 1X Loading Buffer (1:1) at RT prior to running them in the gel. The loading
buffer (1x) is prepared as a 4X stock and diluted to a 1X solution. 10 µl of each sample,
containing 10 µg/µl are diluted in a total volume of 40 µl with RIPA buffer. The samples
are homogenized with a hand-held homogenizer with 10 strokes (6-8 seconds per
stroke) on ice. The samples were boiled at 95oC for 5 minutes and ran in 8% gels.
Protein transfer was performed overnight at 25 Volts and at 4oC. The transferred PVDF
membrane is first blocked with a blocking buffer consisting of 0.5 g of powder milk in
10 ml of TBSt (1X 20 mM Tris, pH 7.5. 150 mM NaCl. 0.1% Tween 20) and washed with
1X TBSt five times for two minutes each. Membranes were then incubated with
chicken anti-GFP antibody (Sigma G1544) at a dilution of 1:500 in blocking buffer overnight at 4oC and washed five times for two minutes each.

The membrane was

incubated with an anti-Chicken secondary antibody tagged with a fluorescent
conjugate Alexa Fluor® 488 (Thermo Fisher Cat #: A-11039) in blocking buffer for 2 hrs
at Room temperature and washed seven times for two minutes each.

Tito - 170

7

REFERENCES

Amenta, F., Bronzetti, E., Cantalamessa, F., El-Assouad, D., Felici, L., Ricci, A., and Tayebati, S.K.
(2001). Identification of dopamine plasma membrane and vesicular transporters in
human peripheral blood lymphocytes. J Neuroimmunol 117, 133-142.
Aso, Y., Hattori, D., Yu, Y., Johnston, R.M., Iyer, N.A., Ngo, T.T., Dionne, H., Abbott, L.F., Axel, R.,
Tanimoto, H., et al. (2014). The neuronal architecture of the mushroom body provides
a logic for associative learning. Elife 3, e04577.
Auluck, P.K., Chan, H.Y., Trojanowski, J.Q., Lee, V.M., and Bonini, N.M. (2002). Chaperone
suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease.
Science 295, 865-868.
Baez, S., Segura-Aguilar, J., Widersten, M., Johansson, A.S., and Mannervik, B. (1997).
Glutathione transferases catalyse the detoxication of oxidized metabolites (o-quinones)
of catecholamines and may serve as an antioxidant system preventing degenerative
cellular processes. Biochem J 324 ( Pt 1), 25-28.
Baloh, R.H., Salavaggione, E., Milbrandt, J., and Pestronk, A. (2007). Familial parkinsonism and
ophthalmoplegia from a mutation in the mitochondrial DNA helicase twinkle. Arch
Neurol 64, 998-1000.
Banati, R.B., Daniel, S.E., and Blunt, S.B. (1998). Glial pathology but absence of apoptotic nigral
neurons in long-standing Parkinson's disease. Mov Disord 13, 221-227.
Barbeau, A., Gillo-Joffroy, L., Mars, H., and Arsenault, A. (1972). [Treatment of Parkinson's
disease with L-dopa alone or combined with Ro 4-4602]. Rev Can Biol 31, Suppl:169174.

Tito - 171

Bender, A., Krishnan, K.J., Morris, C.M., Taylor, G.A., Reeve, A.K., Perry, R.H., Jaros, E.,
Hersheson, J.S., Betts, J., Klopstock, T., et al. (2006). High levels of mitochondrial DNA
deletions in substantia nigra neurons in aging and Parkinson disease. Nat Genet 38,
515-517.
Berg, J., Roch, M., Altschuler, J., Winter, C., Schwerk, A., Kurtz, A., and Steiner, B. (2015). Human
adipose-derived mesenchymal stem cells improve motor functions and are
neuroprotective in the 6-hydroxydopamine-rat model for Parkinson's disease when
cultured in monolayer cultures but suppress hippocampal neurogenesis and
hippocampal memory function when cultured in spheroids. Stem Cell Rev 11, 133-149.
Betarbet, R., Sherer, T.B., MacKenzie, G., Garcia-Osuna, M., Panov, A.V., and Greenamyre, J.T.
(2000). Chronic systemic pesticide exposure reproduces features of Parkinson's disease.
Nat Neurosci 3, 1301-1306.
Bisaglia, M., Mammi, S., and Bubacco, L. (2007). Kinetic and structural analysis of the early
oxidation products of dopamine: analysis of the interactions with alpha-synuclein. J Biol
Chem 282, 15597-15605.
Bisaglia, M., Soriano, M.E., Arduini, I., Mammi, S., and Bubacco, L. (2010). Molecular
characterization of dopamine-derived quinones reactivity toward NADH and
glutathione: implications for mitochondrial dysfunction in Parkinson disease. Biochim
Biophys Acta 1802, 699-706.
Bischof, J., Bjorklund, M., Furger, E., Schertel, C., Taipale, J., and Basler, K. (2013). A versatile
platform for creating a comprehensive UAS-ORFeome library in Drosophila.
Development 140, 2434-2442.
Biyasheva, A., Do, T.V., Lu, Y., Vaskova, M., and Andres, A.J. (2001). Glue secretion in the
Tito - 172

Drosophila salivary gland: a model for steroid-regulated exocytosis. Dev Biol 231, 234251.
Bjorklund, A., and Dunnett, S.B. (2007). Dopamine neuron systems in the brain: an update.
Trends Neurosci 30, 194-202.
Blesa, J., and Przedborski, S. (2014). Parkinson's disease: animal models and dopaminergic cell
vulnerability. Front Neuroanat 8, 155.
Bonifati, V., Rizzu, P., van Baren, M.J., Schaap, O., Breedveld, G.J., Krieger, E., Dekker, M.C.,
Squitieri, F., Ibanez, P., Joosse, M., et al. (2003). Mutations in the DJ-1 gene associated
with autosomal recessive early-onset parkinsonism. Science 299, 256-259.
Brand, A.H., and Perrimon, N. (1993). Targeted gene expression as a means of altering cell fates
and generating dominant phenotypes. Development 118, 401-415.
Brighina, L., Riva, C., Bertola, F., Saracchi, E., Fermi, S., Goldwurm, S., and Ferrarese, C. (2013).
Analysis of vesicular monoamine transporter 2 polymorphisms in Parkinson's disease.
Neurobiol Aging 34, 1712 e1719-1713.
Bromberg-Martin, E.S., Matsumoto, M., and Hikosaka, O. (2010). Dopamine in motivational
control: rewarding, aversive, and alerting. Neuron 68, 815-834.
Brooks, D.J., Torjanski, N., and Burn, D.J. (1995). Ropinirole in the symptomatic treatment of
Parkinson's disease. J Neural Transm Suppl 45, 231-238.
Budnik, V., and White, K. (1988). Catecholamine-containing neurons in Drosophila
melanogaster: distribution and development. J Comp Neurol 268, 400-413.
Burke, C.J., Huetteroth, W., Owald, D., Perisse, E., Krashes, M.J., Das, G., Gohl, D., Silies, M.,
Certel, S., and Waddell, S. (2012). Layered reward signalling through octopamine and
dopamine in Drosophila. Nature 492, 433-437.
Tito - 173

Busch, S., Selcho, M., Ito, K., and Tanimoto, H. (2009). A map of octopaminergic neurons in the
Drosophila brain. J Comp Neurol 513, 643-667.
Bush, W.D., Garguilo, J., Zucca, F.A., Albertini, A., Zecca, L., Edwards, G.S., Nemanich, R.J., and
Simon, J.D. (2006). The surface oxidation potential of human neuromelanin reveals a
spherical architecture with a pheomelanin core and a eumelanin surface. Proc Natl
Acad Sci U S A 103, 14785-14789.
Calleja, M., Herranz, H., Estella, C., Casal, J., Lawrence, P., Simpson, P., and Morata, G. (2000).
Generation of medial and lateral dorsal body domains by the pannier gene of
Drosophila. Development 127, 3971-3980.
Carlsson, A. (1972). Biochemical and pharmacological aspects of Parkinsonism. Acta Neurol
Scand Suppl 51, 11-42.
Cartier, E.A., Parra, L.A., Baust, T.B., Quiroz, M., Salazar, G., Faundez, V., Egana, L., and Torres,
G.E. (2010). A biochemical and functional protein complex involving dopamine
synthesis and transport into synaptic vesicles. J Biol Chem 285, 1957-1966.
Caudle, W.M., Richardson, J.R., Wang, M.Z., Taylor, T.N., Guillot, T.S., McCormack, A.L.,
Colebrooke, R.E., Di Monte, D.A., Emson, P.C., and Miller, G.W. (2007). Reduced
vesicular storage of dopamine causes progressive nigrostriatal neurodegeneration. J
Neurosci 27, 8138-8148.
Cha, G.H., Kim, S., Park, J., Lee, E., Kim, M., Lee, S.B., Kim, J.M., Chung, J., and Cho, K.S. (2005).
Parkin negatively regulates JNK pathway in the dopaminergic neurons of Drosophila.
Proc Natl Acad Sci U S A 102, 10345-10350.
Chang, H.Y., Grygoruk, A., Brooks, E.S., Ackerson, L.C., Maidment, N.T., Bainton, R.J., and Krantz,
D.E. (2006). Overexpression of the Drosophila vesicular monoamine transporter
Tito - 174

increases motor activity and courtship but decreases the behavioral response to
cocaine. Mol Psychiatry 11, 99-113.
Chege, P.M., and McColl, G. (2014). Caenorhabditis elegans: a model to investigate oxidative
stress and metal dyshomeostasis in Parkinson's disease. Front Aging Neurosci 6, 89.
Chen, A., Ng, F., Lebestky, T., Grygoruk, A., Djapri, C., Lawal, H.O., Zaveri, H.A., Mehanzel, F.,
Najibi, R., Seidman, G., et al. (2013). Dispensable, redundant, complementary, and
cooperative roles of dopamine, octopamine, and serotonin in Drosophila melanogaster.
Genetics 193, 159-176.
Clark, I.E., Dodson, M.W., Jiang, C., Cao, J.H., Huh, J.R., Seol, J.H., Yoo, S.J., Hay, B.A., and Guo, M.
(2006). Drosophila pink1 is required for mitochondrial function and interacts
genetically with parkin. Nature 441, 1162-1166.
Cole, S.H., Carney, G.E., McClung, C.A., Willard, S.S., Taylor, B.J., and Hirsh, J. (2005). Two
functional but noncomplementing Drosophila tyrosine decarboxylase genes: distinct
roles for neural tyramine and octopamine in female fertility. J Biol Chem 280, 1494814955.
Coon, S., Stark, A., Peterson, E., Gloi, A., Kortsha, G., Pounds, J., Chettle, D., and Gorell, J. (2006).
Whole-body lifetime occupational lead exposure and risk of Parkinson's disease.
Environ Health Perspect 114, 1872-1876.
Corti, O., Lesage, S., and Brice, A. (2011). What genetics tells us about the causes and
mechanisms of Parkinson's disease. Physiol Rev 91, 1161-1218.
Creese, I., Burt, D.R., and Snyder, S.H. (1976). Dopamine receptor binding predicts clinical and
pharmacological potencies of antischizophrenic drugs. Science 192, 481-483.
Crocker, A., and Sehgal, A. (2008). Octopamine regulates sleep in drosophila through protein
Tito - 175

kinase A-dependent mechanisms. J Neurosci 28, 9377-9385.
Crocker, A., and Sehgal, A. (2010). Genetic analysis of sleep. Genes Dev 24, 1220-1235.
Crosby, M.J., Hanson, J.E., Fleckenstein, A.E., and Hanson, G.R. (2002). Phencyclidine increases
vesicular dopamine uptake. Eur J Pharmacol 438, 75-78.
Damier, P., Hirsch, E.C., Agid, Y., and Graybiel, A.M. (1999). The substantia nigra of the human
brain. I. Nigrosomes and the nigral matrix, a compartmental organization based on
calbindin D(28K) immunohistochemistry. Brain 122 ( Pt 8), 1421-1436.
Daniels, R.W., Collins, C.A., Gelfand, M.V., Dant, J., Brooks, E.S., Krantz, D.E., and DiAntonio, A.
(2004). Increased expression of the Drosophila vesicular glutamate transporter leads to
excess glutamate release and a compensatory decrease in quantal content. J Neurosci
24, 10466-10474.
Dawson, T.M. (2000). New animal models for Parkinson's disease. Cell 101, 115-118.
Dayan, P., and Balleine, B.W. (2002). Reward, motivation, and reinforcement learning. Neuron
36, 285-298.
de Freitas, C.M., Busanello, A., Schaffer, L.F., Peroza, L.R., Krum, B.N., Leal, C.Q., Ceretta, A.P., da
Rocha, J.B., and Fachinetto, R. (2016). Behavioral and neurochemical effects induced by
reserpine in mice. Psychopharmacology (Berl) 233, 457-467.
Dimaline, R., and Struthers, J. (1996). Expression and regulation of a vesicular monoamine
transporter in rat stomach: a putative histamine transporter. J Physiol 490 ( Pt 1), 249256.
Duerr, J.S., Frisby, D.L., Gaskin, J., Duke, A., Asermely, K., Huddleston, D., Eiden, L.E., and Rand,
J.B. (1999). The cat-1 gene of Caenorhabditis elegans encodes a vesicular monoamine
transporter required for specific monoamine-dependent behaviors. J Neurosci 19, 72Tito - 176

84.
Edwards, R.H. (2007). The neurotransmitter cycle and quantal size. Neuron 55, 835-858.
Ehringer, H., and Hornykiewicz, O. (1960). [Distribution of noradrenaline and dopamine (3hydroxytyramine) in the human brain and their behavior in diseases of the
extrapyramidal system]. Klin Wochenschr 38, 1236-1239.
Eisenberg, J., Asnis, G.M., van Praag, H.M., and Vela, R.M. (1988). Effect of tyrosine on attention
deficit disorder with hyperactivity. J Clin Psychiatry 49, 193-195.
El-Kholy, S., Stephano, F., Li, Y., Bhandari, A., Fink, C., and Roeder, T. (2015). Expression analysis
of octopamine and tyramine receptors in Drosophila. Cell Tissue Res 361, 669-684.
Erickson, J.D., Schafer, M.K., Bonner, T.I., Eiden, L.E., and Weihe, E. (1996). Distinct
pharmacological properties and distribution in neurons and endocrine cells of two
isoforms of the human vesicular monoamine transporter. Proc Natl Acad Sci U S A 93,
5166-5171.
Erion, R., DiAngelo, J.R., Crocker, A., and Sehgal, A. (2012). Interaction between sleep and
metabolism in Drosophila with altered octopamine signaling. J Biol Chem 287, 3240632414.
Evans, G.J., and Cousin, M.A. (2007). Activity-dependent control of slow synaptic vesicle
endocytosis by cyclin-dependent kinase 5. J Neurosci 27, 401-411.
Exner, N., Lutz, A.K., Haass, C., and Winklhofer, K.F. (2012). Mitochondrial dysfunction in
Parkinson's disease: molecular mechanisms and pathophysiological consequences.
EMBO J 31, 3038-3062.
Fei, H., Grygoruk, A., Brooks, E.S., Chen, A., and Krantz, D.E. (2008). Trafficking of vesicular
neurotransmitter transporters. Traffic 9, 1425-1436.
Tito - 177

Fei, H., Karnezis, T., Reimer, R.J., and Krantz, D.E. (2007). Membrane topology of the Drosophila
vesicular glutamate transporter. J Neurochem 101, 1662-1671.
Fon, E.A., Pothos, E.N., Sun, B.C., Killeen, N., Sulzer, D., and Edwards, R.H. (1997). Vesicular
transport regulates monoamine storage and release but is not essential for
amphetamine action. Neuron 19, 1271-1283.
Foppoli, C., Coccia, R., Cini, C., and Rosei, M.A. (1997). Catecholamines oxidation by xanthine
oxidase. Biochim Biophys Acta 1334, 200-206.
Fraenkel, G., and Brookes, V.J. (1953). The process by which the puparia of many species of flies
become fixed to a substrate. The Biological Bulletin 105, 8.
Freis, E.D. (1954). Mental depression in hypertensive patients treated for long periods with large
doses of reserpine. N Engl J Med 251, 1006-1008.
Friggi-Grelin, F., Coulom, H., Meller, M., Gomez, D., Hirsh, J., and Birman, S. (2003). Targeted
gene expression in Drosophila dopaminergic cells using regulatory sequences from
tyrosine hydroxylase. J Neurobiol 54, 618-627.
Gibb, W.R., and Lees, A.J. (1991). Anatomy, pigmentation, ventral and dorsal subpopulations of
the substantia nigra, and differential cell death in Parkinson's disease. J Neurol
Neurosurg Psychiatry 54, 388-396.
Gilks, W.P., Abou-Sleiman, P.M., Gandhi, S., Jain, S., Singleton, A., Lees, A.J., Shaw, K., Bhatia,
K.P., Bonifati, V., Quinn, N.P., et al. (2005). A common LRRK2 mutation in idiopathic
Parkinson's disease. Lancet 365, 415-416.
Glatt, C.E., Wahner, A.D., White, D.J., Ruiz-Linares, A., and Ritz, B. (2006). Gain-of-function
haplotypes in the vesicular monoamine transporter promoter are protective for
Parkinson disease in women. Hum Mol Genet 15, 299-305.
Tito - 178

Gnerer, J.P., Venken, K.J., and Dierick, H.A. (2015). Gene-specific cell labeling using MiMIC
transposons. Nucleic Acids Res 43, e56.
Goetz, C.G. (1986). Charcot on Parkinson's disease. Mov Disord 1, 27-32.
Goetz, C.G., Tanner, C.M., Gilley, D.W., and Klawans, H.L. (1989). Development and progression
of motor fluctuations and side effects in Parkinson's disease: comparison of Sinemet CR
versus carbidopa/levodopa. Neurology 39, 63-66; discussion 72-63.
Goldstein, D.S., Sullivan, P., Holmes, C., Miller, G.W., Alter, S., Strong, R., Mash, D.C., Kopin, I.J.,
and Sharabi, Y. (2013). Determinants of buildup of the toxic dopamine metabolite
DOPAL in Parkinson's disease. J Neurochem 126, 591-603.
Graham, D.G., Tiffany, S.M., Bell, W.R., Jr., and Gutknecht, W.F. (1978). Autoxidation versus
covalent binding of quinones as the mechanism of toxicity of dopamine, 6hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro.
Mol Pharmacol 14, 644-653.
Greene, J.C., Whitworth, A.J., Andrews, L.A., Parker, T.J., and Pallanck, L.J. (2005). Genetic and
genomic studies of Drosophila parkin mutants implicate oxidative stress and innate
immune responses in pathogenesis. Hum Mol Genet 14, 799-811.
Greene, J.C., Whitworth, A.J., Kuo, I., Andrews, L.A., Feany, M.B., and Pallanck, L.J. (2003).
Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin
mutants. Proc Natl Acad Sci U S A 100, 4078-4083.
Greenfield, J.G., and Bosanquet, F.D. (1953). The brain-stem lesions in Parkinsonism. J Neurol
Neurosurg Psychiatry 16, 213-226.
Greer, C.L., Grygoruk, A., Patton, D.E., Ley, B., Romero-Calderon, R., Chang, H.Y., Houshyar, R.,
Bainton, R.J., Diantonio, A., and Krantz, D.E. (2005). A splice variant of the Drosophila
Tito - 179

vesicular monoamine transporter contains a conserved trafficking domain and
functions in the storage of dopamine, serotonin, and octopamine. J Neurobiol 64, 239258.
Grygoruk, A., Chen, A., Martin, C.A., Lawal, H.O., Fei, H., Gutierrez, G., Biedermann, T., Najibi, R.,
Hadi, R., Chouhan, A.K., et al. (2014). The redistribution of Drosophila vesicular
monoamine transporter mutants from synaptic vesicles to large dense-core vesicles
impairs amine-dependent behaviors. J Neurosci 34, 6924-6937.
Grygoruk, A., Fei, H., Daniels, R.W., Miller, B.R., Diantonio, A., and Krantz, D.E. (2010). A tyrosinebased motif localizes a Drosophila vesicular transporter to synaptic vesicles in vivo. J
Biol Chem 285, 6867-6878.
Guillot, T.S., and Miller, G.W. (2009). Protective actions of the vesicular monoamine transporter
2 (VMAT2) in monoaminergic neurons. Mol Neurobiol 39, 149-170.
Guo, M. (2012). Drosophila as a model to study mitochondrial dysfunction in Parkinson's
disease. Cold Spring Harb Perspect Med 2.
Hague, S., Rogaeva, E., Hernandez, D., Gulick, C., Singleton, A., Hanson, M., Johnson, J., Weiser,
R., Gallardo, M., Ravina, B., et al. (2003). Early-onset Parkinson's disease caused by a
compound heterozygous DJ-1 mutation. Ann Neurol 54, 271-274.
Han, K.A., Millar, N.S., and Davis, R.L. (1998). A novel octopamine receptor with preferential
expression in Drosophila mushroom bodies. J Neurosci 18, 3650-3658.
Hanna, M.E., Bednarova, A., Rakshit, K., Chaudhuri, A., O'Donnell, J.M., and Krishnan, N. (2015).
Perturbations in dopamine synthesis lead to discrete physiological effects and impact
oxidative stress response in Drosophila. J Insect Physiol 73, 11-19.
Hanson, G.R., Sandoval, V., Riddle, E., and Fleckenstein, A.E. (2004). Psychostimulants and
Tito - 180

vesicle trafficking: a novel mechanism and therapeutic implications. Ann N Y Acad Sci
1025, 146-150.
Hansson, S.R., Hoffman, B.J., and Mezey, E. (1998). Ontogeny of vesicular monoamine
transporter mRNAs VMAT1 and VMAT2. I. The developing rat central nervous system.
Brain Res Dev Brain Res 110, 135-158.
Hardie, R.C. (1987). Is histamine a neurotransmitter in insect photoreceptors? J Comp Physiol A
161, 201-213.
Hardy, J. (2010). Genetic analysis of pathways to Parkinson disease. Neuron 68, 201-206.
Harvey, D.C., Lacan, G., and Melegan, W.P. (2000). Regional heterogeneity of dopaminergic
deficits in vervet monkey striatum and substantia nigra after methamphetamine
exposure. Exp Brain Res 133, 349-358.
Hastings, T.G. (1995). Enzymatic oxidation of dopamine: the role of prostaglandin H synthase. J
Neurochem 64, 919-924.
Hastings, T.G., Lewis, D.A., and Zigmond, M.J. (1996). Role of oxidation in the neurotoxic effects
of intrastriatal dopamine injections. Proc Natl Acad Sci U S A 93, 1956-1961.
Hornykiewicz, O. (1998). Biochemical aspects of Parkinson's disease. Neurology 51, S2-9.
Hostiuc, S., Drima, E., and Buda, O. (2016). Shake the Disease. Georges Marinesco, Paul Blocq
and the Pathogenesis of Parkinsonism, 1893. Front Neuroanat 10, 74.
Huetteroth, W., Perisse, E., Lin, S., Klappenbach, M., Burke, C., and Waddell, S. (2015). Sweet
taste and nutrient value subdivide rewarding dopaminergic neurons in Drosophila. Curr
Biol 25, 751-758.
Humphrey, D.M., Parsons, R.B., Ludlow, Z.N., Riemensperger, T., Esposito, G., Verstreken, P.,
Jacobs, H.T., Birman, S., and Hirth, F. (2012). Alternative oxidase rescues mitochondriaTito - 181

mediated dopaminergic cell loss in Drosophila. Hum Mol Genet 21, 2698-2712.
Inamdar, A.A., Hossain, M.M., Bernstein, A.I., Miller, G.W., Richardson, J.R., and Bennett, J.W.
(2013). Fungal-derived semiochemical 1-octen-3-ol disrupts dopamine packaging and
causes neurodegeneration. Proc Natl Acad Sci U S A 110, 19561-19566.
Jenett, A., Rubin, G.M., Ngo, T.T., Shepherd, D., Murphy, C., Dionne, H., Pfeiffer, B.D., Cavallaro,
A., Hall, D., Jeter, J., et al. (2012). A GAL4-driver line resource for Drosophila
neurobiology. Cell reports 2, 991-1001.
Johri, A., and Beal, M.F. (2012). Mitochondrial dysfunction in neurodegenerative diseases. J
Pharmacol Exp Ther 342, 619-630.
Kidokoro, Y., Kuromi, H., Delgado, R., Maureira, C., Oliva, C., and Labarca, P. (2004). Synaptic
vesicle pools and plasticity of synaptic transmission at the Drosophila synapse. Brain
Res Brain Res Rev 47, 18-32.
Kim, K., Kim, S.H., Kim, J., Kim, H., and Yim, J. (2012). Glutathione s-transferase omega 1 activity
is sufficient to suppress neurodegeneration in a Drosophila model of Parkinson disease.
J Biol Chem 287, 6628-6641.
Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., Yokochi, M.,
Mizuno, Y., and Shimizu, N. (1998). Mutations in the parkin gene cause autosomal
recessive juvenile parkinsonism. Nature 392, 605-608.
Konrad, K.D., and Marsh, J.L. (1987). Developmental expression and spatial distribution of dopa
decarboxylase in Drosophila. Dev Biol 122, 172-185.
Langston, J.W., and Ballard, P.A., Jr. (1983). Parkinson's disease in a chemist working with 1methyl-4-phenyl-1,2,5,6-tetrahydropyridine. N Engl J Med 309, 310.
Lauvrak, S.U., Hollas, H., Doskeland, A.P., Aukrust, I., Flatmark, T., and Vedeler, A. (2005).
Tito - 182

Ubiquitinated annexin A2 is enriched in the cytoskeleton fraction. FEBS Lett 579, 203206.
Lawal, H.O., Chang, H.Y., Terrell, A.N., Brooks, E.S., Pulido, D., Simon, A.F., and Krantz, D.E.
(2010). The Drosophila vesicular monoamine transporter reduces pesticide-induced
loss of dopaminergic neurons. Neurobiol Dis 40, 102-112.
Lee, Y., Paik, D., Bang, S., Kang, J., Chun, B., Lee, S., Bae, E., Chung, J., and Kim, J. (2008). Loss of
spastic paraplegia gene atlastin induces age-dependent death of dopaminergic neurons
in Drosophila. Neurobiol Aging 29, 84-94.
Lesage, S., Durr, A., Tazir, M., Lohmann, E., Leutenegger, A.L., Janin, S., Pollak, P., Brice, A., and
French Parkinson's Disease Genetics Study, G. (2006). LRRK2 G2019S as a cause of
Parkinson's disease in North African Arabs. N Engl J Med 354, 422-423.
Li, H., Chaney, S., Roberts, I.J., Forte, M., and Hirsh, J. (2000). Ectopic G-protein expression in
dopamine and serotonin neurons blocks cocaine sensitization in Drosophila
melanogaster. Curr Biol 10, 211-214.
Lindquist, N.G., Larsson, B.S., and Lyden-Sokolowski, A. (1988). Autoradiography of
[14C]paraquat or [14C]diquat in frogs and mice: accumulation in neuromelanin.
Neurosci Lett 93, 1-6.
Linert, W., Herlinger, E., Jameson, R.F., Kienzl, E., Jellinger, K., and Youdim, M.B. (1996).
Dopamine, 6-hydroxydopamine, iron, and dioxygen--their mutual interactions and
possible implication in the development of Parkinson's disease. Biochim Biophys Acta
1316, 160-168.
Liu, C., Placais, P.Y., Yamagata, N., Pfeiffer, B.D., Aso, Y., Friedrich, A.B., Siwanowicz, I., Rubin,
G.M., Preat, T., and Tanimoto, H. (2012). A subset of dopamine neurons signals reward
Tito - 183

for odour memory in Drosophila. Nature 488, 512-516.
Liu, Y., and Edwards, R.H. (1997). The role of vesicular transport proteins in synaptic
transmission and neural degeneration. Annu Rev Neurosci 20, 125-156.
Lohr, K.M., Bernstein, A.I., Stout, K.A., Dunn, A.R., Lazo, C.R., Alter, S.P., Wang, M., Li, Y., Fan, X.,
Hess, E.J., et al. (2014). Increased vesicular monoamine transporter enhances
dopamine release and opposes Parkinson disease-related neurodegeneration in vivo.
Proc Natl Acad Sci U S A 111, 9977-9982.
Lohr, K.M., and Miller, G.W. (2014). VMAT2 and Parkinson's disease: harnessing the dopamine
vesicle. Expert Rev Neurother 14, 1115-1117.
Lucking, C.B., Durr, A., Bonifati, V., Vaughan, J., De Michele, G., Gasser, T., Harhangi, B.S., Meco,
G., Denefle, P., Wood, N.W., et al. (2000). Association between early-onset Parkinson's
disease and mutations in the parkin gene. N Engl J Med 342, 1560-1567.
Lundell, M.J., and Hirsh, J. (1994). Temporal and spatial development of serotonin and
dopamine neurons in the Drosophila CNS. Dev Biol 165, 385-396.
Mao, Z., and Davis, R.L. (2009). Eight different types of dopaminergic neurons innervate the
Drosophila mushroom body neuropil: anatomical and physiological heterogeneity.
Front Neural Circuits 3, 5.
Martin, I., Dawson, V.L., and Dawson, T.M. (2011). Recent advances in the genetics of
Parkinson's disease. Annu Rev Genomics Hum Genet 12, 301-325.
Matsui, H., Uemura, N., Yamakado, H., Takeda, S., and Takahashi, R. (2014). Exploring the
pathogenetic mechanisms underlying Parkinson's disease in medaka fish. J Parkinsons
Dis 4, 301-310.
McGeer, P.L., Itagaki, S., Boyes, B.E., and McGeer, E.G. (1988). Reactive microglia are positive for
Tito - 184

HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains.
Neurology 38, 1285-1291.
Miller, G.W., Gainetdinov, R.R., Levey, A.I., and Caron, M.G. (1999). Dopamine transporters and
neuronal injury. Trends Pharmacol Sci 20, 424-429.
Monastirioti, M., Linn, C.E., Jr., and White, K. (1996). Characterization of Drosophila tyramine
beta-hydroxylase gene and isolation of mutant flies lacking octopamine. J Neurosci 16,
3900-3911.
Mooslehner, K.A., Chan, P.M., Xu, W., Liu, L., Smadja, C., Humby, T., Allen, N.D., Wilkinson, L.S.,
and Emson, P.C. (2001). Mice with very low expression of the vesicular monoamine
transporter 2 gene survive into adulthood: potential mouse model for parkinsonism.
Molecular and cellular biology 21, 5321-5331.
Moriyama, Y., and Futai, M. (1990). H(+)-ATPase, a primary pump for accumulation of
neurotransmitters, is a major constituent of brain synaptic vesicles. Biochem Biophys
Res Commun 173, 443-448.
Myohanen, T.T., Schendzielorz, N., and Mannisto, P.T. (2010). Distribution of catechol-Omethyltransferase (COMT) proteins and enzymatic activities in wild-type and soluble
COMT deficient mice. J Neurochem 113, 1632-1643.
Nagarkar-Jaiswal, S., DeLuca, S.Z., Lee, P.T., Lin, W.W., Pan, H., Zuo, Z., Lv, J., Spradling, A.C., and
Bellen, H.J. (2015a). A genetic toolkit for tagging intronic MiMIC containing genes. Elife
4.
Nagarkar-Jaiswal, S., Lee, P.T., Campbell, M.E., Chen, K., Anguiano-Zarate, S., Gutierrez, M.C.,
Busby, T., Lin, W.W., He, Y., Schulze, K.L., et al. (2015b). A library of MiMICs allows
tagging of genes and reversible, spatial and temporal knockdown of proteins in
Tito - 185

Drosophila. Elife 4.
Nall, A.H., Shakhmantsir, I., Cichewicz, K., Birman, S., Hirsh, J., and Sehgal, A. (2016). Caffeine
promotes wakefulness via dopamine signaling in Drosophila. Sci Rep 6, 20938.
Naudon, L., Raisman-Vozari, R., Edwards, R.H., Leroux-Nicollet, I., Peter, D., Liu, Y., and Costentin,
J. (1996). Reserpine affects differentially the density of the vesicular monoamine
transporter and dihydrotetrabenazine binding sites. Eur J Neurosci 8, 842-846.
Neckameyer, W.S., and White, K. (1993). Drosophila tyrosine hydroxylase is encoded by the pale
locus. J Neurogenet 8, 189-199.
Nern, A., Pfeiffer, B.D., and Rubin, G.M. (2015). Optimized tools for multicolor stochastic labeling
reveal diverse stereotyped cell arrangements in the fly visual system. Proc Natl Acad Sci
U S A 112, E2967-2976.
Neumann, J., Bras, J., Deas, E., O'Sullivan, S.S., Parkkinen, L., Lachmann, R.H., Li, A., Holton, J.,
Guerreiro, R., Paudel, R., et al. (2009). Glucocerebrosidase mutations in clinical and
pathologically proven Parkinson's disease. Brain 132, 1783-1794.
Ng, C.H., Guan, M.S., Koh, C., Ouyang, X., Yu, F., Tan, E.K., O'Neill, S.P., Zhang, X., Chung, J., and
Lim, K.L. (2012). AMP kinase activation mitigates dopaminergic dysfunction and
mitochondrial abnormalities in Drosophila models of Parkinson's disease. J Neurosci
32, 14311-14317.
Nieoullon, A. (2002). Dopamine and the regulation of cognition and attention. Prog Neurobiol
67, 53-83.
Nirenberg, M.J., Chan, J., Liu, Y., Edwards, R.H., and Pickel, V.M. (1996). Ultrastructural
localization of the vesicular monoamine transporter-2 in midbrain dopaminergic
neurons: potential sites for somatodendritic storage and release of dopamine. J
Tito - 186

Neurosci 16, 4135-4145.
Nirenberg, M.J., Chan, J., Liu, Y., Edwards, R.H., and Pickel, V.M. (1997). Vesicular monoamine
transporter-2: immunogold localization in striatal axons and terminals. Synapse 26,
194-198.
Nirenberg, M.J., Liu, Y., Peter, D., Edwards, R.H., and Pickel, V.M. (1995). The vesicular
monoamine transporter 2 is present in small synaptic vesicles and preferentially
localizes to large dense core vesicles in rat solitary tract nuclei. Proc Natl Acad Sci U S A
92, 8773-8777.
Nunes, E.J., Randall, P.A., Hart, E.E., Freeland, C., Yohn, S.E., Baqi, Y., Muller, C.E., Lopez-Cruz, L.,
Correa, M., and Salamone, J.D. (2013). Effort-related motivational effects of the VMAT-2
inhibitor tetrabenazine: implications for animal models of the motivational symptoms
of depression. J Neurosci 33, 19120-19130.
Ottone, C., Galasso, A., Gemei, M., Pisa, V., Gigliotti, S., Piccioni, F., Graziani, F., and Verrotti di
Pianella, A. (2011). Diminution of eIF4E activity suppresses parkin mutant phenotypes.
Gene 470, 12-19.
Paillart, C., Li, J., Matthews, G., and Sterling, P. (2003). Endocytosis and vesicle recycling at a
ribbon synapse. J Neurosci 23, 4092-4099.
Paisan-Ruiz, C., Jain, S., Evans, E.W., Gilks, W.P., Simon, J., van der Brug, M., Lopez de Munain, A.,
Aparicio, S., Gil, A.M., Khan, N., et al. (2004). Cloning of the gene containing mutations
that cause PARK8-linked Parkinson's disease. Neuron 44, 595-600.
Pesah, Y., Pham, T., Burgess, H., Middlebrooks, B., Verstreken, P., Zhou, Y., Harding, M., Bellen,
H., and Mardon, G. (2004). Drosophila parkin mutants have decreased mass and cell
size and increased sensitivity to oxygen radical stress. Development 131, 2183-2194.
Tito - 187

Peter, D., Liu, Y., Sternini, C., de Giorgio, R., Brecha, N., and Edwards, R.H. (1995). Differential
expression of two vesicular monoamine transporters. J Neurosci 15, 6179-6188.
Pfeiffer, B.D., Jenett, A., Hammonds, A.S., Ngo, T.T., Misra, S., Murphy, C., Scully, A., Carlson, J.W.,
Wan, K.H., Laverty, T.R., et al. (2008). Tools for neuroanatomy and neurogenetics in
Drosophila. Proc Natl Acad Sci U S A 105, 9715-9720.
Pifl, C., Bertel, O., Schingnitz, G., and Hornykiewicz, O. (1990). Extrastriatal dopamine in
symptomatic and asymptomatic rhesus monkeys treated with 1-methyl-4-phenyl1,2,3,6-tetrahydropyridine (MPTP). Neurochem Int 17, 263-270.
Pifl, C., Rajput, A., Reither, H., Blesa, J., Cavada, C., Obeso, J.A., Rajput, A.H., and Hornykiewicz,
O. (2014). Is Parkinson's disease a vesicular dopamine storage disorder? Evidence from
a study in isolated synaptic vesicles of human and nonhuman primate striatum. J
Neurosci 34, 8210-8218.
Pifl, C., Reither, H., and Hornykiewicz, O. (2015). The profile of mephedrone on human
monoamine transporters differs from 3,4-methylenedioxymethamphetamine primarily
by lower potency at the vesicular monoamine transporter. Eur J Pharmacol 755, 119126.
Pifl, C., Schingnitz, G., and Hornykiewicz, O. (1988). The neurotoxin MPTP does not reproduce in
the rhesus monkey the interregional pattern of striatal dopamine loss typical of human
idiopathic Parkinson's disease. Neurosci Lett 92, 228-233.
Podurgiel, S.J., Nunes, E.J., Yohn, S.E., Barber, J., Thompson, A., Milligan, M., Lee, C.A., LopezCruz, L., Pardo, M., Valverde, O., et al. (2013). The vesicular monoamine transporter
(VMAT-2) inhibitor tetrabenazine induces tremulous jaw movements in rodents:
implications for pharmacological models of parkinsonian tremor. Neuroscience 250,
Tito - 188

507-519.
Podurgiel, S.J., Spencer, T., Kovner, R., Baqi, Y., Muller, C.E., Correa, M., and Salamone, J.D.
(2016). Induction of oral tremor in mice by the acetylcholinesterase inhibitor
galantamine: Reversal with adenosine A2A antagonism. Pharmacol Biochem Behav
140, 62-67.
Polymeropoulos, M.H., Lavedan, C., Leroy, E., Ide, S.E., Dehejia, A., Dutra, A., Pike, B., Root, H.,
Rubenstein, J., Boyer, R., et al. (1997). Mutation in the alpha-synuclein gene identified
in families with Parkinson's disease. Science 276, 2045-2047.
Pothos, E.N., Larsen, K.E., Krantz, D.E., Liu, Y., Haycock, J.W., Setlik, W., Gershon, M.D., Edwards,
R.H., and Sulzer, D. (2000). Synaptic vesicle transporter expression regulates vesicle
phenotype and quantal size. J Neurosci 20, 7297-7306.
Prado, V.F., Martins-Silva, C., de Castro, B.M., Lima, R.F., Barros, D.M., Amaral, E., Ramsey, A.J.,
Sotnikova, T.D., Ramirez, M.R., Kim, H.G., et al. (2006). Mice deficient for the vesicular
acetylcholine transporter are myasthenic and have deficits in object and social
recognition. Neuron 51, 601-612.
Pringsheim, T., Jette, N., Frolkis, A., and Steeves, T.D. (2014). The prevalence of Parkinson's
disease: a systematic review and meta-analysis. Mov Disord 29, 1583-1590.
Rana, A., Rera, M., and Walker, D.W. (2013). Parkin overexpression during aging reduces
proteotoxicity, alters mitochondrial dynamics, and extends lifespan. Proc Natl Acad Sci
U S A 110, 8638-8643.
Rehavi, M., Roz, N., and Weizman, A. (2002). Chronic clozapine, but not haloperidol, treatment
affects rat brain vesicular monoamine transporter 2. Eur Neuropsychopharmacol 12,
261-268.
Tito - 189

Reiter, L.T., Potocki, L., Chien, S., Gribskov, M., and Bier, E. (2001). A systematic analysis of
human disease-associated gene sequences in Drosophila melanogaster. Genome Res
11, 1114-1125.
Richards, D.A., Guatimosim, C., and Betz, W.J. (2000). Two endocytic recycling routes selectively
fill two vesicle pools in frog motor nerve terminals. Neuron 27, 551-559.
Riddle, E.L., Topham, M.K., Haycock, J.W., Hanson, G.R., and Fleckenstein, A.E. (2002).
Differential trafficking of the vesicular monoamine transporter-2 by methamphetamine
and cocaine. Eur J Pharmacol 449, 71-74.
Riemensperger, T., Issa, A.R., Pech, U., Coulom, H., Nguyen, M.V., Cassar, M., Jacquet, M., Fiala,
A., and Birman, S. (2013). A single dopamine pathway underlies progressive locomotor
deficits in a Drosophila model of Parkinson disease. Cell Rep 5, 952-960.
Rilstone, J.J., Alkhater, R.A., and Minassian, B.A. (2013). Brain dopamine-serotonin vesicular
transport disease and its treatment. N Engl J Med 368, 543-550.
Rinne, U.K., Bracco, F., Chouza, C., Dupont, E., Gershanik, O., Marti Masso, J.F., Montastruc, J.L.,
Marsden, C.D., Dubini, A., Orlando, N., et al. (1997). Cabergoline in the treatment of
early Parkinson's disease: results of the first year of treatment in a double-blind
comparison of cabergoline and levodopa. The PKDS009 Collaborative Study Group.
Neurology 48, 363-368.
Ritz, M.C., Lamb, R.J., Goldberg, S.R., and Kuhar, M.J. (1988). Cocaine self-administration
appears to be mediated by dopamine uptake inhibition. Prog Neuropsychopharmacol
Biol Psychiatry 12, 233-239.
Rizzoli, S.O., and Betz, W.J. (2005). Synaptic vesicle pools. Nat Rev Neurosci 6, 57-69.
Rodriguez-Boulan, E., and Powell, S.K. (1992). Polarity of epithelial and neuronal cells. Annu Rev
Tito - 190

Cell Biol 8, 395-427.
Rodriguez-Oroz, M.C., Jahanshahi, M., Krack, P., Litvan, I., Macias, R., Bezard, E., and Obeso, J.A.
(2009). Initial

clinical

manifestations of Parkinson's disease:

features and

pathophysiological mechanisms. Lancet Neurol 8, 1128-1139.
Romero-Calderon, R., Uhlenbrock, G., Borycz, J., Simon, A.F., Grygoruk, A., Yee, S.K., Shyer, A.,
Ackerson, L.C., Maidment, N.T., Meinertzhagen, I.A., et al. (2008). A glial variant of the
vesicular monoamine transporter is required to store histamine in the Drosophila visual
system. PLoS Genet 4, e1000245.
Saini, N., Georgiev, O., and Schaffner, W. (2011). The parkin mutant phenotype in the fly is
largely rescued by metal-responsive transcription factor (MTF-1). Mol Cell Biol 31,
2151-2161.
Sang, T.K., Chang, H.Y., Lawless, G.M., Ratnaparkhi, A., Mee, L., Ackerson, L.C., Maidment, N.T.,
Krantz, D.E., and Jackson, G.R. (2007). A Drosophila model of mutant human parkininduced toxicity demonstrates selective loss of dopaminergic neurons and dependence
on cellular dopamine. J Neurosci 27, 981-992.
Sarthy, P.V. (1991). Histamine: a neurotransmitter candidate for Drosophila photoreceptors. J
Neurochem 57, 1757-1768.
Scarffe, L.A., Stevens, D.A., Dawson, V.L., and Dawson, T.M. (2014). Parkin and PINK1: much
more than mitophagy. Trends Neurosci 37, 315-324.
Schwab, R.S., Amador, L.V., and Lettvin, J.Y. (1951). Apomorphine in Parkinson's disease. Trans
Am Neurol Assoc 56, 251-253.
Segura-Aguilar, J., and Lind, C. (1989). On the mechanism of the Mn3(+)-induced neurotoxicity
of dopamine:prevention of quinone-derived oxygen toxicity by DT diaphorase and
Tito - 191

superoxide dismutase. Chem Biol Interact 72, 309-324.
Sejourne, J., Placais, P.Y., Aso, Y., Siwanowicz, I., Trannoy, S., Thoma, V., Tedjakumala, S.R., Rubin,
G.M., Tchenio, P., Ito, K., et al. (2011). Mushroom body efferent neurons responsible for
aversive olfactory memory retrieval in Drosophila. Nat Neurosci 14, 903-910.
Shulman, J.M., De Jager, P.L., and Feany, M.B. (2011). Parkinson's disease: genetics and
pathogenesis. Annu Rev Pathol 6, 193-222.
Simon, A.F., Daniels, R., Romero-Calderon, R., Grygoruk, A., Chang, H.Y., Najibi, R., Shamouelian,
D., Salazar, E., Solomon, M., Ackerson, L.C., et al. (2009). Drosophila vesicular
monoamine transporter mutants can adapt to reduced or eliminated vesicular stores of
dopamine and serotonin. Genetics 181, 525-541.
Singleton, A.B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., Hulihan, M.,
Peuralinna, T., Dutra, A., Nussbaum, R., et al. (2003). alpha-Synuclein locus triplication
causes Parkinson's disease. Science 302, 841.
Sitaraman, D., Zars, M., Laferriere, H., Chen, Y.C., Sable-Smith, A., Kitamoto, T., Rottinghaus, G.E.,
and Zars, T. (2008). Serotonin is necessary for place memory in Drosophila. Proc Natl
Acad Sci U S A 105, 5579-5584.
Song, C.H., Fan, X., Exeter, C.J., Hess, E.J., and Jinnah, H.A. (2012). Functional analysis of
dopaminergic systems in a DYT1 knock-in mouse model of dystonia. Neurobiol Dis 48,
66-78.
Song, H., Ming, G., Fon, E., Bellocchio, E., Edwards, R.H., and Poo, M. (1997). Expression of a
putative vesicular acetylcholine transporter facilitates quantal transmitter packaging.
Neuron 18, 815-826.
Spencer, J.P., Jenner, P., Daniel, S.E., Lees, A.J., Marsden, D.C., and Halliwell, B. (1998).
Tito - 192

Conjugates of catecholamines with cysteine and GSH in Parkinson's disease: possible
mechanisms of formation involving reactive oxygen species. J Neurochem 71, 21122122.
Spradling, A.C., and Rubin, G.M. (1982). Transposition of cloned P elements into Drosophila
germ line chromosomes. Science 218, 341-347.
Steiner-Mordoch, S., Shirvan, A., and Schuldiner, S. (1996). Modification of the pH profile and
tetrabenazine sensitivity of rat VMAT1 by replacement of aspartate 404 with
glutamate. J Biol Chem 271, 13048-13054.
Stokes, A.H., Hastings, T.G., and Vrana, K.E. (1999). Cytotoxic and genotoxic potential of
dopamine. J Neurosci Res 55, 659-665.
Sulzer, D., Bogulavsky, J., Larsen, K.E., Behr, G., Karatekin, E., Kleinman, M.H., Turro, N., Krantz,
D., Edwards, R.H., Greene, L.A., et al. (2000). Neuromelanin biosynthesis is driven by
excess cytosolic catecholamines not accumulated by synaptic vesicles. Proc Natl Acad
Sci U S A 97, 11869-11874.
Sulzer, D., and Zecca, L. (2000). Intraneuronal dopamine-quinone synthesis: a review. Neurotox
Res 1, 181-195.
Sweeney, S.T., Hidalgo, A., de Belle, J.S., and Keshishian, H. (2011). Dissection of adult Drosophila
brains. Cold Spring Harb Protoc 2011, 1472-1474.
Tain, L.S., Mortiboys, H., Tao, R.N., Ziviani, E., Bandmann, O., and Whitworth, A.J. (2009).
Rapamycin activation of 4E-BP prevents parkinsonian dopaminergic neuron loss. Nat
Neurosci 12, 1129-1135.
Takahashi, N., Miner, L.L., Sora, I., Ujike, H., Revay, R.S., Kostic, V., Jackson-Lewis, V., Przedborski,
S., and Uhl, G.R. (1997). VMAT2 knockout mice: heterozygotes display reduced
Tito - 193

amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced
MPTP toxicity. Proc Natl Acad Sci U S A 94, 9938-9943.
Taylor, T.N., Alter, S.P., Wang, M., Goldstein, D.S., and Miller, G.W. (2014). Reduced vesicular
storage of catecholamines causes progressive degeneration in the locus ceruleus.
Neuropharmacology 76 Pt A, 97-105.
Taylor, T.N., Caudle, W.M., and Miller, G.W. (2011). VMAT2-Deficient Mice Display Nigral and
Extranigral Pathology and Motor and Nonmotor Symptoms of Parkinson's Disease.
Parkinsons Dis 2011, 124165.
Thompson, C.M., Capdevila, J.H., and Strobel, H.W. (2000). Recombinant cytochrome P450 2D18
metabolism of dopamine and arachidonic acid. J Pharmacol Exp Ther 294, 1120-1130.
Tomassoni, D., Traini, E., Mancini, M., Bramanti, V., Mahdi, S.S., and Amenta, F. (2015).
Dopamine, vesicular transporters, and dopamine receptor expression in rat major
salivary glands. Am J Physiol Regul Integr Comp Physiol 309, R585-593.
Tordera, R.M., Totterdell, S., Wojcik, S.M., Brose, N., Elizalde, N., Lasheras, B., and Del Rio, J.
(2007). Enhanced anxiety, depressive-like behaviour and impaired recognition memory
in mice with reduced expression of the vesicular glutamate transporter 1 (VGLUT1). Eur
J Neurosci 25, 281-290.
Torres, G.E., Gainetdinov, R.R., and Caron, M.G. (2003). Plasma membrane monoamine
transporters: structure, regulation and function. Nat Rev Neurosci 4, 13-25.
Trempe, J.F., and Fon, E.A. (2013). Structure and Function of Parkin, PINK1, and DJ-1, the Three
Musketeers of Neuroprotection. Front Neurol 4, 38.
Trinh, K., Andrews, L., Krause, J., Hanak, T., Lee, D., Gelb, M., and Pallanck, L. (2010).
Decaffeinated coffee and nicotine-free tobacco provide neuroprotection in Drosophila
Tito - 194

models of Parkinson's disease through an NRF2-dependent mechanism. J Neurosci 30,
5525-5532.
Tse, D.C., McCreery, R.L., and Adams, R.N. (1976). Potential oxidative pathways of brain
catecholamines. J Med Chem 19, 37-40.
Valente, E.M., Abou-Sleiman, P.M., Caputo, V., Muqit, M.M., Harvey, K., Gispert, S., Ali, Z., Del
Turco, D., Bentivoglio, A.R., Healy, D.G., et al. (2004). Hereditary early-onset Parkinson's
disease caused by mutations in PINK1. Science 304, 1158-1160.
Valles, A.M., and White, K. (1988). Serotonin-containing neurons in Drosophila melanogaster:
development and distribution. J Comp Neurol 268, 414-428.
Venken, K.J., Schulze, K.L., Haelterman, N.A., Pan, H., He, Y., Evans-Holm, M., Carlson, J.W., Levis,
R.W., Spradling, A.C., Hoskins, R.A., et al. (2011). MiMIC: a highly versatile transposon
insertion resource for engineering Drosophila melanogaster genes. Nat Methods 8,
737-743.
Waddell, S. (2010). Dopamine reveals neural circuit mechanisms of fly memory. Trends Neurosci
33, 457-464.
Waddell, S. (2016). Neural Plasticity: Dopamine Tunes the Mushroom Body Output Network.
Curr Biol 26, R109-112.
Wakamatsu, K., Murase, T., Zucca, F.A., Zecca, L., and Ito, S. (2012). Biosynthetic pathway to
neuromelanin and its aging process. Pigment Cell Melanoma Res 25, 792-803.
Wang, Y., Li, S., Liu, W., Wang, F., Hu, L.F., Zhong, Z.M., Wang, H., and Liu, C.F. (2016). Vesicular
monoamine transporter 2 (Vmat2) knockdown elicits anxiety-like behavior in zebrafish.
Biochem Biophys Res Commun 470, 792-797.
Wang, Y.M., Gainetdinov, R.R., Fumagalli, F., Xu, F., Jones, S.R., Bock, C.B., Miller, G.W.,
Tito - 195

Wightman, R.M., and Caron, M.G. (1997). Knockout of the vesicular monoamine
transporter 2 gene results in neonatal death and supersensitivity to cocaine and
amphetamine. Neuron 19, 1285-1296.
Wangler, M.F., Yamamoto, S., and Bellen, H.J. (2015). Fruit flies in biomedical research. Genetics
199, 639-653.
Wanrooij, S., Luoma, P., van Goethem, G., van Broeckhoven, C., Suomalainen, A., and Spelbrink,
J.N. (2004). Twinkle and POLG defects enhance age-dependent accumulation of
mutations in the control region of mtDNA. Nucleic Acids Res 32, 3053-3064.
Whitehead, R.E., Ferrer, J.V., Javitch, J.A., and Justice, J.B. (2001). Reaction of oxidized dopamine
with endogenous cysteine residues in the human dopamine transporter. J Neurochem
76, 1242-1251.
Whitley, J., Parsons, J., Freeman, J., Liu, Y., Edwards, R.H., and Near, J.A. (2004). Electrochemical
monitoring of transport by a vesicular monoamine transporter expressed in Xenopus
oocytes. J Neurosci Methods 133, 191-199.
Whitworth, A.J., Theodore, D.A., Greene, J.C., Benes, H., Wes, P.D., and Pallanck, L.J. (2005).
Increased glutathione S-transferase activity rescues dopaminergic neuron loss in a
Drosophila model of Parkinson's disease. Proc Natl Acad Sci U S A 102, 8024-8029.
Wilson, N.R., Kang, J., Hueske, E.V., Leung, T., Varoqui, H., Murnick, J.G., Erickson, J.D., and Liu,
G. (2005). Presynaptic regulation of quantal size by the vesicular glutamate transporter
VGLUT1. J Neurosci 25, 6221-6234.
Winklhofer, K.F. (2014). Parkin and mitochondrial quality control: toward assembling the puzzle.
Trends Cell Biol 24, 332-341.
Wise, R.A. (2004). Dopamine, learning and motivation. Nat Rev Neurosci 5, 483-494.
Tito - 196

Wittkopp, P.J., Carroll, S.B., and Kopp, A. (2003). Evolution in black and white: genetic control of
pigment patterns in Drosophila. Trends Genet 19, 495-504.
Wojcik, S.M., Katsurabayashi, S., Guillemin, I., Friauf, E., Rosenmund, C., Brose, N., and Rhee, J.S.
(2006). A shared vesicular carrier allows synaptic corelease of GABA and glycine.
Neuron 50, 575-587.
Wojcik, S.M., Rhee, J.S., Herzog, E., Sigler, A., Jahn, R., Takamori, S., Brose, N., and Rosenmund,
C. (2004). An essential role for vesicular glutamate transporter 1 (VGLUT1) in postnatal
development and control of quantal size. Proc Natl Acad Sci U S A 101, 7158-7163.
Wolff, T., Iyer, N.A., and Rubin, G.M. (2015). Neuroarchitecture and neuroanatomy of the
Drosophila central complex: A GAL4-based dissection of protocerebral bridge neurons
and circuits. J Comp Neurol 523, 997-1037.
Wright, T.R. (1987). The genetics of biogenic amine metabolism, sclerotization, and melanization
in Drosophila melanogaster. Adv Genet 24, 127-222.
Wu, J.S., and Luo, L. (2006). A protocol for dissecting Drosophila melanogaster brains for live
imaging or immunostaining. Nat Protoc 1, 2110-2115.
Xu, Y., An, F., Borycz, J.A., Borycz, J., Meinertzhagen, I.A., and Wang, T. (2015). Histamine
Recycling Is Mediated by CarT, a Carcinine Transporter in Drosophila Photoreceptors.
PLoS Genet 11, e1005764.
Yahr, M.D. (1978). Overview of present day treatment of Parkinson's disease. J Neural Transm
43, 227-238.
Yamagata, N., Ichinose, T., Aso, Y., Placais, P.Y., Friedrich, A.B., Sima, R.J., Preat, T., Rubin, G.M.,
and Tanimoto, H. (2015). Distinct dopamine neurons mediate reward signals for shortand long-term memories. Proc Natl Acad Sci U S A 112, 578-583.
Tito - 197

Yamamoto, S., and Seto, E.S. (2014). Dopamine dynamics and signaling in Drosophila: an
overview of genes, drugs and behavioral paradigms. Exp Anim 63, 107-119.
Yang, Y., Gehrke, S., Imai, Y., Huang, Z., Ouyang, Y., Wang, J.W., Yang, L., Beal, M.F., Vogel, H., and
Lu, B. (2006). Mitochondrial pathology and muscle and dopaminergic neuron
degeneration caused by inactivation of Drosophila Pink1 is rescued by Parkin. Proc Natl
Acad Sci U S A 103, 10793-10798.
Yao, J., Erickson, J.D., and Hersh, L.B. (2004). Protein kinase A affects trafficking of the vesicular
monoamine transporters in PC12 cells. Traffic 5, 1006-1016.
Yelin, R., and Schuldiner, S. (1995). The pharmacological profile of the vesicular monoamine
transporter resembles that of multidrug transporters. FEBS Lett 377, 201-207.
Zhang, W., Phillips, K., Wielgus, A.R., Liu, J., Albertini, A., Zucca, F.A., Faust, R., Qian, S.Y., Miller,
D.S., Chignell, C.F., et al. (2011). Neuromelanin activates microglia and induces
degeneration of dopaminergic neurons: implications for progression of Parkinson's
disease. Neurotox Res 19, 63-72.
Zhao, C.M., Chen, D., Lintunen, M., Panula, P., and Hakanson, R. (1999). Effects of reserpine on
ECL-cell ultrastructure and histamine compartmentalization in the rat stomach. Cell
Tissue Res 295, 131-140.
Zhu, M., Li, X., Tian, X., and Wu, C. (2015). Mask loss-of-function rescues mitochondrial
impairment and muscle degeneration of Drosophila pink1 and parkin mutants. Hum
Mol Genet 24, 3272-3285.

Tito - 198

8

APPENDIX
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Appendix 2: Map for pUAST-dVMAT1-eGFP
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Appendix 3: Map for pUAST-dVMAT2-eGFP
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